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FOREWORD 
Intensive research has been undertaken in recent times to understand the 
pathophysiologic mechanisms of chronic hepatitis and HCC. Newer therapeutic 
agents that inhibit receptor tyrosine protein kinases have been developed as a 
result of targeting specific proteins in signaling cascades or molecular events 
within cells, thus demonstrating the importance of understanding the pathological 
regulation of cellular and molecular events, as those that occur in chronic 
hepatitis and preceding the development of HCC. Therefore using this approach 
is useful in identifying critical steps in signaling that are important to link these 
two disease processes. In this way signaling pathways that influence growth or 
generate anti-apoptotic signals can be profiled so that aberrant signaling within 
the cascade can be readily isolated and characterized, and inhibitors or 
activators can later be tested to assess effect on outcomes with respect to 
tumour growth. Alternatively the expression of key target molecules or proteins 
can potentially be identified, that may be subsequently used as serum/tissue 
biomarkers to either predict or diagnose early disease and provide information 
regarding prognosis. 
The aim of this work was to use novel approaches in an attempt to 
understand the pathogenesis of chronic hepatitis and its progression to HCC. 
The first chapter discusses the overall aims and objectives and provides the 
significance of and rationale for the research. Included therein is a background 
section that places the research in the context of clinical disease.  Chapters two, 












but related elements on objectives of this research. Each of these chapters has 
its own introduction/background, materials and methods, results and discussion 
sections. Chapter eight is the conclusion and integrates the findings of the 
previous chapters and finally, it discusses proposed future directions of this 
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The most common risk factors for chronic liver disease, cirrhosis, and 
hepatocellular carcinoma (HCC) include chronic alcohol abuse and infection with 
hepatitis B (HBV) or hepatitis C (HCV) virus. Growing evidence from human 
studies and experimental models suggests that pre-degenerative and pre-
malignant abnormalities include disturbances in intracellular signaling and on-
going injury with oxidative stress, inflammation, and lipotoxicity. The major signal 
transduction pathways affected in both degenerative and neoplastic disease 
states in liver include: insulin/IGF, Wnt/β-catenin, and others. The role of Notch 
signaling in HCC is an emerging area.  Chronic alcohol exposure, which causes 
cirrhosis but is also a co-factor for HCC development, inhibits insulin signaling 
thus resulting in insulin resistance, increased DNA damage, and impaired 
hepatocellular growth, viability, and energy metabolism.  HCC is associated with 
increased activation and dysregulation of insulin/IGF, Wnt/β-catenin, and 
probably Notch signaling, together with increased DNA damage and increased 
cell turnover. In this work, the goal was to compare factors that contribute to the 
progression of liver disease towards cirrhosis on the one hand, and the 
subsequent development of a malignant neoplastic state, i.e. dysplasia and HCC, 
on the other hand, focusing on the roles of abnormal signaling through 
insulin/IGF, Wnt/β-catenin and Notch pathways. The research plan was 
organized under two specific aims. The first aim was to examine the effects of 
chronic ethanol exposure on the expression of genes that regulate insulin/IGF 












evaluate the therapeutic effects of N-acetylcysteine and ceramide inhibitors on 
these indices of chronic alcohol-induced liver disease. The second aim was to 
examine the role of dysregulated Wnt/β-catenin signaling in the pathogenesis of 
HCC in double-transgenic mouse model that constitutively over-expresses the 
HBx and IRS-1 genes in liver.  Results were correlated with progression of liver 
disease in humans from stages of chronic injury with hepatic steatosis, to 
dysplasia, and finally HCC. For our purposes we utilized human tissue samples 
and robust experimental animal models. The experimental approaches included 
qRT-PCR analysis, multiplex and targeted array analysis of gene expression, 
multiplex ELISAs, histopathologic studies, lipid biochemistry, precision cut slice 
culture ex vivo models, and biostatistics. These same approaches could be used 












































1.1 Purpose of the study 
Alcoholic liver disease (ALD) progresses from normal hepatocytes, chronic 
inflammation, fibrosis and ultimately cirrhosis, which is a chief risk factor (4-5 
fold) for the development of HCC in this context. However with chronic Hepatitis 
B and C infection (HBV and HCV) the risk is much higher (30-40 fold). The 
cellular mechanisms responsible for either progression from chronic hepatitis to 
cirrhosis or cirrhosis to a malignant phenotype are many, but not fully understood 
with respect to ALD. These mechanisms include the role of the innate immune 
system, oxidative stress, transcription factors and the activation of stellate cells 
and their interaction with signaling events that modulate these functions 
(Mandrekar & Szabo, 2009). Aberrant signal transduction is involved in 
promoting injury and progression of liver disease. Insulin signaling is required for 
many cellular functions including energy metabolism, regeneration and ultimately 
cell survival (Banerjee, Mohr, Wands, & de la Monte, 1998; Carter & Wands, 
1985; Li, Liu, & Yanoff, 1995; Mohr, Tanaka, & Wands, 1998; Sasaki et al., 
1994). By disrupting lipid metabolism and homeostasis, and impairing 
regenerative capabilities of injured hepatocytes, impaired insulin signaling 
contributes to the pathogenesis of ALD. Free fatty acids and triglycerides have 
traditionally been posited to be the culprits mediating lipid accumulation and its 
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both alcoholic and non-alcoholic steatohepatitis) in promoting lipotoxicity in 
animal models has been described. In addition to being bi-lipid layer 
components, ceramides affect multiple signaling pathways including the insulin 
pathway. Studies performed in our laboratory as well as others have shown that 
alcohol impairs insulin signaling at many levels but mainly by inhibiting insulin 
receptor binding (de la Monte et al., 2008; Patel, D'Arville, Iwahashi, & Simon, 
1991) and suppressing the function of insulin receptor tyrosine kinases (Banerjee 
et al., 1998; Mohr et al., 1998; Sasaki & Wands, 1994), thus causing insulin 
resistance.  
 
 HCC may be the end-result of many years of cirrhotic liver disease due to 
any aetiology. HCC has tumour initiation and promotion stages, and progresses 
in a step-wise fashion influenced in part by cellular signaling mechanisms. 
Dysregulation of signaling pathways has been observed at even the earlier 
stages of disease, thus identification of aberrant signaling polypeptides that could 
be useful as novel biomarkers to predict the presence of pre-malignant disease. 
Previous studies in humans and experimental animal models indicate that three 
distinct signaling pathways in particular, that crosstalk at various levels, are 
frequently dysregulated in HCC. These include: 1) insulin/IGF, insulin receptor 
substrate (IRS) (Longato et al., 2009), and downstream mediators including 
PI3K/Akt and Erk/MAPK (Banerjee et al., 1998; Huynh et al., 2003); 2) Wnt/β-
catenin (Merle et al., 2004); and 3) Notch/Hey/Hes (Cantarini et al., 2006) 












turnover, oxidative stress, adduct formation, and increased DNA damage (Seitz 
& Stickel, 2007). Consequences of dysregulation of these pathways, combined 
with increased hepatocyte injury and turnover, followed by enhanced motility, and 
invasive potential, leads to the transformed phenotype and the development of 
HCC.  
 Several independent studies have demonstrated variable degrees to 
which increased activation of one or more of these major signaling pathways is 
associated with HCC development and/or its progression. Studies in transgenic 
mice have shown that simple up-regulation of any given signaling pathway is not 
sufficient to cause HCC, despite increased growth and cell turnover in the liver. 
The challenge in our understanding of HCC pathogenesis stems from the lack of 
sufficient information about progressive shifts in gene expression and signaling 
that occur prior to and during the transformation process. Without a robust 
experimental animal model, it is not be possible to dissect these mechanisms 
because human studies are mainly cross-sectional in nature, or at best employ 
two or three longitudinal time points of tissue analysis. Our laboratory succeeded 
in developing a double-transgenic mouse model (ATX) in which the hepatitis B x 
(HBx) and IRS-1 genes were over-expressed in liver under the control of liver-
specific promoters. The rationale for generating this model was that previous 
studies suggested that HBx protein, a viral regulatory protein found expressed in 
acute and chronic hepatitis B virus infection mediates trans-activation of HBV 
transcription and activates growth factor signaling pathways in the chronic HBV 
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DNA damage. A second point is that in most cases of human HCC examined, 
there is striking up-regulation of the IRS-1 gene, resulting in increased signaling 
downstream through PI3kinase/Akt and Erk/MAPK, which regulate growth and 
hepatocyte survival. Initial studies using this model demonstrated that there was 
no increase in HCC development in mice carrying a single transgene e.g. IRS-1. 
In contrast, progressive hepatocellular injury and turnover, dysplasia, and 
eventually HCC development occurred in male mice, beginning at 15 months of 
age, in double transgenic mice that expressed both HBx and IRS-1 transgenes 
(Longato et al., 2009). Using targeted PCR arrays, we also demonstrated that the 
expression levels of several epigenetic regulatory genes shifted over time and 
with increasing age, which are of intense interest in understanding the molecular 
pathogenesis of this devastating disease.  
 To summarize, both ALD and chronic HBV and HCV are common serious 
conditions with significant morbidity, mortality and economic cost and lead to or 
contribute to the development of HCC. Impaired signaling is operational and thus 
we aim to utilize animal and human models and tissues to interrogate the role of 



















To understand the role of impaired signaling in the liver, one major goal of this 
work was to determine the degree to which chronic ethanol exposure adversely 
affects insulin-signaling pathways and to determine the mediators of insulin 
resistance since it is associated with oxidative stress and DNA damage, which 
may participate in the development of HCC. We examined such factors in a 
robust experimental animal model of alcoholic steatohepatitis and in an ex vivo 
system as well. In addition, we used the same molecular approaches to 
determine how chronic alcohol abuse in humans alters constitutive insulin and 
Notch signaling pathways in the liver. The human studies allowed us to draw 
direct comparisons between humans and experimental animal models of chronic 
alcoholic liver disease in relation to these critical signaling alterations. 
 The second major goal was to characterize the aging and time-dependent 
shifts in Notch signaling-related genes in the ATX (HBx overexpression) model of 
HCC development. Since it takes approximately 15 months for the double 
transgenic mice (HBx/IRS-1) to develop HCC, despite constitutive over-
expression of both HBx and IRS-1 from birth, we proposed that aging and 
chronic injury may be important factors that lead to continuous oxidative stress, 
cell turnover, and together with adduct formation and ultimately DNA damage 
which are major risk factors for hepatic oncogenesis. We characterized changes 
in Wnt gene and protein expression in liver and correlated responses with the 
histologic development of dysplasia, which may progress to HCC. Currently, 










6	  |	  P a g e 	  
	  
1 transgene, as well as endogenous insulin and IGF signaling molecules. We 
analyzed both Notch and insulin/IGF signaling pathways to better understand the 
molecular events associated with HCC development. A desired analysis of 
oxidative stress-induced adduct formation was beyond the scope of this work, 
however may be a relevant extension to this research in the future. 
 
1.3 Specific aims  
Aim 1: To examine the effects of chronic ethanol exposure on the expression of 
genes that regulate insulin/IGF signaling, toxic lipid accumulation and lipotoxicity, 
ER stress, and inflammation, and evaluate the therapeutic effects of N-
acetylcysteine (NAC) and ceramide inhibitors on these indices of chronic alcohol-
induced liver disease using in vivo and ex vivo systems respectively. Additionally, 
to correlate our findings with a similar analysis of liver obtained from patients with 
ALD.    
Hypothesis: Alcoholic liver di ease is associated with inhibition of insulin/IGF 
signaling, and increased oxidative stress mediated by lipotoxicity, particularly 
excess ceramide generation. Treatment with anti-oxidants and ceramide 
inhibitors may be effective in restoring insulin resistance and reducing lipotoxicity 
in the liver.    
 
Aim 2: To examine the role of dysregulated Wnt and Notch signaling in the 
pathogenesis of HCC. In the first instance we used a double-transgenic 












genes in liver to study Wnt signaling.  Results were correlated with progression of 
liver disease from stages of chronic injury with hepatic steatosis, to dysplasia, 
and finally HCC. This analysis was followed by a repeat of tests of Wnt and 
Notch signaling, this time using human liver tissue. 
Hypothesis: Constitutive over-expression of the HBx and IRS-1 genes in liver 
accelerates aging-associated increases in mediators of oxidative stress leading 
to increased lipid peroxidation, DNA damage, and possibly adduct formation 
These secondary but fundamental pre-malignant abnormalities mediate the 
eventual dysregulation of Wnt/β-catenin signaling pathways, and appear 
fundamental to the pathogenesis of HCC.  
 
1.4 Background 
Chronic liver diseases (CLDs) including cirrhosis constitute a large proportion of 
disease burden worldwide, and are in the top twenty of all causes of mortality 
(World Health Organization, 2003).  CLDs encompass a spectrum of disease 
pathology, that progress through various stages in a similar fashion, irrespective 
of aetiology. Classically, from the normal liver the disease will progress to a mild, 
followed by a more severe chronic inflammatory state characterized by a 
lymphocytic inflammatory infiltrate (in the case of chronic viral hepatitis) and 
altered architecture of the hepatic lobule. This is followed by progression to end-
stage disease characterized by regenerative nodules, surrounded by bands of 
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mortality and is the chief risk factor for the development of hepatocellular 
carcinoma (HCC).  
 The commonest risk factors for the development of chronic liver diseases 
are alcohol, hepatitis B (HBV) and C (HCV) infections, obesity, and in some parts 
of the Asia and Africa aflatoxins. HCV is a significant cause of CLD and HCC 
especially in the United States and Japan; the incidence of hepatocellular 
carcinoma has risen 3-fold in the last 30 years as a result of an increasing 
number of chronic HCV infections (Altekruse, McGlynn, & Reichman, 2009; 
Armstrong et al., 2006). HBV is more prevalent in East Asia and Sub-Saharan 
Africa (SSA), and is the commonest cause for HCC in these parts of the globe, 
with higher incidences of HCC than elsewhere. Worldwide 80-90% of HCC are 
associated with chronic HBV and HCV infection (El-Serag & Rudolph, 2007; 
Nordenstedt, White, & El-Serag, 2010). Consequently, currently HCC is the fifth 
most common cancer in the world with the 3rd-highest cause of all cancer-related 
mortality (Parkin, Bray, Ferlay, & Pisani, 2005). Alcoholic liver disease (ALD) is 
also a major health problem; other than the social problems it causes, it results in 
alcoholic hepatitis that has significant mortality, progresses to cirrhosis in 25-50% 
of individuals, accounts for 7-15% of HCCs (Poynard et al., 1991; Schafer & 
Sorrell, 1999) and is the second most common liver disease for orthotopic liver 
transplantation (Starzl et al., 1988). 
 Currently, although effective treatments for chronic liver disease exist, 
they are generally expensive and not universally available. Thus the overall 












to HCC, prognosis remains exceptionally poor as a result of late diagnosis, and 
chemoresistance to current treatments that are available. Therefore, there is a 
need to understand underlying pathophysiologic mechanisms that can aid in 
either identifying biomarkers whereby disease can be detected early, or find 
novel molecular targets to develop more effective treatments is crucial. 
 
1.5 Alcoholic liver disease 
Alcoholic liver disease (ALD) is the most common and the deleterious 
consequences of chronic alcohol consumption results in up to 12,000 liver-
related deaths per annum in the US (Centers for Disease Control Prevention). 
ALD encompasses a spectrum of histologic features, which can progress from 
simple steatosis, to more serious stages of steato-hepatitis, cirrhosis, and 
hepatocellular carcinoma (HCC) (Adachi & Brenner, 2005; Tilg & Day, 2007). 
Steatosis (i.e. the accumulation of lipids in liver cells) occurs almost universally 
with alcohol consumption. This stage is considered to be the first, relatively 
“benign” stage of liver injury (first hit). This is because in most cases steatosis is 
reversible with cessation of alcohol intake (Maher, 2002; Siegmund, Dooley, & 
Brenner, 2005). More than 50% of those consuming more than six drinks per day 
will develop steato-hepatitis (Bellentani et al., 2000; Maher, 2002) although even 
in those who cease consumption may develop cirrhosis in 18% (Teli, Day, Burt, 
Bennett, & James, 1995). Many factors are contributed to the development of 
steatosis. These include but are not limited to the metabolism of alcohol, which 
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Nicotinamide adenine dinucleotide phosphate (NADP), thus causing increased 
production and esterification of fatty acids. Additionally alcohol suppresses β -
oxidation of fatty acids by mitochondria; therefore both these factors potentiate 
the accumulation of lipids. Furthermore, the accumulation of intracellular ectopic 
fat is mediated by up-regulation of sterol-binding regulatory element protein-1 
(SREBP-1) and the down-regulation of adenosine monophosphate kinase 
(AMPK) and peroxisome proliferator- activated receptors (PPARs) signaling 
pathways (Crabb, 2004; Galli, Pinaire, Fischer, Dorris, & Crabb, 2001; Nanji, 
Dannenberg, Jokelainen, & Bass, 2004; You, Fischer, Deeg, & Crabb, 2002; 
You, Matsumoto, Pacold, Cho, & Crabb, 2004). Impaired signaling by alcohol in 
both cascades, results in increased lipogenesis and steatosis. Other 
mechanisms involved in lipid accumulation include the role of cytokines; TNF-α 
causes an increase in free fatty acid release from adipocytes adjacent to the liver 
and thus increases lipogenesis and inhibitis β-oxidation of fatty acids (Feingold & 
Grunfeld, 1987; Hardardottir, Doerrler, Feingold, & Grunfeld, 1992; Nachiappan, 
Curtiss, Corkey, & Kilpatrick, 1994).  
           Up to one third of patients who continue to drink heavily develop alcoholic 
steatohepatitis (ASH) (McCullough & O'Connor, 1998). ASH is characterized by 
steatosis associated with a chronic inflammatory infiltrate, ballooning 
degeneration of cells, apoptosis, Mallory’s hyaline (Brunt, 2002) and portends a 
grave prognosis in half the patients. Although not fully understood, the 
pathogenesis of ASH is mediated by a so-called “second hit” or insult.  The 












oxidative stress, lipotoxicity, DNA damage, and pro-inflammatory cytokine 
activation (Carter-Kent, Zein, & Feldstein, 2008; Farrell & Larter, 2006). 
Progression of alcohol-related liver disease (ALD) is partly mediated by impaired 
lipid metabolism and homeostasis, which lead to ectopic hepatic accumulation of 
mainly triglycerides and subsequent lipotoxicity, defined as a state where the 
cell’s storage and metabolic capabilities are overwhelmed. Lipotoxic states as the 
name suggests are toxic to hepatocytes; initially the accumulating hepatic fat 
causes rupture of the cell membrane, and results in lipid peroxidation of 
membranes. Consequences of lipid peroxidation include the formation of 
acetaldehyde lipid and hybrid adducts. Moreover, toxic lipids can activate anti-
survival signaling pathways, thereby affecting cell functioning and stimulation of 
pro-cytokine activation that results in activation of stellate cells, which lay down 
scar tissue. These repeated cycles of cell injury followed by repair are in the 
long-term damaging to the liver, and are the cause of the hepatitis-fibrosis-
cirrhosis-cancer sequence.  
         The detoxification and elimination of consumed alcohol is primarily 
performed in the liver via a series of oxidative chemical reactions known as 
oxidative metabolism (Thiele, Klassen, & Tuma, 2008; Tuma & Casey, 2003). 
This process consists of three major steps:  the reversible oxidation of ethanol to 
acetaldehyde, the non-reversible metabolism of the toxic acetaldehyde to 
acetate, and finally the breakdown of acetate to water and carbon dioxide.  
Alcohol dehydrogenase (ADH), the main oxidizing enzyme, with a high affinity for 
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hepatocytes.  A second pathway, CYP2E1 (inducible by chronic alcohol 
consumption) functions to form acetaldehyde in the peroxisome, and catalase 
oxidizes ethanol in microsomes (Barry & Williams, 1988; Crabb, 2004). The 
second step of alcohol metabolism, the breakdown of acetaldehyde, is carried 
out by mitochondrial aldehyde dehydrogenase (ALDH).  However, the 
metabolism of alcohol (particularly by CYP2E1) results in the generation of 
reactive oxygen species (ROS). In addition Kupffer cells produce ROS during 
ethanol metabolism (Arteel, 2003) and in response to lipopolysaccharide (LPS) 
(Spolarics, 1998). Further, alcohol suppresses mitochondrial function, and 
together with acetaldehyde toxicity facilitate depletion of radical scavengers i.e. 
glutathione (GSH). These effects combined, result in increased oxidative stress, 
the consequences of which are to induce liver injury (Arteel, 2003; Hoek & 
Pastorino, 2002; Wheeler et al., 2001).  
          In addition, secondary to alcohol metabolism are the formation of various 
acetaldehyde-protein and DNA adducts, which impair protein function in the 
former (reviewed by Niemela, 1999) and can stimulate potent immunological 
response in the latter (Hoerner, Behrens, Worner, & Lieber, 1986; Niemela, 
1999; Niemela et al., 1987) further causing hepatocyte injury. Additionally, 
acetaldehyde-DNA adducts are implicated in triggering DNA replication errors 
and mutations in oncogenes or onco-suppressor genes (Seitz & Stickel, 2007) 
that mediate transformation to cancer. 
Tied in with the metabolic effects of alcohol leading to oxidative stress is the 












function, thereby the ability for fatty acid oxidation and ATP synthesis (Bailey, 
2003) and suppression of key mitochondrial metabolism enzymes, including 
ALDH (Coleman & Cunningham, 1991; Venkatraman et al., 2004). Mitochondria 
are also inhibited by acetaldehyde during alcohol metabolism, and result in a 
decrease in the availability of mitochondrial GSH, in addition to being major 
sources of ROS production (Boveris & Chance, 1973). Moreover, acetaldehyde 
damages the electron transport chain (ETC) of mitochondria, causing 
mitochondrial permeability transition (MPT), thereby inducing pro-apoptotic 
signaling (Kim, He, & Lemasters, 2003). The endoplasmic reticulum (critical for 
protein maturation and lipid synthesis) is an organelle which is extremely 
sensitive to oxidative stress and the increased NADPH/NADH ratio that occurs 
with alcohol. Conversely the ER is also a significant source of ROS, where 
singlet oxygen is generated by leakage of electrons from the NADPH cytochrome 
P450 reductase (Cross & Jones, 1991). Changes at trans-membrane level are 
detected by inositol requiring enzyme (IRE), activating transcription factor 6 
(ATF-6) and RNA-activated protein kinase-like ER kinase (PERK) (Ji & 
Kaplowitz, 2006; Marciniak & Ron, 2006; Schroder & Kaufman, 2005). As a 
result, in response to endoplasmic reticulum (ER) stress, these trans-membrane 
sensors activate an unfolded protein response (UPR) comprising an attenuation 
of protein synthesis, and transcription of degradation chaperones and genes that 
up-regulate ER-associated degradation (ERAD) and improve protein folding to 
restore homeostasis. Specifically glucose-regulated protein 78 (GRP78), an 
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the trans-membrane receptors; activated IRE-1α cleaves X-box-binding protein 1 
(XBP-1) mRNA, thereby activating it; this causes up-regulation of genes 
important for ERAD, and a degradation of genes encoding for secretory and 
membrane proteins (Hollien & Weissman, 2006). ATF-6 translocates to the 
nucleus to up-regulate chaperones such as GRP78 and others that increase 
protein folding of the ER (Ji, Chan, & Kaplowitz, 2006; Marciniak & Ron, 2006; 
Schroder & Kaufman, 2005). Activated PERK on the other hand phosphorylates 
eukaryotic translation initiation factor 2α (eIF-2α). However with prolonged ER 
stress, apoptotic signals transmitted through IRE-1α-mediated signaling are 
activated, and these act through Bax/Bak, JNK, and ATF-4 (which increases 
expression of C/EBP-homologous protein (CHOP). CHOP is a transcription factor 
that along with GRP78 is the hallmark of the UPR and stress response (Ji, 2008) 
and is associated with ER-stress-induced apoptosis.  
         Another important component of progression of alcohol-related liver injury 
to steatohepatitis is mediated by cytokine activation. Tumour necrosis factor-α 
(TNF-α), the prototypical cytokine, along with other inflammatory mediators (e.g. 
interleukins 1, 6 a d 8) is produced by macrophages, in response to LPS-
mediated stimulation via Toll-like receptor 4 (TLR-4) and MyD88 complex (Szabo 
& Bala, 2010). In the same vein, anti-inflammatory cytokines interleukins 4, 10 
and 13 are produced, to counter the effects of their pro-inflammatory 
counterparts. Therefore it is the imbalance in favour of pro-inflammatory 
cytokines that results in liver injury in the early stages of ALD. Activation of 












failure of cell regeneration and ultimately progression of disease to cirrhosis, 
through stellate cell activation (Crews et al., 2006). Interestingly, recent evidence 
points to the fact that progression of disease to fibrosis/cirrhosis in chronic 
alcohol consumption occurs as a result of the switch from a pro-inflammatory Th-
1 to an anti-inflammatory Th-2 response, via activation of transforming growth 
factor-beta (TGF-β) (Crews et al., 2006). 
        The only effective treatment to prevent progression of ALD is complete and 
sustained abstinence.  However, only one third of patients on alcohol 
rehabilitation programs are able to consistently abstain from alcohol. Therefore 
therapeutic agents to limit liver injury secondary to ALD are necessary. Currently 
medications to treat craving, decompensated disease and to improve nutritional 
status of patients are used to treat ALD. Many of these drugs reduce cravings, 
frequency of drinking and improve outcomes in the short-term; their long-term 
effects of survival however are less clear. Therefore a search of newer agents 
operating on different mechanisms would be welcomed. Hepatic insulin 
resistance mediated by ceramide-induced lipotoxicity is a key feature in alcoholic 
steatohepatitis (ASH), as such novel treatments such as ceramide inhibitors may 
provide a useful way in which ALD can be targeted. 
           Therefore to sum up, the pathophysiologic process of progression of 
alcoholic liver disease from “simple” steatosis to steatohepatitis is rooted in the 
key roles of oxidative stress, cytokine activation and organelle dysfunction; this 
has been shown in both animal models and human studies. With prolonged 










16	  |	  P a g e 	  
	  
ability to regenerate, thus leading to cell death, tissue destruction and 
subsequent tissue/organ failure. 
  
1.6 Hepatocellular carcinoma (HCC) 
HCC is the most common form of primary liver cancer. The majority of patients 
present with advanced disease and thus HCC is generally diagnosed late. 
Consequently, the prognosis is generally poor (only a few months). More 
concerning, are the mortality rates from HCC, which are equivalent to incidence 
rates. Thus despite recent advances in therapies for HCC, the impact is 
significant. The development and progression of cancer is considered to be a 
multi-step process, from a premalignant chronic inflammatory to a neoplastic 
stage. This occurs in a similar fashion to the well-described adenoma-carcinoma 
sequence of colorectal cancer (CRC).  Chronically inflamed or cirrhotic 
hepatocytes undergo abnormal proliferation, and become dysplastic, particularly 
noted with HBV and HCV infections (Libbrecht, Craninx, Nevens, Desmet, & 
Roskams, 2001; Makino et al., 2000) and these lesions are definite risk factors 
for virus-related HCC (Makino et al., 2000; Terasaki, Kaneko, Kobayashi, 
Nonomura, & Nakanuma, 1998). A different type of lesion with different 
pathological features similarly occurs in the background of cirrhosis and 
represents a pre-malignant condition (Ferrell, Crawford, Dhillon, Scheuer, & 
Nakanuma, 1993; Roncalli, 2004). This lesion is the dysplastic nodule (DN) and 
is divided into low or high grade based on the histopathological features. The 












researchers showing evidence that the majority (80%) of DNs disappear or 
remain stable (Seki et al., 2000) whereas others definitively predicting malignant 
transformation/hepatocarcinogenesis (Borzio et al., 2003). The next distinctive 
histological lesion is HCC, which is divided into early and late HCC. By definition 
early HCC is well-differentiated with an obscure tumour margin, and must be 
distinguished from a high grade DN. Early HCC carries a good prognosis, 
regrettably few patients have symptoms and will therefore not usually present at 
this early stage. Late HCC by contrast carries with it a grave prognosis, and 
survival of only a few months. 
 There are several key and interrelated mechanisms that result in cancer 
formation. These include gene mutations of oncogenes and tumour suppressor 
genes, loss of heterozygosity (LOH) of chromosome 8p, epigenetic changes, the 
epithelial mesenchymal transition (EMT) and role of stem cells. A comprehensive 
review of all these mechanisms is beyond the scope of this work however, in the 
next section, the key tenets of cancer formation at molecular and cellular level 
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1.7 General mechanisms of cancer (Hanahan & Weinberg, 2000) 
The result of any type of cancer is a consequence of six critical acquired 
alterations in cell regulatory circuits viz: autonomous or self-sustaining growth 
signals, insensitivity to anti-growth signals, evasion of inherent protective 
mechanisms i.e. apoptosis, unlimited ability of cells to replicate, sustained 
angiogenesis (which promotes tumor invasiveness) and ability of cells to invade 
and replace normal tissue. All these mechanisms have to act in concert and over 
prolonged periods to induce malignant transformation.  
 
Self-sustaining growth signals 
For cells to proliferate normally, they need growth signals to be able to transition 
from a quiescent to an active state. These signals are transmitted by 
transmembrane receptors (that bind various messenger molecules) to the interior 
of the cell.  The difference between normal and malignant cells is that the latter 
are capable of circumventing heterotypic signaling (whereby growth factors made 
by one type of cell can stimulate the proliferation of another type of cell), in that 
way obviating their dependence on extrinsic growth factors, thus they become 
more autonomous in their responses to in-coming signals. Cell surface receptors 
are also targets of deregulation by cancer cells, usually by overexpression and 
selection of the most efficient of these at the cell surface, making the cancer cell 
overly responsive to messages. This modification may be ligand-dependent or 
independent.  Downstream the most important cascade linking received 












to carcinogenesis is simplistic i.e. by not taking into account various 
interconnections between signaling cascades, and their target cells within an 
organ, it makes for a useful model to understand some of the basic tenets of 
malignant transformation. 
 
Insensitivity to anti-growth signals 
Soluble growth inhibitors exist to maintain homeostasis within normal tissues, 
and similar to pro-growth signals, these anti-growth inhibitory factors work 
through ligand-transmembrane-intracellular signaling interactions.  These 
inhibitory signals can be disrupted resulting in tumor cells having a growth 
advantage. Most of these anti-proliferative signals are co-ordinated with the G1 
phase of the cell cycle, and are mediated mainly through the retinoblastoma 
protein (pRb). Normally pRb blocks proliferation of cells by sequestering and 
altering the function of E2F transcription factors that control the expression of 
genes necessary for progre sion from G1 into the S phase (Hanahan & 
Weinberg, 2000). Thus disruption of pRB releases E2F thereby allowing 
proliferation of cells. The best-studied molecule by which this mechanism 
operates is through transforming growth factor beta (TGF-β), which can be 
disrupted by losing its responsiveness or that of its downstream targets, as a 
result of down-regulation, mutations, and sequestration by viral oncoproteins (i.e. 
E7) to name but a few. Thus its regulation on pRb is lost in tumours, allowing the 
malignant cells to proliferate. In addition, malignant cells acquire an ability to 
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differentiated), but to promote growth by causing over-expression of the c-Myc 
oncoproteins.  Essentially many effectors are operational that have not as yet 
been elucidated, and in combination with the cell cycle machinery facilitate 
avoidance of transmission of these anti-proliferative signals.  
 
Evasion of apoptosis 
Apoptosis or programmed cell death is the cell’s inherent protective mechanism 
whereby abnormal cells can be lost, allowing for the proliferation of new normal 
cells as replacement. Therefore cell proliferation must be balanced by cell loss to 
maintain homeostasis and well-functioning systems.  Currently there is ample 
evidence from animal and human studies that the ability to resist apoptosis is 
perhaps the sine qua non of all types of cancer.  The apoptotic machinery 
includes cell surface receptors that bind either survival (e.g. IGF-1 and IGF-2 
through IGF-1R) or death factors (e.g. Fas ligand binding Fas receptor and TNF-
α and its receptor). These apoptotic signals work through mitochondria, which 
release cytochrome C, a potent catalyst of apoptosis. Members of the Bcl-2 
family of proteins have either pro-apoptotic (Bax, Bak, Bid, Bim) or anti-apoptotic 
(Bcl-2, Bcl-XL, Bcl-W) properties, which govern mitochondrial signaling through 
cytochrome release. Therefore, for instance p53, a prototypical tumor suppressor 
promotes apoptosis by up-regulating the expression of Bax in response to 
sensing DNA damage; Bax in turn stimulates the release of cytochrome C.  
Every signal requires an effector; in the case of apoptosis proteases termed 












as Fas or cytochrome release by mitochondria respectively.  Downstream these 
function with other effector caspases to effect apoptosis of subcellular structures, 
organelles and genomes (Hanahan & Weinberg, 2000). Apoptosis-evading 
strategies include loss of pro-apoptotic regulators by way of mutations; a good 
example of this is the p53 tumor suppressor gene.  This results in inactivation of 
the p53 protein, and this is observed in more than fifty percent of all human 
cancers. Other strategies include the inactivation of anti-apoptotic survival 
mechanisms, such as those mediated by the PI3 kinase-AKT/PKB pathway, by 
inhibition of IGF-1/2 signaling, or loss of PTEN tumor suppressor function. 
 
Unlimited ability of cells to replicate 
While interruption of cell signaling is important to cause cancer, there is sufficient 
data to show that this alone is not sufficient to cause cancer.  Inherently cells 
have mechanisms to prevent unregulated growth i.e. cells have finite replicative 
properties; therefore in order to cause tumors, this ability must also be impaired. 
This property is called senescence, which can be disabled by a mutation or 
inactivation of for example a tumor suppressor gene. This would result in the cell 
multiplying until it reaches a crisis state, characterized by massive cell death, 
karyotypic disarray, and even the emergence of a variant with an acquired ability 
to multiply indefinitely. This function is termed immortalization, and represents a 
key ability of malignant cells. However even these cells’ replicative ability is 
undermined by apoptosis, accounting for a lot of attrition.  This occurs because of 
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chromosomal DNA during the S phase. Thus the unprotected chromosomal ends 
can cause chromosomal fusions, yielding the karyotypic disarray associated with 
the crisis state. This too however, can be prevented by telomerase maintenance 
(seen in up to ninety percent of tumors). This occurs by up-regulation of the 
expression of the telomerase enzyme, which adds six base pair repeats to the 
ends of telomeric DNA, thus preventing cell loss.  This evidence was gained from 
cell culture/line studies, or transgenic mice lacking telomerase function. 
 
Sustained angiogenesis 
To function and proliferate normally, cells require nutrients supplied by blood 
vessels; as a result many cells reside very close to capillaries. Once the tissue is 
formed, new capillaries are formed (termed angiogenesis), however this is a 
closely regulated process. As a result incipient malignant cells have to acquire 
angiogenic ability in order to survive. Pro- or anti-angiogenic signals are 
transmitted by soluble factors and their receptors on the surface of endothelial 
cells. The prototypical growth factors are vascular endothelial growth factor 
(VEGF) and fibroblast growth factors (FGF) 1 and 2. There are angiogenic 
growth inhibitors as well i.e. thrombospondin-1. Other important components of 
angiogenic signaling include the role of integrins and adhesion molecules that 
mediate cell-matrix and cell-to-cell interactions respectively.  Inactive cells 
express one type of integrin, whereas malignant cells express a different type.  
Evidence suggests that neovascularization is a pre-requisite of clonal expansion 












phases, and this was shown in pre-malignant lesions of human cervical, breast 
and skin cancer. Tumors achieve disruption of signaling by altering the balance 
of pro- and anti-angiogenic factors, commonly done by altering gene expression.  
Therefore for instance many tumors evidence increased expression of VEGF 
and/or FGFs compared to their normal counterparts, by incompletely understood 
mechanisms. However this can occur by inhibition of p53 activity, or proteases, 
which can regulate the bioavailability of angiogenic activators or inhibitors, by 
either sequestering or making available these factors. 
 
Tissue invasion and metastases 
The last requirement for tumor cells to exert their dominance over normal cells is 
the ability to not only spread from the primary site, but to invade normal tissue at 
a secondary site. Metastases are the cause of ninety percent of tumor-related 
deaths in humans. Similar to the formation of the original tumor, for metastases 
to occur the same five acquired abilities are necessary. However the 
mechanisms by which this occurs are complex and not well known. Certain 
proteins that are involved in ‘adhering’ cells to their surroundings in tissue are 
altered in metastatic/invasive cells. These proteins include the cell-to-cell 
adhesion molecules (CAMs) i.e. cadherins and integrins, which mediate cell to 
extracellular matrix substrates. The most widely noted alteration to this signaling 
in cancer involves E-cadherin expressed on epithelial cells. Normally E-cadherin 
results in the transmission of antigrowth signals through the interaction with β-
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LEF/TCF transcription factor. Thus, loss of function of E-cadherin results in the 
majority of epithelial cell cancers by mechanisms that include mutational 
inactivation of E-cadherin or β -catenin genes, transcriptional repression or 
proteolysis of the extracellular cadherin domain. Forced expression in cultured 
cells and transgenic mice impairs and interference with E-cadherin function in 
both enhances tumor invasiveness and metastatic potential. Shifts in the 
spectrum of integrin α or β subunits in tumor cells are also a key feature of the 
tumor cells’ ability to successfully colonize secondary tissues. For example 
cancerous cells facilitate invasion by shifting their expression of integrins from 
those that favour the ECM present in normal epithelium to the integrins that 
preferentially bind degraded stromal components produced by extracellular 
proteases. These proteases are also necessary in this acquired ability of cancer 
cells to metastasize. Protease genes are either upregulated, or protease 
inhibitors down-regulated or inactive zymogen forms of proteases are converted 
into active enzymes. The mechanism by which this occurs is thought to be 
through the docking of active proteases on the cell surface, which can facilitate 
invasion of cancer cells into nearby stroma, across blood vessel walls and 
through normal epithelia cell layers. In summary, the activation of extracellular 
proteases and the altered binding specificities of cadherins, CAMs and integrins 















1.8 The molecular basis of HCC: signaling impairments 
As has already been stated in preceding sections, pathogenic mechanisms of 
HCC include cirrhosis and mutations of oncogenes and/or tumour suppressor 
genes. These mechanisms are linked with alterations in key cellular signaling 
pathways, including the insulin/IGF, phosphatidylinositol-3 kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR), Wnt/β-catenin, 
transforming growth factor-α/epidermal growth factor, RAF/MEK/ERK pathways 
(Whittaker, Marais, & Zhu, 2010) to mention but a few. Additionally, the key 
tenets of the development of cancer involve cell-to-cell interactions mediated by 
signaling mechanisms.  For our purposes we will limit the ensuing discussion to 
the three pathways of interest that are frequently dysregulated in HCC, i.e. the 
insulin/IGF, Wnt/β-catenin pathways and the Notch pathway, the role of which is 
not yet clearly delineated. 
 
1.8.1 Insulin/Insulin growth factor (IGF) signaling 
Normal signaling: This pathway has been conclusively shown to be involved in 
the growth and survival of multiple solid tumours (Cheng, Lindsley, Cheng, Yang, 
& Nicosia, 2005). Activation of this cascade requires the binding of insulin, IGF-1 
or 2 to the transmembrane insulin receptor, causing a conformational change in 
the intracellular portion of the receptor. This results in autophosphorylation of a 
number of tyrosine kinases present on the receptor of the β subunit.  So-called 
adaptor or docking proteins i.e. the insulin receptor substrate proteins IRS-1, 2 
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activation, these IRS proteins are recognized by a lipid kinase, the p85 regulatory 
subunit of phospho-inositol-3 kinase (PI3-K), and PI3-K phophorylates 
phophotidylinositol 3,4 biphosphate to 3, 4, 5 triphosphate. Akt is a key 
downstream effector of phosphatidylinositol 3,4,5 triphosphate, which recruits 
cytosolic enzymes to the cell membrane. Active Akt enters the cytoplasm where 
it leads to phosphorylation and subsequent inactivation of glycogen synthase 
kinase-3 (GSK-3). Inhibition of GSK-3 inactivates inhibition of glycogen 
synthesis, and thereby promotes glycogen storage.  In addition to carbohydrate 
metabolism through the action of Akt insulin signaling regulates both protein and 
lipid by promoting their anabolic properties, by increasing the uptake of fatty 
lipids and amino acids, whilst simultaneously preventing their catabolism.  
 
Impaired signaling in HCC: In HCC the insulin/IGF pathway is activated via 
overexpression of IGF-2 acting through the IGF-1R (Breuhahn et al., 2004; 
Desbois-Mouthon et al., 2009; Nussbaum et al., 2008; Sohda, Yun, Iwata, 
Soejima, & Okumura, 1996; Tovar et al., 2010) and these changes are 
associated with proliferation of tumours and/or metastases. In fact activation of 
IGF-2 may be the mechanism by which aflatoxin B1 exerts its pro-tumourigenic 
properties in HCC cell lines (Ubagai, Kikuchi, Fukusato, & Ono, 2010). Even in 
an in vivo system of IRS-1 overexpression, in association with another insult, i.e. 
alcohol exposure, there is up-regulation of IGF-2 similar to that seen in HCC 
(Longato, de la Monte, Califano, & Wands, 2008). Conversely, selective blockade 












enhanced apoptosis in HCC cells (Yao, Liu, Sheng, & Huang, 2011), decreased 
cell viability and proliferation in human HCC (Tovar et al., 2010) and reduced 
tumour cell motility and migration (Nussbaum et al., 2008). This effect has been 
interrogated in a study where salirasib, a ras/mTOR inhibitor, caused inhibition of 
HCC cell lines in vitro, and tumour growth in vivo (Charette et al., 2010), and with 
blockade of IGF1-receptor tyrosine kinase, with resultant antineoplastic effects 
(Hopfner et al., 2006). Impairments in HCC are also observed in the response of 
HCV to treatment. For instance, chemoresistance mechanisms are activated via 
the insulin signaling (Chen et al., 2011; Desbois-Mouthon et al., 2009). Thus 
signaling via IGF-2 and IGF1-R appears to be critical in HCC and therefore 
inhibition of IGF-1R can be potentially useful for the treatment of HCC. 
 
1.8.2 Wnt/β-catenin signaling 
Normal signaling: The Wnt/β-catenin pathway has important roles in motility, 
proliferation, morphology and embryogenesis, but in the adult or cancerous state, 
either up-regulates or represses genes important for cancer growth (Cadigan & 
Nusse, 1997; Korinek et al., 1998; Miller, 2002; Polakis, 2000). In the inactivated 
state, β-catenin is phosphorylated by GSK-3β and thus targeted for degradation 
by the APC complex consisting of adenomatosis polyposis coli (APC), glycogen 
synthase (GSK) 3-β, and Axin. Contrastingly, when activated, a Wnt ligand binds 
to the receptor, which binds to the frizzled (FZD)/ low-density lipoprotein receptor 
related protein (LRP) complex (Bhanot et al., 1996; Tekmal & Keshava, 1997; 
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Varmus, & Nusse, 1997). DSH in turn phosphorylates the APC complex, which 
becomes deactivated, resulting in intracellular accumulation of β-catenin, which 
translocates to the nucleus (Behrens et al., 1996) to bind to T-cell factor 
(TCF)/Lymphoid enhancing factor (LEF) family of DNA binding proteins leading 
to activation of transcription of Wnt target genes i.e. c-myc, cyclin D1 (Behrens et 
al., 1996; He et al., 1998; Tetsu & McCormick, 1999) and WISP-1.  Therefore 
when activated, the transcription of oncogenic growth factors is enhanced. In 
fact, activation/deregulation of this pathway has been observed in cancer 
including HCC. 
 
Impaired signaling in HCC: The Wnt/β-catenin pathway is a major pathway that 
is dysregulated in HCC resulting in increased proliferation and differentiation of 
tissue. Dysregulation occurs in about one third of HCCs (Takigawa & Brown, 
2008), and two thirds of HCC have increased levels of β-catenin (Wong, Fan, & 
Ng, 2001). The general mechanisms of Wnt activation in HCC include mutations 
of the APC complex (small proportion of HCC) or Axin1, promoter epigenetic 
changes that cause APC inactivation or dysregulation by overexpression of 
various ligands, receptors or polypeptides of Wnt signaling (Wong & Ng, 2008), 
Activation of Wnt signaling was observed even in Farnesoid X receptor knock-out 
mice (Wolfe et al., 2011), which spontaneously normally develop HCC, 
suggesting a strong independent risk of Wnt signaling activation. In HBV infection 
one mechanism for Wnt activation is via displacement of Wnt from the APC 












genes (Hsieh, Kim, Lim, Yu, & Jung, 2011), or via the transactivating protein 
HBx, which acts via Wnt 1 to suppress GSK-3β (Cha, Kim, Park, & Ryu, 2004). 
However, activation of Wnt occurs more readily in HCV-related HCC than in 
HBV-related HCC (Hsu et al., 2000; Huang et al., 1999; Thorgeirsson & Grisham, 
2002).  Ligand-receptor interactions were evaluated in a study, which showed 
that Wnt 3 and Frizzled 7 interacted to resukt in increased β -catenin nuclear 
transcriptional activity and that of its downstream target genes (Kim et al., 2008). 
And similar to the “two-hit” hypothesis of ALD and NAFLD, in a study where both 
IRS-1 and Hepatitis B x proteins were overexpressed in a double transgenic 
mouse model, dysplasia and HCC occurred with a higher frequency than in the 
single transgenic mice (Longato et al., 2009). In this study, there were also high 
levels of activation of Wnt 3 and Frizzled 7 in the double transgenics. 
Furthermore, similar to insulin/IGF signaling, activation of Wnt is associated with 
chemoresistance to combination therapy for HCC (Noda et al., 2009), thus 
showing evidence that it is a multi-functional oncoprotein that acts on different 
mechanisms not only to promote but to worsen the outcome of treated HCC.  
 
1.8.3 Notch signaling in HCC  
Normal signaling: Notch genes were discovered more than 30 years following 
the discovery of mutant Drosophilia with a notched wing phenotype. 
Subsequently it was discovered that this gene is highly conserved in various 
species, including C elegans and indeed humans. Notch signaling consists of cell 
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Notch domain and key downstream effectors. The main function of Notch 
signaling is the regulation of cell fate determination and differentiation that 
determines organ phenotype. Signaling through Notch is dependent on both 
canonical and non-canonical mechanisms, whereby in the former, two adjacent 
cells communicate with each other and with neighbouring or similar cells. The 
direction of the communication is dependent on which of two adjacent cells 
possesses the receptor. Under normal conditions one of the Notch ligands 
(Jagged-1, Jagged-2, DII-1, DII-3 and DII-4) which are cell surface proteins, and 
include numerous EGF-like repeats within their extracellular domains, bind to the 
transmembrane receptors (Notch1, 2, 3 and 4), thereby causing proteolytic 
cleavage of the receptors by a gamma secretase and metalloproteinase 
complex. This results in the liberation and dissociation of the Notch intracellular 
domain (NICD) from the cell membrane (F. Wang et al., 2010).  NICD 
translocates to the nucleus to activate transcription factors of the Notch target 
genes including helix-loop-helix transcription factors of the hairy and enhancer of 
split (Hes) family and the Hes-related repressor protein (Hey) family (Artavanis-
Tsakonas, Matsuno, & Fortini, 1995; Bray, 2006). The end-result of this activation 
is pro-survival and proliferative signals; this was evident in a partial hepatectomy 
rat model where activation of the NICD was associated with an increase in 
hepatocyte DNA synthesis (Kohler et al., 2004). 
 
Impaired signaling in cancer: Dysregulated Notch signaling is implicated in a 












functions as an oncogene in a variety of human cancers such as T-cell 
leukaemia, pancreatic, prostrate and breast cancer (Wang et al., 2010). 
However, the role of abnormal Notch signaling in HCC has not been extensively 
studied, may be either up or downregulated in promoting HCC and therefore 
deserves further attention. Up or downregulation of Notch, particularly Notch-1 is 
context and cell-type specific. Whereas expression of Notch-1 was suppressed in 
HCC 66% compared to adjacent peri-tumour and normal tissue (Wang et al., 
2009) and by up-regulating apoptosis by sensitizing TRAIL in HCC cells by 
inhibiting p53-mediated degradation (Wang et al., 2009), thus turning down 
oncogenic potential, some studies have shown upregulation of Notch1 and HES-
1 in HCC compared to adjacent non-tumour liver (Cantarini et al., 2006; Gao et 
al., 2008; Qi et al., 2003). Similarly studies have yielded divergent results relating 
to the role of Notch 3 and Notch 4. In one study that evaluated the expression of 
Notch receptors (3 and 4) and their downstream targets (Hes-1 and Hes-6), while 
Notch receptors were abnormally expressed in HCC tissue 78% and 68% 
respectively, Notch-3 mRNA was upregulated in 95% of HCC and Notch-4 
mRNA down-regulated in 80% HCC. HES-6 mRNA expression was higher in 
HCC than cirrhotic tissue, corresponding to increased Notch 3 upregulation 
(Gramantieri et al., 2007). In a contrasting study, which evaluated the role of 
cytoplamic and nuclear components of Notch receptors, while nuclear Notch 4 
was upregulated (p<0.05) in HCC compared to peri-tumour tissue, cytoplasmic 
Notch 3 and 4 were similar in both types of tissue. To summarize, the role of 
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cell and tissue type, molecular context, the cellular localization of Notch receptor 
i.e. cytoplasmic or nuclear and acts as both as an oncoprotein and tumour 
suppressor.  Thus its role in hepatocarcinogenesis deserves further study, as it 
may uncover mechanisms that could prove useful in detecting and/or treating 
HCC.  
 
1.9 Cross-talk of signaling cascades 
Cell-to-cell and cell-to-matrix communications are critical to how cells of different 
tissues function as a unit; therefore the role of signaling cascades is important in 
this context. It is therefore intuitive that different cascades would act in concert to 
either nullify or amplify a desired effect. Several lines of evidence show that 
some signaling cascades do in fact intersect at various points to have an effect 
on outcome. This is particularly evident in haematologic contexts, and the 
selection of stem and progenitor cells to more differentiated cell lines. For 
instance haemopoetic differentiation involves integrated, balanced and integrated 
Wnt and Notch signalling (Zhou et al., 2010). In HCC as stated previously several 
signalling cascades are dysregulated, and the majority of papers have evaluated 
each of these in isolation, with only a few exceptions where two pathways were 
simultaneously studied (Cantarini et al., 2006; M. Wang et al., 2009; Zhou et al., 
2010). Although the insulin/IGF, Wnt/β-catenin and Notch signalling pathways 
are implicated in hepatocarcinogenesis individually, there are converging points 
in their pathways where they could potentially interact. Furthermore, aspartyl-












differentiation and migration (Lasky & Wu, 2005; Yoon & Gaiano, 2005) and is 
overexpressed in many cancers (Yang et al., 2010), including HCC and is 
associated with adverse outcomes (Wang et al., 2010) AAH is linked to both 
Notch and insulin signaling by hydroxylating and enhancing the expression of 
Notch and Jagged, but is itself stimulated by insulin/IGF via the ERK/MAPK and 
PI-3K/Akt pathways (Cantarini et al., 2006; de la Monte et al., 2006; Lahousse, 
Carter, Xu, Wands, & de la Monte, 2006). In a paper by Cantarini MC et al, 
overexpression of aspartyl-(asparagyl)-beta-hydroxylase (AAH), a cell membrane 
enzyme resulted in an increase in the mRNA transcripts of IGF-1 and IGF-2, as 
well as Notch-1 and HES-1 and an interaction between AAH and Notch and 
Jagged (Cantarini et al., 2006), suggesting that there is a complex interaction 
between AAH/Notch and insulin signaling cascades. As reviewed above, insulin 
signaling is transmitted downstream by the effector kinase PI-3K, which 
phosphorylates and thereby inactivates GSK-3β, to result in glycogen storage. 
More interestingly, inhibition of GSK-3β increased AAH protein probably by 
inhibiting the phosphorylation of AAH (Carter et al., 2008). Additionally, when 
activated, Wnt signaling phosphorylates and thereby de-activates GSK-3β thus 
avoiding ubiquitination and accumulation of β -catenin. It is possible that 
deactivation of GSK-3β by Wnt could also activate AAH, in this way connecting 
the Wnt and AAH/Notch pathways.  
In a paper by Cantarini (2006), overexpression of aspartyl-(asparagyl)-beta-
hydroxylase (AAH), a cell membrane enzyme resulted in an increase in the 
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interaction between AAH and Notch and Jagged (Cantarini et al., 2006), 
suggesting that there is bi-directional regulation between AAH and insulin. 
Therefore we hypothesize that the interaction points linking this triad of signaling 
pathways, is via AAH and GSK-3β. Further lines of evidence for cross-talk and 
interactions in signaling include the HBx protein, which is known to activate 
several signaling pathways including Ras-Raf-MAPK, SAPK/JNK, PI3 K-Akt and 
Janus kinase/STAT pathways (Doria, Klein, Lucito, & Schneider, 1995; Lee & 
Yun, 1998; Natoli et al., 1994). Therefore conceivably, HBx, a promiscuous 
transactivating protein, may also interact with the insulin/IGF cascade via PI3 K-
Akt. While this hypothesis is attractive, there is a study showing that in HBV-
related liver disease, down-regulation of Notch was associated with up-regulation 
of β-catenin (r = -0.125, p = 0.023) showing an inverse relationship (M. Wang et 
al., 2009). Therefore the interactive role of these three pathways is still unclear 
and needs further elucidation. 
 In summary, the progression of CLD of any aetiology through the stages 
of chronic hepatitis, cirrhosis and subsequent transformation to HCC which 
occurs in a step-wise stage is critical to our understanding of defining which 
patients are at risk of progression, the molecular factors underlying this 
progression and the identification of early HCC. This can be achieved by 
examining dysfunctional signaling pathways especially at points of convergence 
such that multiple cascades can be potentially targeted simultaneously utilizing a 
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CHAPTER  2 
 
Limited Therapeutic Effect of N-Acetylcysteine on Hepatic 




Background:  Alcohol-related steatohepatitis is associated with increased 
oxidative stress, DNA damage, lipotoxicity, and insulin resistance in liver.   
Hypothesis: Since inflammation and oxidative stress can promote insulin 
resistance, effective treatment with anti-oxidants, e.g. N-acetylcysteine (NAC), may 
restore ethanol-impaired insulin signaling in the liver.   
Methods:  Adult male Sprague-Dawley rats were fed for 130 days with liquid diets 
containing 0% or 37% ethanol by caloric content, and simultaneously treated with 
vehicle or NAC.  Chow-fed controls were studied in parallel.  Liver tissues were 
used for histopathology, cytokine activation, and insulin/IGF-1 signaling assays.   
Results: There was a significant positive trend of increasing severity of 
steatohepatitis (P=0.016) with accumulation of neutral lipid (P=0.0002) and 
triglycerides (P=0.0004) from chow to control, to the ethanol diet, irrespective of 
NAC treatment. In ethanol-fed rats, NAC reduced inflammation, converted the 
steatosis from a predominantly micro-vesicular to a mainly macro-vesicular 












load and acid sphingomyelinase activity, and increased expression of IGF-1 and 
IGF-2 receptors and IGF-2 in liver. However, it did not abrogate ethanol-mediated 
impairments in signaling through insulin/IGF-1 receptors, IRS-1, Akt, GSK-3β, or 
p70S6K, nor did it significantly reduce pro-ceramide or GM3 ganglioside gene 
expression in liver. 
Conclusions: Anti-oxidant treatments reduce the severity of chronic alcohol-
related steatohepatitis, possibly due to decreased expression of inflammatory 
mediators and ceramide accumulation, but they do not restore insulin/IGF-1 
signaling in liver. Effective treatment of alcohol-related steatohepatitis most likely 
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2.1 INTRODUCTION 
Acute alcohol exposure causes simple hepatic steatosis, but with continued 
alcohol abuse, this relatively benign state of lipid (mainly triglyceride) accumulation 
can progress through stages of steatohepatitis, followed by fibrosis, cirrhosis, and 
finally liver failure (de Alwis & Day, 2008). In addition, chronic alcohol abuse can 
lead to hepatocellular carcinoma (HCC). Progression of alcohol-related liver 
disease (ALD) is partly mediated by impaired lipid metabolism and homeostasis, 
which lead to lipotoxicity, oxidative stress, pro-inflammatory cytokine activation, 
and insulin resistance (Carter-Kent, Zein, & Feldstein, 2008; Farrell & Larter, 
2006).  Lipotoxic states themselves activate pro-apoptotic, anti-growth, and anti-
survival pathways, and they compromise reparative and regenerative mechanisms 
in the liver (Day, 2006; Day & James, 1998).   
Growing evidence suggests that ceramides are key mediators of lipotoxicity 
with attendant increased inflammation, oxidative stress, and insulin resistance in 
both ALD and non-alcoholic fatty liver disease (Chavez et al., 2003; Fernandez-
Checa, Colell, Mari, & Garcia-Ruiz, 2005; Holland et al., 2007; Pickersgill, 
Litherland, Greenberg, Walker, & Yeaman, 2007; Schutze et al., 1992).  
Ceramides constitute a family of lipids generated from fatty acid and sphingosine 
(Liu, Obeid, & Hannun, 1997; Reynolds, Maurer, & Kolesnick, 2004; Summers, 
2006; Tilg & Hotamisligil, 2006).  Ceramides are distributed in cell membranes, and 
in addition to their structural functions, regulate signaling pathways that mediate 
growth, proliferation, motility, adhesion, differentiation, senescence, and apoptosis.  
Ceramides are generated biosynthetically through the actions of ceramide 
synthase and serine palmitoyltransferase (Hannun, Luberto, & Argraves, 2001; 
Hauck et al., 2000; Laviad et al., 2008; Mizutani, Kihara, & Igarashi, 2005; Shah et 












sphingomyelinase activity (Holland et al., 2007; Reynolds et al., 2004; Shah et al., 
2008). Sphingomyelinases are activated by pro-inflammatory cytokines, e.g. TNF-
α (Carter-Kent et al., 2008; Summers, 2006), and pro-apoptotic stimuli including 
ionizing radiation, Fas, and trophic factor withdrawal (Hannun & Obeid, 2002; Liu 
et al., 1997; Marchesini & Hannun, 2004; Reynolds et al., 2004).  Ceramides 
impair cellular functions and cause apoptosis by: 1) modulating the 
phosphorylation states of various proteins, including those that regulate insulin 
signaling (Silveira et al., 2008); 2) activating enzymes such as interleukin-1β 
converting enzyme (ICE)-like proteases, which promote apoptosis (Smyth et al., 
1996); and 3) inhibiting Akt phosphorylation and kinase activity (Chalfant et al., 
1999; Summers, Garza, Zhou, & Birnbaum, 1998; Zhou, Summers, Birnbaum, & 
Pittman, 1998) through activation of protein phosphatase 2A (Chalfant et al., 1999; 
Dobrowsky, Kamibayashi, Mumby, & Hannun, 1993).   
Free fatty acid accumulation in hepatocytes stimulates lipogenesis, and 
factors related to increased stress promote lipotoxicity, which leads to oxidative 
stress and cell death (Marra, Gastaldelli, Svegliati Baroni, Tell, & Tiribelli, 2008). 
Oxidative stress itself plays a key role in the progression of simple steatosis to 
steatohepatitis, and the eventual activation pro-fibrogenic cascades (Albano, 2008; 
Dowman, Tomlinson, & Newsome, 2010).  Susceptibility to oxidative and radical 
injury rests on maintaining a balance between pro-oxidant and anti-oxidant factors.  
Glutathione (GSH) is a radical scavenger and key attenuator of oxidative stress in 
liver, and hepatic glutathione levels are reduced in both ALD and non-alcoholic 
fatty liver disease (Das, Balakrishnan, Mukherjee, & Vasudevan, 2008; Videla et 
al., 2004).  N-acetylcysteine (NAC), one of the anti-oxidants used to manage acute 
liver failure caused by acetaminophen poisoning (Marzullo, 2005), acts by donating 
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Atkuri, Mantovani, & Herzenberg, 2007). Therefore, NAC therapy may reduce liver 
injury and progression from simple steatosis to steatohepatitis in ALD. Reduced 
inflammation and severity of steatohepatitis effectuated by NAC or other anti-
inflammatory agents could lead to decreased generation of toxic lipids, including 
ceramides, and consequently improve hepatic insulin sensitivity. The present study 
utilizes a rat model of chronic ethanol feeding to evaluate the potential use of NAC 
for reducing the severity of alcohol-related steatohepatitis, lipotoxicity, pro-












2.2 MATERIALS AND METHODS 
Materials:  The bicinchoninic acid (BCA) kit to measure protein concentration was 
purchased from Pierce Chemical Co (Rockford, IL).  Histochoice fixative was 
purchased from Amresco, Inc (Solon, OH).  Nile Red fluorescent dye, the Amplex 
Red Cholesterol Assay Kit, Amplex UltraRed soluble flourophore, and the Akt 
Pathway Total and Phospho 7-Plex panels were purchased from Invitrogen 
(Carlsbad, CA).  Triglyceride Reagent Kit was purchased from Analox Instruments 
Ltd (London, UK).  The rat cytokine Milliplex xMAP ELISA kit was purchased from 
Millipore (Billerica, MA).  Maxisorp 96-well plates used for enzyme-linked 
immunosorbant assays (ELISAs) were from Nunc (Thermo Fisher Scientific; 
Rochester, NY). Superblock-TBS, horseradish peroxidase conjugated antibodies, 
and SuperSignal Enhanced Chemiluminescence Reagent was from Pierce 
Chemical Co (Rockford, IL).  Monoclonal anti-ceramide and synthetic 
oligonucleotides used in quantitative polymerase chain reaction (qPCR) assays 
were purchased from Sigma-Aldrich Co (St. Louis, MO).  All other antibodies and 
immunodetection reagents were purchased from Abcam (Cambridge, MA), Upstate 
(Billerica, MA), Vector Laboratories (Burlingame, CA), Invitrogen (Carlsbad, CA) or 
Chemicon (Temecula, CA).  Fine chemicals were purchased from CalBiochem 
(Carlsbad, CA), or Sigma-Aldrich (St Louis, Mo).  QIAzol Lysis Reagent for RNA 
extraction and QuantiTect SYBR Green PCR Mix were obtained from Qiagen, Inc 
(Valencia, CA).  The AMV 1st Strand cDNA Synthesis Kit was purchased from 
Roche Applied Science (Indianapolis, IN).     
Experimental Model: We utilized the Tsukamoto and French intra-gastric feeding 
model of total enteral nutrition (TEN) to administer the control or ethanol-containing 
liquid diets (Baumgardner, Shankar, Hennings, Badger, & Ronis, 2008; Ronis et 
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model, the entire range of pathological changes, including steatosis, 
steatohepatitis, and fibrosis, can be produced in rodents (Nanji & French, 2003).  
In brief, adult male Sprague Dawley rats were fitted with intra-gastric cannulae to 
infuse isocaloric TEN liquid diets (187 kcal/kg/day) containing 0% (N=18) or 37% 
(N=14) ethanol (caloric content) (Table 1).  Ethanol was substituted for 
carbohydrates (12 g/kg/day).  In subsets of control (N=9) and ethanol (N=7) fed 
rats, NAC (1.2 g/kg/day) was added to the diets.  Chow-fed controls (ad libitum) 
were studied in parallel (N=7).  Diets were adjusted weekly to maintain similar 
weights among the experimental groups, and after 130 days of feeding, rats were 
sacrificed and livers were harvested for study (Ronis et al., 2010).  Liver tissue was 
immersion fixed in Histochoice and embedded in paraffin for histopathological 
studies.  Fresh snap frozen tissue was used for biochemical and molecular 
analyses.  Our experimental protocol was approved by the ‘Institutional Animal 
Care and Use Committee’ of the University of Arkansas for Medical Sciences.  The 
protocol was compliant with NIH guidelines provided in the Guide for the Care and 




















Table 1:  Composition of diets  
Diet Name Composition 
1 Chow Chow ad libitum 
2 Control TEN  Diet containing 41% carbohydrates and 43% fat 
3 Control TEN+ 
NAC 
Diet containing 41% carbohydrates, 43% fat and NAC  
(1.2 g/kg/day) 
4 EtOH TEN Diet containing 36% carbohydrates from ethanol and 43% fat 
5 EtOH TEN+NAC Diet containing 36% carbohydrates from ethanol, 43% fat and NAC  
(1.2 g/kg/day) 
 *Abbreviations: TEN, Total Enteral Nutrition; NAC, N-Acetylcysteine; EtOH, Ethanol 
 
Histopathology: Histological sections (5 µm thick) were stained with Haematoxylin 
and Eosin (H&E) and scored under code by a pathologist using a semi-quantitative 
scale (1-4) to assess severity and extent of macro- and micro-steatosis, 
inflammation, and necrosis (including apoptotic bodies) (Table 2).  The scoring 
system was graded as follows: 1=no significant abnormalities, i.e. expected cord-
like architecture, minimal or absent inflammation, necrosis, apoptosis or 
anisocoria; 2=mild pathological changes, i.e. micro- and macrosteatosis affecting 
less than 25% hepatocytes, slight derangement of the cord-like architecture, rare 
scattered foci of inflammation near portal areas; and absent necrosis/apoptosis; 
3=moderate steatohepatitis with 25-50% micro- or macrosteatosis, moderate 
disruption of the cord-like architecture, inflammation extending into lobules, and 
conspicuous foci of apoptosis; and 4=severe steatohepatitis with micro- and 
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Table 2: Liver histopathology scoring system 
Grade Classification Features 
1 Normal Normal liver cords, absent or minimal steatosis, inflammation, 
necrosis or apoptosis. 
2 Mild Slight derangement of the cord-like architecture, micro- or 
macrosteatosis affecting < than 25% hepatocytes, rare scattered 
foci of inflammation near portal areas and absent 
necrosis/apoptosis. 
3 Moderate Moderate disruption of the cord-like architecture, 25-50% 
hepatocytes with micro- or macrosteatosis, inflammation extending 
into lobules, and conspicuous foci of apoptosis. 
4 Severe Marked architectural distortion, micro- and/or macrosteatosis 
involving > than 50% of parenchyma, severe inflammation with 
evidence of apoptotic bodies and foci of necrosis. 
*Adapted from Brunt (1999). This semi-quantitative grading scheme was used to evaluate liver 
histopathology in Sprague-Dawley adult male rats that were subjected to chronic feeding with control 
or ethanol-containing total enteral nutrition (TEN) diets and concomitant treatment with vehicle or 
NAC. Chow fed controls were simultaneously studied. The liver histopathology was reviewed under 














Lipid studies: Lipids were extracted from fresh frozen liver with 2:1 chloroform-
methanol (Lyn-Cook et al., 2009). Lipid content was measured using the Nile red 
fluorescence-based microplate assay as described (Lyn-Cook et al., 2009).  
Cholesterol was measured with the Cholesterol Amplex Red kit, and triglycerides 
were measured using the Analox Instruments GM7 Analyzer.  Results were 
normalized to sample weight.  Ceramide immuoreactivity was measured in lipid 
extracts using a direct-binding ELISA (Brade, Vielhaber, Heinz, & Brade, 2000).  In 
brief, duplicate 50 µl samples were dried onto the bottom surfaces of 96-well 
Polysorb plates. Samples were blocked for 1 hour at r om temperature with 
Superblock-TBS.  The samples were incubated with mouse monoclonal anti-
ceramide (2.0 µg/ml) overnight at 4°C with gentle platform agitation.  
Immunoreactivity was detected with horseradish peroxidase-conjugated anti-
mouse IgG (1:10000) and enhanced chemiluminescence substrate. Luminescence 
was quantified in a Topcount machine.  Between steps, the wells were washed 3 
times with PBS (Brade et al., 2000).  C6 synthetic ceramide (500 ng) served as a 
positive control.  Negative controls included reactions in which the primary or 
secondary antibody was omitted.  
Multiplex ELISA: We used bead-based multiplex ELISAs to examine the integrity of 
insulin and IGF-1 signaling networks, or measure immunoreactivity to selected pro-
inflammatory cytokines and chemokines in liver tissue. With regard to insulin/IGF-1 
signaling, we measured immunoreactivity to the insulin receptor (IR), IGF-1 
receptor (IGF-1R), IRS-1, Akt, glycogen synthase kinase 3β (GSK-3β), p70S6 
kinase (p70S6K), and proline-rich Akt substrate 40 (PRAS40), and their 
phosphorylated counterparts pYpY1162/1163-IR, pYpY1135/1136-IGF-1R, pS312-IRS-1, pS473-
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manufacturer's protocol.  Regarding pro-inflammatory cytokine and chemokine 
activation, we measured immunoreactivity to interleukin (IL) 1β, IL-2, IL-4, IL-6, 
TNF-α, GM-CSF, GRO/KC, and VEGF. Liver tissues were homogenized in buffer 
containing 50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 2 mM EGTA, 10 mM EDTA, 
100 mM NaF, 1 mM Na4P2O7, 2 mM Na3VO4, and protease and phosphatase 
inhibitors (Lyn-Cook et al., 2009). Samples containing 200 ng protein were 
incubated with the beads, and capture antigens were detected with biotinylated 
secondary antibody and phycoerythrin-conjugated Streptavidin. Plates were read 
in a Bio-Plex 200 system (Bio-Rad, Hercules, CA). Data are expressed as 
fluorescence light units corrected for protein concentration. 
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Assays:  Liver tissue was homogenized in QIAzol reagent. RNA isolated using the 
EZ1 RNA Universal Tissue Kit and the BIO Robot EZ1 (Qiagen Inc., Valencia, CA), 
was reverse transcribed with random oligodeoxynucleotide primers and the AMV 
First Strand cDNA synthesis kit. The cDNAs were used to measure gene 
expression by qPCR with gene-specific primer pairs (Table 3).  Primers were 
designed using MacVector 10 software (MacVector, Inc., Cary, NC) and target 
specificity was verified using NCBI-BLAST (Basic Local Alignment Search Tool).  
The Master ep realplex instrument and software (Eppendorf AG, Hamburg, 
Germany) were used to detect amplified signals from triplicate reactions.  Relative 
mRNA abundance was calculated from the ng ratios of specific mRNA to 18S 
measured in the same samples (Moroz, Tong, Longato, Xu, & de la Monte, 2008). 
Template-free reactions served as negative controls.  
Statistical Analysis: Data depicted in box plots reflect group median, 95% 
confidence interval limits and range (whiskers), while tabulated data reflect means 












analysis of variance (ANOVA) with Tukey post-hoc tests.  In addition, we 
performed linear trend analysis to gauge the impact of ethanol relative to chow and 
control TEN with regard to severity of steatosis, lipid/triglyceride accumulation, and 
ceramide immunoreactivity in liver. Data were analyzed using GraphPad Prism 5 
software (GraphPad Software, Inc., San Diego, CA).  Significant P-values (<0.05) 
























64	  |	  P a g e 	  
	  
Table 3:  Rat Primer Pairs Used for qRT-PCR Assays  





Insulin For TTC TAC ACA CCC AAG TCC CGT C 145 135 
Insulin Rev ATC CAC AAT GCC ACG CTT CTG C 279  
Insulin Receptor For TGA CAA TGA GGA ATG TGG GGA C 875 129 
Insulin Receptor Rev GGG CAA ACT TTC TGA CAA TGA CTG   1003  
IGF-1 For GAC CAA GGG GCT TTT ACT TCA AC 65 127 
IGF-1 Rev TTT GTA GGC TTC AGC GGA GCA C 191  
IGF-1 Receptor  For GAA GTC TGC GGT GGT GAT AAA GG    2138 113 
IGF-1 Receptor  Rev TCT GGG CAC AAA GAT GGA GTT G    2250  
IGF-2 For CCA AGA AGA AAG GAA GGG GAC C  763 95 
IGF-2 Rev GGC GGC TAT TGT TGT TCA CAG C  857  
IGF-2 Receptor For TTG CTA TTG ACC TTA GTC CCT TGG   1066 91 
IGF-2 Receptor Rev AGA GTG AGA CCT TTG TGT CCC CAC   1156  
IRS-1 For GAT ACC GAT GGC TTC TCA GAC G  604 134 
IRS-1 Rev TCG TTC TCA TAA TAC TCC AGG CG  737  
IRS-2 For CAA CAT TGA CTT TGG TGA AGG GG 255 109 
IRS-2 Rev TGA AGC AGG ACT ACT GGC TGA GAG 263  












IRS-4 Rev TGT GTG GGG TTT AGT GGT CTG G 2540  
Cytokine signaling 
IL-1β For CAC AGT TGC TGG CTC ATC AT 233 60 
IL-1β Rev CTT CTC CAC AGC CAC AAT GA 292  
IL-2 For CAC TTG GAA GAC GCT GGA A 309 111 
IL-2 Rev        CAC AGT TGC TGG CTC ATC AT 419  
IL-6 For ATG TTG TTG ACA GCC ACT GC 116 51 
IL-6 Rev GTC TCC TCTCCG GAC TTG TG 166  
TNF-α For ATG TGG AAC TGG CAG AGG AG 26 84 
TNF-α Rev AGA AGA GGC TGA GGC ACA GA  109  
Ceramide signaling 
SPTLC-1 For CTA ACC TTG GGC AAA TCG AA    2581 96 
SPTLC-1 Rev TGA GCA GGG AGA AGG GAC TA    2676  
SPTLC-2 For GGA CAG TGT GTG GCC TTT CT   1823 50 
SPTLC-2 Rev TCA CTG AAG TGT GGC TCC TG   1872  
SMPD-1 For CAG TTC TTT GGC CAC ACT CA   1443 65 
SMPD-1 Rev CGG CTC AGA GTT TCC TCA TC   1507  
SMPD-3 For TCT GCT GCC AAT GTT GTC TC    2704 98 
SMPD-3 Rev CCG AGC AAG GAG TCT AGG TG    2801  
CERS-1 For TGC GTG AAC TGG AAG ACT TG 947 98 
CERS-1 Rev CTT CAC CAG GCC ATT CCT TA  1044  
CERS-2 For CTC TGC TTC TCC TGG TTT GC  698 82 
CERS-2 Rev CCA GCA GGT AGT CGG AAG AG  779  
CERS-4 For CGA GGC AGT TTC TGA AGG TC   1240 72 
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UGCG For GAT GCT TGC TGT TCA CTC CA   2682 67 
UGCG Rev GCT GAG ATG GAA GCC ATA GG   2748  
CERD2 For TCC TAA TCC ACA CGG GAG AG 1523 50 
CERD2 Rev ATC TGG TTG CCA AGG ATG AG 1572  
CERD3 For AGG TGT GAC AAT GTG CGT GT 590 53 
CERD3 Rev CAC CAA AGG CCA GAG AAG AG 642  
GM3 
SYNTHASE 
For TGT CGG ACG CTG AAT ACT ACG C  1237 142 
GM3 
SYNTHASE 
Rev TCT GCC ACC TGC TTC CAA AAG  1378  
ATF-4 For GAG TCC TAC CTG GGC TCT CC 712 90 
ER Stress signaling  
ATF-4 Rev AGA ACC ACG AGG AAC ACC TG 801  
GRP78 For AGC CCA CCG TAA CAA TCA AG  1430 96 
GRP78 Rev CAG GAG GGA TTC CAG TCA GA  1525  
CHOP For CAT GAA CTG TTG GCA TCA CC 669 96 
CHOP Rev CAG CAT GTG CAC TGG AGA TT 764  
18S rRNA For GGA CAC GGA CAG GAT TGA CA 1278 50 
18S rRNA Rev ACC CAC GGA ATC GAG AAA GA 1327  
 
*Abbreviations: qPCR, Quantitative Polymerase Chain Reaction; IGF, Insulin Growth Factor; IRS, 
Insulin Receptor Substrate; SPTLC, Serine Palmitoyltransferase; CERS, Ceramidase Synthase; 
SMPD, Sphingomyelin Phosphodiesterase; CERD, N-acylsphingosine Amidohydrolase 
(Ceramidase); UGCG, UDP-Glucose Ceramide Glucosyltransferase; IL, Interleukin; TNF, Tumour 












homologous protein; GRP78, glucose regulated protein 78;  rRNA, ribosomal RNA;  For, forward 
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2.3 RESULTS 
General characteristics of the model (Ronis et al., 2010):  Previous studies using 
samples from this model demonstrated significantly increased serum levels of 
alanine aminotransferase (ALT) activity and hepatic apoptosis indices and 
endonuclease G immunoreactivity in ethanol-exposed relative to chow and TEN-
fed controls (Table 4). Treatment with NAC significantly reduced serum ALT and 
hepatic apoptosis and endonuclease G staining in ethanol-fed rats.   
 
 
Table 4: Effects of ethanol and NAC on markers of hepatocellular 
injury 
 
Group ALT1 (serum) Apoptosis (TUNEL2) Endonuclease G3 
Chow 42.50 ± 4.10a 0.055 ± 0.05a 5500 ± 1000a 
Control TEN 45.40 ± 3.40a 0.135 ± 0.03b 8000 ± 1000a,b 
Control TEN+NAC 48.88 ± 6.90a 0.160 ± 0.04b 7800 ± 3000a,b 
EtOH TEN 105.37 ± 23.0b 0.197 ± 0.05b 15100 ± 8100b 
EtOH TEN+NAC 64.20 ± 16.80a 0.070 ± 0.02a 12000 ± 3500b 
 
1ALT = alanine aminotransferase activity (U/L), 2TUNEL as measure by % positive cells, 
3Endouclease G measured the staining intensity per cell. Data are represented as mean ± SEM. 
Column means without a common superscript letter are significantly different (P<0.05) by one-















Chronic ethanol exposure significantly reduced hepatic glutathione and increased 
bovine serum albumin adducted with malondialdehyde and lipid peroxide, while 
concomitant treatment with NAC inhibited these effects of alcohol on oxidative 
stress mediators. The levels of thiobarbituric-reactive products in liver were 
unaffected by ethanol exposure or NAC treatment (Table 5).  
 
 
Table 5: Effects of ethanol and NAC on hepatic CYP2E1 activity and oxidative 
stress 
 
Group Glutathione1 TBARS2 BSA-MDA3 BSA-LOOH4 
Chow 27.34 ± 4.54b 0.59 ± 0.30 0.30 ± 0.02b 0.19 ± 0.02a 
Control TEN 22.50 ± 2.24b 0.55 ± 0.50 0.22 ± 0.01a 0.24 ± 0.01a 
Control TEN+NAC 26.59 ± 6.70b 0.70 ± 0.50 0.24 ± 0.02a 0.22 ± 0.02a 
EtOH TEN 18.20 ± 0.78a 0.75 ± 0.80 0.44 ± 0.02c 0.42 ± 0.03b 
EtOH TEN+NAC 31.44 ± 3.35b 0.74 ± 0.40  0.34 ± 0.01b 0.29 ± 0.02a 
 
1Glutathione (GSH) measured in nmol GSH per mg protein, 2TBARS = thiobarbituric acid-reactive 
products/g liver in nmol, 3BSA-MDA = Antibody titer against bovine serum albumin (BSA) adducted 
with malondialdehyde, 4BSA-LOOH = Antibody titer against BSA adducted with lipid peroxide. Data 
are represented as mean ± SEM. Column means without a common superscript letter are 
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Chronic ethanol exposure increased the expression of pro-fibrogenesis genes 
(mRNAs), but did not significantly alter hepatic hydroxyproline content. Quantitative 
RT-PCR analysis detected significantly elevated levels of α-1collagen Types I and 
III, and matrix metalloproteinase (MMP) 3, MMP-9, and MMP-13, but not TIMP-1 in 
ethanol-exposed relative to control livers (Table 6). Concomitant NAC treatment 
significantly reduced hepatic expression of MMP-9 in ethanol-exposed livers, but 





























Table 6: Effects of ethanol and NAC on hepatic hydroxyproline content and 





Type I mRNA2 
α-1 collagen Type 
III mRNA2 




Chow 1.70 ± 0.40 1.00 ± 0.25a 1.00 ± 0.07a 1.00 ± 0.14a 1.00 ± 0.50a 1.00 ± 0.20a 1.00 ± 0.43 
Control TEN 2.32 ± 0.50 1.29 ± 0.11a 1.23 ± 0.09a 1.67 ± 0.27a 1.42 ± 0.07a 3.20 ± 0.62a 1.30 ± 1.27 
Control TEN+NAC 2.02 ± 0.40 1.30 ± 0.12a 1.34 ± 0.27a 5.72 ± 1.97a 5.17 ± 2.32a 3.47 ± 2.21a 1.21 ± 0.44 
EtOH TEN 2.97 ± 1.15 2.62 ± 0.65b 1.97 ± 0.21b 4.82 ± 1.42a,b 7.51 ± 3.25a,b 5.60 ± 1.98a 2.24 ± 0.96 
EtOH TEN+NAC 1.96 ± 0.60 2.59 ± 0.70b 2.82 ± 0.49b 6.52 ± 1.47b 2.78 ±3.14b 13.80 ± 3.36b 1.18 ± 0.23 
 
1Hydroxyproline measured in % per protein content, 2mRNA data as measured by RT-PCR expressed as 
gene expression normalized to expression of 18S. Data are represented as mean ± SEM. Column 
means without a common superscript letter are significantly different (P<0.05) by one-way ANOVA 
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Effects of ethanol and NAC on steatohepatitis: H&E stained sections of chow-fed 
livers demonstrated the expected cord-like architecture with minimal or absent 
portal lympho-mononuclear inflammatory cell infiltrates, and scattered hepatocytes 
with macrosteatosis (Figures 2.1 A, F, K).  Control-TEN livers exhibited micro-
vesicular steatosis that was predominantly distributed in Zone 2, but extended 
close to Zones 1 and 3.  In addition, control-TEN livers contained small foci of 
lobular lympho-mononuclear cell inflammation and scattered apoptotic bodies and, 
the regular cord-like architecture was mildly disrupted (Figures 2.1 B, G, L).  
Treatment of control-TEN rats with NAC converted the predominantly micro-
steatosis to macrosteatosis, and minimized the inflammation.  However, the 
presence of scattered apoptotic bodies and mildly disrupted hepatic cord 
architecture persisted despite NAC treatment (Figures 2.1 C, H, M).  
Chronic ethanol feeding caused moderate to severe steatohepatitis that was 
pan-lobular, i.e. distributed from Zone 1 through Zone 3, and mainly micro-
vesicular in nature (Figures 2.1 D, I, N).  Inflammation was prominent, multi-focal, 
and nodular. Apoptotic bodies were abundant, and the hepatic architecture was 
markedly disorganized.  Co-treatment with NAC reduced the inflammation and 
converted the predominantly micro-vesicular steatosis to mainly macro-vesicular 
steatosis (Figures 2.1 E, J, O).  Semi-quantitative grading of the liver histology 
under code, using the 1 to 4 scale (see Methods) revealed a significant trend of 
increasing severity of steatohepatitis, with minimal injury observed in chow-fed 
rats, to mild or moderate disease in the control-TEN group, to severe liver injury in 
the ethanol-TEN fed rats (P=0.0157; Figure 2.2 A). Overall, there were no 
discernible effects of the NAC treatments on the mean scores assigned to livers of 















Figure 2.1:  Effects of chronic ethanol feeding and NAC treatment on steatohepatitis. Adult 
male Sprague-Dawley rats were fed for 130 days with chow (A, F, K), control TEN (B, G, L), control 
TEN supplemented with NAC (C, H, M), ethanol TEN (37% by caloric content; D, I, N), or ethanol 
TEN supplemented with NAC (E, J, O).  Paraffin-embedded histological sections (5 µm thick) of 
liver were stained with H&E and photographed at 40x (A-E), 160x (F-J), and 400x (K-O) 
magnifications.  Note reduced inflammation and shift from microvesicular steatosis to 
macrovesicular steatosis associated with NAC treatments, but persistence of hepatic cord 
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Hepatic steatosis was further characterized by measuring neutral lipid, 
triglyceride, cholesterol, and ceramide content. The Nile Red assay demonstrated 
generally higher mean levels of neutral lipids in livers of TEN-fed relative to chow-
fed rats. A borderline significant trend was observed indicating increased hepatic 
neutral lipid accumulation with respect to diet and ethanol feeding, i.e. from chow, 
to control-TEN, and then ethanol-TEN feeding (P=0.05; R2=0.097).  In addition, 
chronic ethanol feeding, with or without NAC treatment, significantly increased 
hepatic neutral lipid content relative to chow-fed but not TEN-fed controls (Figure 
2.2 B). With regard to triglycerides, a significant positive trend for increasing 
hepatic triglyceride content with respect to treatment group (Chow < Control TEN < 
Ethanol TEN) was demonstrated (R2=0.29; P=0.0004). The mean hepatic 
triglyceride content was significantly higher in the control-TEN and ethanol-TEN 
relative to chow fed rats, irrespective of NAC treatment (all P<0.01; Figure 2.2 C). 
In contrast, mean hepatic cholesterol levels were similar in all 5 groups (Figure 2.2 
D). This result differs from findings in other studies in which chronic ethanol 
feeding significantly increased hepatic cholesterol levels (Wang, Yao, & Song, 
2010). However, our result could be due to the use of TEN rather than a standard 
Lieber-De Carli diet. Finally, although no significant trend relating diet or treatment 
to hepatic ceramide content was observed, ANOVA tests demonstrated significant 
inter-group differences (P=0.007) with the highest level in the ethanol-TEN group, 
and significant differences in the mean levels between ethanol-TEN and ethanol-
TEN+NAC (P<0.05; Figure 2.2 E). This indicates that ethanol-induced increases in 




























Figure 2.2: Lipid and ceramide accumulations in liver following chronic ethanol and NAC 
treatment.  (A) Severity of hepatic steatosis observed in H&E stained histological sections was 
graded blind on a scale from 1 to 4.  (B-E) Lipid extracted from fresh frozen liver tissue was 
analyzed for (B) neutral lipid content using the Nile Red assay, (C) triglycerides, (D) cholesterol, or 
(E) ceramide immunoreactivity (see Material and Methods), and values were normalized to tissue 
sample weight or protein content. Box plots depict medians (horizontal bars), 95% confidence 
interval limits, and range (whiskers).  Inter-group comparisons were made using one-way ANOVA 
with the Tukey multiple comparison and linear trend post hoc tests.  Significant P-values are 
indicated within the panels. Significant post-hoc linear trend analysis results are shown in the upper 
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To determine if increased hepatic ceramide was mediated by increased pro-
ceramide gene expression or sphingomyelinase enzymatic activity, we measured 
mRNA levels of ceramide synthases 1, 2, and 4 (CERS), ceramidase 2 and 3 
(CERD), serine palmitoyl transferase 1 and 2 (SPTLC), and sphingomyelinase 1 
and  3 (SMPD), UDP-glucose ceramide glucosyltransferae (UGCG), and GM3 
synthase by qRT-PCR analysis (Table 7), and acid (ASMase) and neutral 
(NSMase) sphinogmyelinase activities using a commercial assay (Invitrogen, 
Carlsbad, CA) (Figure 2.3).  The genes selected for analysis were based on 
previous studies demonstrating which mRNA transcripts were modulated with 
increasing steatohepatitis in animal models (de la Monte, Tong, Lawton, & 
Longato, 2009; Lyn-Cook et al., 2009; Shah et al., 2008). However, in the present 
study, similar mean levels of CERS2, CERD2, SPTLC2, and SMPD1 were 
measured in all experimental groups (Table 7).  On the other hand, ASMase 
activity was significantly elevated in livers from control-TEN+NAC, ethanol-TEN, 
and ethanol-TEN+NAC relative to chow fed rats (Figure 2.3 A). Moreover, ethanol-
TEN feeding significantly increased ASMase activity relative control-TEN, while 
NAC treatment abolished that difference. The mean levels of NSMase activity were 
similar in the five study groups (Figure 2.3 B). These findings suggest that NAC 
treatment may reduce hepatic ceramide accumulation in ALD through inhibition of 

















Table 7: Effects of Chronic Ethanol Feeding and Treatment with NAC on pro-
Sphingolipid Gene Expresson in Liver 
 
GENE Chow Con TEN Con TEN + 
NAC 
EtOH TEN EtOH TEN + 
NAC 
F-Ratio p-Value 

























































b*** ± 0.0328 
38.30 <0.0001 








































































*Abbreviations: Con, Control; TEN, Total Enteral Nutrition; NAC, N-Acetylcysteine; EtOH, Ethanol; CERS, 
Ceramide Synthase; CERD, N-acylsphingosine Amidohydrolase (Ceramidase); SPTLC, Serine 
Palmitoyltransferase; SMPD, Sphingomyelin Phosphodiesterase; UGCG, UDP-Glucose Ceramide 
Glucosyltransferase; GM3SYN, GM3 Synthase. Gene expression was measured by qPCR using gene-
specific primers (Table 3) and levels were normalized to 18S rRNA measured in the same samples. 
Results depict mean ± SEM of mRNA/18S rRNA (x10-6) calculated for each group. Inter group statistical 
comparisons were made by one-way ANOVA with the Kruskal-Wallis post-hoc test. Superscripted letters 
indicate inter-group differences that are statistically significant, *p <0.05; **p < 0.01; ***p < 0.001 relative to 

























Figure 2.3:  Role of sphingomyelinase activity as a mediator of increased hepatic ceramide 
levels following chronic ethanol feeding, and therapeutic effects of NAC. (A) Acid (ASMase) and (B) 
neutral (NSMase) sphingomyelinase activities were measured using a standard fluorometric assay 
and results were normalized to protein concentration.  Inter-group comparisons were made using 
one-way ANOVA with the Tukey multiple comparison tests.  Significant P-values are indicated 















Effects of ethanol and NAC treatments on cytokine levels in liver: Activation of pro-
inflammatory cytokines, including TNF-α, IL-6, and IL-1β, is a common feature of 
steatohepatitis (Carter-Kent et al., 2008; Larter & Farrell, 2006; McClain, Barve, 
Deaciuc, Kugelmas, & Hill, 1999; McClain & Cohen, 1989; Tilg & Hotamisligil, 
2006).  In addition, ALD is associated with increased levels of GRO/KC (Maltby, 
Wright, Bird, & Sheron, 1996; Ohki et al., 1998; Shiratori et al., 1993), which is a 
small CXC cytokine with mitogenic properties that mediates inflammation and 
angiogenesis (Haskill et al., 1990).  We measured hepatic levels of these 
cytokines, plus IL-2, IL-4, GM-CSF, and VEGF by multiplex ELISA to determine the 
degree to which chronic ethanol feeding stimulates pro-inflammatory states and 
angiogenesis, and whether NAC treatment reduces cytokine activation. The 
studies demonstrated similar mean levels of TNF-α, IL-4, IL-6, and VEGF overall 
among the five study groups (Table 8; Figure 2.4). IL-1β expression was 
significantly higher in livers of control-TEN (P=0.036) but not in ethanol-TEN 
relative to chow fed rats (Figure 2.4 A). IL-2 expression was significantly higher in 
livers of ethanol-TEN ± NAC treated compared with chow-fed rats (P<0.05). 
Although the expression levels of GM-CSF and GRO/KC were generally higher in 
livers of control- and ethanol-TEN fed relative to chow-fed rats, significant 
differences were o ly observed between the chow and control-TEN fed groups 
(Table 4, P=0.001; and P=0.012 respectively). In aggregate, we observed 
significantly increased IL-2 immunoreactivity in ethanol-TEN fed rats relative to 
controls, but minimal or no significant modulation of pro-inflammatory cytokine 
expression mediated by the NAC treatments (Figure 2.4 B). mRNA levels of 
CYP2E1 were generally higher in the ethanol compared to the vehicle TEN group, 
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Effects of ethanol and NAC on insulin and IGF signaling mechanisms in liver:  
Previous studies demonstrated that steatohepatitis produced by high fat diet or 
chronic ethanol feeding impairs insulin and IGF signaling in the liver (de la Monte 
et al., 2008; Svegliati-Baroni et al., 2006; Yeon, Califano, Xu, Wands, & De La 
Monte, 2003). We re-investigated this concept and also interrogated the potential 
therapeutic effects of NAC on ethanol-mediated inhibition of insulin/IGF signaling 
by measuring mRNA levels of insulin, IGF-1, and IGF-2 polypeptides, their 
corresponding receptors, and IRS-1, IRS-2, and IRS-4 by qRT-PCR analysis 
(Figure 2.5), and IR, pYpY1162/1163-IR, IGF-1R, pYpY1135/1136-IGF-1R, IRS-1, pS312-IRS-
























Table 8: Influence of Chronic Ethanol Feeding and NAC on Pro-Inflammatory Cytokine 
Levels in Liver 
 *Abbreviations: C, Control; TEN, Total Enteral Nutrition; IL-4, Int rleukin 4; GM-CSF, Granulocyte 
 Macrophage Colony-Stimulating Factor; GRO/KC, CXC Chemokine; VEGF, Vascular Endothelial Growth 
 Factor. Effects of chronic ethanol and NAC treatment on pro-inflammatory cytokine expression in liver. Liver 
 protein homogenates were used to measure immunoreactivity to IL-4, GM-CSF, GRO/KC and VEGF by 
 multiplex ELISA. Immunoreactivity was normalized to protein concentration and data reflect mean ± SEM of 
 fluorescence light units (arbitrary). Inter-group comparisons were detected with the post-hoc Kruskal-Wallis 
 multiple comparison tests. Superscripted letters indicate inter-group differences that are statistically 
 significant, *p <0.05; **p < 0.01; ***p < 0.001 relative to group with superscripted letter but no asterisk. 
 
Protein Chow Con TEN Con TEN+ 
NAC 
EtOH TEN EtOH TEN+ 
NAC 
F-Ratio p-Value 
IL-4 17.97 ± 2.545 40.19 ± 11.3 25.59 ± 5.391 36.16 ± 17.56 25.97 ± 3.068 4.25 NS 
GM-CSF 36.07a ± 7.817 195.1a***± 36.58 82.28 ± 12.83 142.1 ± 43.76 83.83 ± 10.96 18.05 0.001 
GRO/KC 98.33a ± 7.55 199.9a ± 34.37 142.4 ± 14.39 180.7 ± 43.24 123.5 ± 5.058 12.90 0.012 
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 Figure 2.4:  Effects of chronic ethanol and NAC treatment on pro-inflammatory cytokine 
and CYP2E1 gene expression in liver.  RNA extracted from liver was reverse transcribed and the 
cDNAs were used to measure to (A) IL-1β, (B) IL-2, (C) IL-6, (D) TNF-α, and (E) CYP2E1 by qPCR 
using gene-specific primers (Table 3). Inter-group comparisons were made using one-way ANOVA 












p70S6K, pTpS421/424-p70S6K, PRAS40, and pT246-PRAS40 immunoreactivities by 
multiplex ELISA (Figures 2.6 and 2.7). The qRT-PCR analyses demonstrated 
similar mean levels of insulin, IGF-1, IR, IRS-1, and IRS-2 expression in all groups.  
Hepatic IGF-2 polypeptide (P<0.05) and IGF-1R (P<0.01) mRNA levels were 
significantly higher in ethanol-TEN+NAC than in chow-fed rats (Figures 2.5 E and 
C).  In addition, IGF-2R expression was significantly higher in livers of ethanol-
TEN+NAC compared with chow and control-TEN fed rats (Figure 2.5 D). Finally, 
with regard to IRS-4, the mean hepatic mRNA levels were similar for chow, control- 
and ethanol-TEN fed rats, but the levels were significantly reduced by the NAC 
treatments relative to the corresponding control- and ethanol-TEN groups (Figure 
2.5 H). 
Analysis of the upstream signaling networks using multiplex ELISAs 
revealed similar mean levels of IR, IGF-1R, and IRS-1 in all groups (Figures 2.6 A-
C). The mean hepatic levels of pYpY1162/1163-IR (Figure 2.6 D) and the pYpY1162/1163-
IR/Total IR ratio (Figure 2.6 G) were significantly reduced in ethanol-TEN ± NAC 
relative to control-TEN fed rats (both P<0.01). The mean hepatic levels of 
pYpY1135/1136-IGF-1R were significantly lower in ethanol-TEN (P<0.05) and ethanol-
TEN+NAC (P<0.001) relative to control-TEN fed rats (Figure 2.6 E).  Finally, the 
mean hepatic pS312-IRS-1 and the pS312-IRS-1/total IRS-1 ratio were significantly 
reduced in ethanol-TEN+NAC relative to control-TEN ± NAC fed rats (Figures 2.6 
F and I). Therefore, chronic ethanol feeding suppressed hepatic signaling through 
IR, IGF-1R, and IRS-1, with no demonstrated protective effects of the NAC 
treatments.   
Downstream signaling through insulin/IGF-1 in liver, showed similar mean levels of 
Akt, GSK-3β, p70S6K, and PRAS40 in all five groups (Figures 2.7 A-D). Hepatic 
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ethanol-TEN relative to control-TEN feeding, and NAC treatment had no significant 


















Figure 2.5:  Effects of chronic ethanol and NAC treatment on insulin/IGF signaling network 
genes.  RNA extracted from liver was reverse transcribed to measure (A) IGF-1, (B) insulin 












mRNA expression by PCR. Inter-group comparisons were made using one-way ANOVA with the 
Tukey multiple comparison tests.  Significant P-values are indicated within the panels. 
Figure 2.6: Effects of chronic ethanol and NAC treatment on upstream mediators of 
insulin/IGF signaling. Liver protein homogenates were used to measure immunoreactivity 
corresponding to (A) insulin receptor (R), (B) IGF-1R, (C) IRS-1, (D) pYpY1162/1163-IR, (E) pYpY1135/1136-
IGF-1R, (F) pS312-IRS-1 with a bead-based Multiplex ELISA platform (see Methods and Methods).  
(G-I) In addition, the phosphorylated/total protein ratios for were calculated to assess relative levels 
of phosphorylation of each protein.  Data were analyzed statistically using one-way ANOVA with the 
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hepatic levels of pS9-GSK-3β were significantly reduced in the ethanol-TEN relative 
to control-TEN fed rats (Figure 2.7 F), and the mean pS9-GSK-3β/GSK-3β ratio was 
significantly lower in ethanol-TEN+NAC fed relative to all control groups (P<0.05; 
Figure 2.7 J).  Signaling through p70S6K was also impaired by ethanol as 
demonstrated by the significantly lower mean levels pTpS421/424-p70S6K in ethanol-
TEN relative to control-TEN, particularly with respect to the control-TEN+NAC 
treated group (Figure 2.7 G). The mean ratio of pTpS421/424-p70S6K/total p70S6K 
was significantly lower in the ethanol-TEN+NAC relative to the control-TEN+NAC 
(P<0.01), and ethanol-TEN (P<0.05) fed groups (Figure 2.7 K). Finally, the mean 
hepatic levels of pT246-PRAS40 and the pT246-PRAS40/total PRAS40 ratio were 
























Figure 2.7:  Effects of chronic ethanol, and NAC treatment on the downstream mediators of 
insulin/IGF signaling.  Liver protein homogenates were used in bead-based Multiplex ELISAs to 
measure (A) Akt, (B) GSK-3β, (C) p70S6K, (D) PRAS40, (E) pS473-Akt, (F) pS9-GSK3β, (G) pTpS421/424-
p70S6K and (H) pT246-PRAS40 immunoreactivities. (I-L) In addition, the phosphorylated/total protein 
ratios for were calculated to assess relative levels of phosphorylation of each protein.  Data were 
analyzed statistically using one-way ANOVA with the Tukey multiple comparison tests.  Significant 
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2.4 DISCUSSION 
Total enteral nutrition (TEN) diets caused hepatic steatosis with mild inflammation, 
whereas superimposed chronic ethanol feeding strikingly increased the severity of 
steatohepatitis. Biochemical studies confirmed that the TEN diets increased 
hepatic lipid content (mainly triglycerides) relative to chow feeding, and that the 
addition of ethanol to the diets caused only modest further increases total hepatic 
lipid over TEN alone. Therefore, factors other than simply lipid load must play 
critical roles in mediating severity of steatohepatitis. One consideration is that 
ethanol may alter the composition of lipids accumulated in hepatocytes, and 
perhaps render them cytotoxic. It is noteworthy that the lipid droplets found in 
ethanol-TEN fed rat livers were mainly micro-vesicular and associated with 
prominent inflammation, apoptosis, necrosis, and disarray of the hepatic cord 
architecture, while in control-TEN fed rats, the lipid droplets were mixed micro- and 
macrovesicular, and the inflammation and cell injury were less severe.  Given the 
similar overall mean triglyceride contents in livers of control-TEN and ethanol-TEN 
fed rats, other factors must account for the striking differences in the levels of 
inflammation and injury. Corresponding with earlier findings (Lyn-Cook et al., 
2009), it appears that the micro-vesicular pattern of steatosis may mark a 
pathological state, whereas the macro-vesicular pattern of steatosis may be more 
benign.  In this regard, it is noteworthy that the major effects of NAC were to 
reduce inflammation and shift hepatic steatosis from a micro-vesicular to mainly 
macro-vesicular pattern with accompanying reductions in apoptosis, necrosis, and 
architectural disarray in both groups, yet total hepatic lipid content was not 
significantly reduced by NAC.   
Oxidative stress contributes to progression of simple steatosis to 












attenuate oxidative stress. Since hepatic glutathione levels in ALD and non-
alcoholic liver disease are reduced (Das et al., 2008; Videla et al., 2004), we 
investigated the therapeutic effects of NAC, an anti-oxidant that promotes 
glutathione synthesis (Aruoma et al., 1989; Atkuri et al., 2007), on the severity of 
alcohol-induced steatohepatitis.  In the present study, NAC reduced inflammation, 
but not lipid content (Nile Red and triglyceride assays) in liver.  However, NAC 
treatment shifted the sizes of intra-hepatic lipid droplets, converting them from 
microvesicular to mainly macrovesicular in nature. These findings correspond with 
results obtained in an earlier study showing that with progression of non-alcoholic 
steatohepatitis, the histopathology shifted from predominantly macro-vesicular to 
micro-vesicular steatosis, and was associated with increased inflammation, 
apoptosis, disorganization of the hepatic lobular architecture, and increased 
ceramide levels in liver (Lyn-Cook et al., 2009).  However, contrary to findings in 
other models (Cai et al., 2005; McClain et al., 1999; Ronis et al., 2008; Wang et al., 
2010), we did not observe a significant role for NAC inhibition of pro-inflammatory 
cytokines in relation to the reduced severity of alcohol-related steatohepatitis.  
Moreover, we did not detect significant ethanol-associated increases in pro-
inflammatory cytokines in liver. Although the latter observation is not in agreement 
with previous reports (Thakur, Pritchard, McMullen, & Nagy, 2006), the 
discrepancies could be explained by the fact that in those studies, cytokine 
activation was measured in isolated Kupffer cells, whereas our assays were 
performed with liver homogenates. The use of tissue homogenates probably 
masked any differences present in Kupffer cells, which represent a relatively small 
percentage of the liver cell population. 
This study demonstrated that an important consequence of the TEN diets 
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ceramide in TEN fed rats, with our without superimposed ethanol and/or NAC 
treatments, were likely mediated by increased acid sphingomyelinase activity, 
rather than increased expression of pro-ceramide genes, indicating that these 
responses may have been effectuated by post-transcriptional mechanisms. In a 
recent study, increased sphingomyelinase activity was associated with hepatic 
steatosis caused by chronic high fat feeding (Chocian et al., 2010). 
Mechanistically, sphingomyelinase activity can be induced by activation of hepatic 
stellate cells (Moles et al., 2010), and sphingomyelinases are activated by 
oxidative stress, reactive oxygen species, and reactive nitrogen species, and 
inhibited by glutathione and other anti-oxidants (Ichi et al., 2009; Levy, Castillo, & 
Goldkorn, 2006; Navas et al., 2002; Won & Singh, 2006). Therefore, increased 
oxidative stress was probably an important factor contributing to the increased 
levels of acid sphingomyelinase activity, and the attendant increased ceramide 
levels in livers of ethanol fed rats.  
As ceramides can cause cytotoxicity, inflammation, apoptosis, and insulin 
resistance (Hannun & Obeid, 2008; Holland & Summers, 2008; Morales, Lee, 
Goni, Kolesnick, & Fernandez-Checa, 2007; Summers, 2006), the NAC-associated 
improvements in alcohol-induced steatohepatitis could have been mediated by 
reduced oxidative stress-stimulated sphingomyelinase activity, and consequential 
reductions in ceramide accumulation. Mechanistically, anti-oxidant treatments may 
help stabilize membranes of large lipid globules, preventing their rupture and 
release of cytotoxic lipids, including ceramides.  In addition, recent preliminary 
studies using a precision-cut slice culture model revealed that chemical inhibition 
of ceramide synthases significantly reduces oxidative stress, lipotoxicity and insulin 
resistance in ethanol exposed livers (Setshedi et al., 2010). Therefore, inhibition of 












synthesis could be therapeutically effective for chronic alcoholic liver disease, 
although inhibition of ceramide synthesis may be more efficacious in restoring 
hepatic insulin responsiveness. 
Gangliosides are glycosphingolipids that contain sialic acid and are 
expressed on mammalian plasma membranes. Gangliosides, like ceramides, are 
important signaling molecules that can promote insulin resistance (Holland et al., 
2007; Yamashita et al., 2003) particularly in response to inflammatory mediators 
such as TNF-α (Tagami et al., 2002). Insulin resistance induced by TNF-α was 
shown to be associated with increased GM3 and reduced insulin receptor 
accumulation in detergent-resistant membrane microdomains, together with 
uncoupling of insulin receptor-IRS-1 signaling (Kabayama et al., 2005; Kabayama 
et al., 2007). Correspondingly, chemical inhibition of GM3 restores insulin 
responsiveness in leptin-deficient, insulin-resistant states (van Eijk et al., 2009). 
Our studies demonstrated striking and significantly increased expression of GM3 
synthase in ethanol-fed rats, with only modest reductions in GM3 synthase gene 
expression in livers of the NAC-treated rats. Therefore, the combined effects of 
increased ceramide and GM3 ganglioside levels in the liver likely mediated 
ethanol-induced hepatic insulin resistance. The limited reductions in hepatic 
ceramide levels and GM3 expression effectuated by NAC treatment correspond 
with the modest rescue effects of NAC on the ethanol-induced hepatic insulin 
resistance. 
Steatohepatitis produced by ethanol or chronic high fat feeding leads to 
impaired insulin and IGF signaling in liver (de la Monte et al., 2008; Svegliati-
Baroni et al., 2006; Yeon et al., 2003). Included among the factors contributing to 
this phenotype are reduced hepatic expression of insulin/IGF polypeptides, their 
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of receptor tyrosine kinases and IRS proteins (de la Monte et al., 2008; Yeon et al., 
2003).  In addition, chronic ethanol exposure causes insulin resistance with 
inhibition of signaling downstream through growth and survival pathways (He, 
Butler, Liu, & McNamara, 2006; Mohr, Tanaka, & Wands, 1998; Pang et al., 2009; 
Ronis et al., 2007; Sasaki & Wands, 1994). Correspondingly, in the present study, 
the main effects of chronic ethanol feeding were to inhibit phosphorylation and 
signaling through the insulin receptor, IGF-1 receptor, and IRS-1, as well as 
through Akt and p70S6K, while increasing activation of GSK-3β.  
Reduced levels of pS473-pAkt indicate constitutive inhibition of growth and 
survival signaling in liver (Nawano et al., 1999), while the reduced levels of pS9-
GSK-3β reflect constitutively increased GSK-3β activity, and this also inhibits cell 
survival (Cross, Alessi, Cohen, Andjelkovich, & Hemmings, 1995). The findings of 
reduced Akt and increased GSK-3β activities in ethanol-exposed livers are 
consistent with previous reports (de la Monte et al., 2008; Yeon et al., 2003).  In 
addition to the impairments in survival and carbohydrate metabolism, we 
demonstrated significant ethanol inhibition of signaling downstream of PI3 kinase-
Akt through p70S6K, and mTOR-dependent PRAS40 pathways, indicating that 
chronic ethanol feeding inhibits protein synthesis (Berven & Crouch, 2000) 
(Nascimento & Ouwens, 2009). Ethanol inhibition of p70S6K phosphorylation could 
have been mediated by inhibition of Akt, mTOR, or both, as the multiplex-ELISA 
detected pTpS421/424-p70S6K; the T421 and S424 residues on p70S6K are 
phosphorylated by Akt and mTOR (Guillen, Navarro, Robledo, Valverde, & Benito, 
2006).  Since none of the inhibitory effects of ethanol on insulin/IGF/Akt signaling 
were abrogated by NAC treatment, anti-oxidant therapy alone would probably not 













In conclusion, this study demonstrates that NAC treatment has a role in 
reducing the severity of alcohol-induced steatohepatitis, but the therapeutic 
benefits are limited due to persistence of insulin/IGF signaling impairments in liver.  
In addition to decreasing inflammation, NAC reduced ceramide levels in liver.  This 
effect was mediated by reductions in sphingomyelinase activity rather than 
changes in gene expression.  We hypothesize that the NAC-mediated reductions 
in oxidative stress (Ronis et al., 2005; Samuhasaneeto, Thong-Ngam, Kulaputana, 
Patumraj, & Klaikeaw, 2007) led to improved membrane stabilization and attendant 
reductions in lipid breakdown with release of toxic sphingolipids, including 
ceramides. We propose that the histological correlate of this phenomenon is the 
NAC-associated shift in the pattern of steatosis from micro-vesicular to macro-
vesicular. The findings herein reinforce our hypothesis that ethanol-induced 
steatohepatitis has dual independent but interactive pathogenic mechanisms: 
oxidative stress/inflammation and insulin/IGF resistance.  While NAC and other 
anti-oxidant and radical scavenger treatments may aid in reducing the severity of 
oxidative stress/inflammation, additional therapeutic agents such as insulin 
sensitizers are probably needed to arrest the insulin/IGF-1 resistance arm of this 
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CHAPTER 3 
Cytokine Profile and Effects of N-Acetylcysteine Treatment in a 
Rat Model of Alcohol-Induced Steatohepatitis  
 
ABSTRACT  
Background: Alcoholic steatohepatitis (ASH) is associated with pro-inflammatory 
cytokine activation, which correlates with progression and severity of alcoholic liver 
disease (ALD).  The roles of tumor necrosis factor-α (TNF-α) and interleukins (IL-) 
2, 6, 8 and 10 have been thoroughly investigated, but the contribution of other 
cytokines that may be important in the pathogenesis of oxidative stress and tissue 
injury with progression of ALD requires further study.   
Hypothesis:  Hepatic expression of pro-inflammatory and anti-inflammatory 
cytokines and chemokines is dysregulated by chronic ethanol exposure. Anti-
oxidant treatment may reduce hepatocellular injury by normalizing inflammation 
and pro-inflammatory cytokine/chemokine expression in liver.  
Methods: Adult male Sprague Dawley rats fed by total enteral nutrition (TEN) for 
130 days, and were divided into 4 groups: control+vehicle (n=13); control+NAC 
(n=6); ethanol+vehicle (n=9); and ethanol+NAC (n=7). Ethanol comprised 37% of 
the caloric content in the liquid diets. Livers were used to measure cytokine and 













Results: Pro-inflammatory TNF-α, IFN-γ, IL-1β, IL-2, IL-6, and IL-12, and anti-
inflammatory IL-4, IL-10 and IL-13 cytokines and the CXCL1, CCL11, CCL5 
chemokines were similarly expressed in livers of control and ethanol TEN-fed rats.  
However, IL-1α expression was significantly increased in the ethanol-exposed 
relative to controls, although NAC treatment did not decrease hepatic IL-1α 
expression in either group. GM-CSF, G-CSF, MCP-1, and MIP-1α were more 
abundantly expressed in alcohol TEN-fed relative to the control TEN-fed rats and 
the effect of NAC was to further increase G-CSF expression in both groups.  Leptin 
on the other hand was not different among the study groups. 
Conclusion: In this model cytokine/chemokine activation were in favor of a pro-
inflammatory state, corresponding to the degree of hepatocyte inflammation. Anti-
oxidant therapy had limited effect in modulating these effects, suggesting that the 
inflammatory response mechanisms may be independent of oxidative stress. 
Therefore other treatments are required to treat alcohol-induced liver injury 
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3.1 INTRODUCTION 
Alcoholic liver disease (ALD) encompasses a spectrum of pathological features, 
which can progress from simple steatosis, to more serious stages of steato-
hepatitis, cirrhosis and hepatocellular carcinoma (HCC) (Adachi & Brenner, 2005; 
Tilg & Day, 2007).  Alcoholic steatohepatitis (ASH) the malign form of ALD, is 
characterized by hepatocyte necrosis and apoptosis, degeneration, and is 
associated with significant mortality (Sandahl, Jepsen, Thomsen, & Vilstrup, 2011).  
Central to the development of alcoholic steatohepatitis is endotoxin-mediated 
inflammatory response of Kupffer cells to alcohol (Adachi, Moore, Bradford, Gao, & 
Thurman, 1995; Nanji, Khettry, Sadrzadeh, & Yamanaka, 1993).  Chronic alcohol 
exposure sensitizes CD14/Toll-like receptors on the surface of Kupffer cells to gut-
derived lipopolysaccharides (LPS) (Nagy, 2003), which stimulate the production of 
cytokines. The functions of pro-, anti-inflammatory cytokines and chemokines are 
described in Table 9.   
Tumor necrosis factor alpha (TNF-α), IL-1β and IL-6 are the predominant 
pro-inflammatory cytokines implicated in ASH (Crews et al., 2006), leading to 
inflammation and hepatic necrosis.  On the other hand Th2-mediated responses 
aim to counteract the effects of pro-inflammatory cytokine activation; therefore, it is 
the imbalance in favor of pro-inflammatory to anti-inflammatory cytokine milieu that 
mediates progression of alcoholic liver disease. Indeed in patients with ALD, serum 
(Bird, Sheron, Goka, Alexander, & Williams, 1990; McClain & Cohen, 1989) and 
adipose tissue (Naveau et al., 2010) TNF-α levels are elevated and correlate with 












reported in the bloods of rats and mice exposed to ethanol (Thurman et al., 1998). 
Similarly, other lines of evidence show that IL-6, IL-8 and IL-12 levels correlate with 
ongoing alcohol consumption and disease severity (Huang et al., 1996; Tung et al., 
2010), including clinical features of portal hypertension (Swiatkowska-Stodulska & 
Bakowska, 2004; Swiatkowska-Stodulska, Bakowska, & Drobinska-Jurowiecka, 
2006) and mortality (Dominguez et al., 2009; Swiatkowska-Stodulska & Bakowska, 
2004).  
While the roles of pro- and anti-inflammatory cytokines in mediating injury in 
ALD have been studied, the role of chemokines, growth factors and leptin that 
could be potentially important has not been adequately assessed.   
Simultaneously, the metabolism of alcohol contributes significantly to the 
pathogenesis of alcoholic steatohepatitis by promoting oxidative stress. One of the 
mechanisms of increased oxidative stress is depletion of glutathione (GSH), a 
radical scavenger and key attenuator of oxidative stress in liver. Alcohol feeding 
sensitizes hepatocytes to TNF-α as a result of reduced availability of mitochondrial 
glutathione (mGSH) (Fernandez-Checa & Kaplowitz, 2005). This observation was 
reproduced in vitro by selective pharmacological depletion of mGSH, which 
sensitized hepatocytes to TNF-mediated cell death (Colell et al., 1998). Moreover, 
oxidative stress also contributes to LPS-mediated stimulation of extracellular 
signal-regulated kinase (ERK) (Thakur, Pritchard, McMullen, & Nagy, 2006), 
further perpetuating the inflammatory response. In another study the prevalence of 
abnormal TNF-α was 5-fold higher in heavy drinkers with oxidative stress-induced 
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key role in TNF-mediated alcoholic liver injury. Susceptibility to oxidative and 
radical injury however, rests on maintaining a balance between pro-oxidant and 
anti-oxidant factors.  
Therefore, NAC therapy may reduce liver injury associated with pro-cytokine 
and chemokine inflammation and progression from simple steatosis to 
steatohepatitis in ALD. The present study utilizes a rat model of chronic ethanol 
feeding to evaluate the cytokine milieu and the potential use of NAC for reducing 
























3.2 MATERIALS AND METHODS 
Materials:  The protein concentration was measured as before using the 
bicinchoninic acid (BCA) kit and the rat cytokine Milliplex xMAP kit was utilized for 
the multiplex ELISAs (see Chapter 2).  
Experimental Model: The same model as that described in Chapter 2 was used for 
cytokine measurements. 
Multiplex ELISA: We used the same methods as those previously described to 
measure immunoreactivity to a panel of 24 selected pro-inflammatory cytokines 
and chemokines in liver tissue.  
Statistical Analysis: Data depicted in box plots reflect group median, 95% 
confidence interval limits and range (whiskers), while tabulated data reflect means 
± SEMs for each group.  Intergroup comparisons were made using the Kruskal-
Wallis one-way analysis of variance (ANOVA) with the Dunn’s multiple 
comparisons test. Data were analyzed using GraphPad Prism 5 software 
(GraphPad Software, Inc., San Diego, CA).  Significant P-values (<0.05) are 
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3.3 RESULTS 
Effects of ethanol and NAC treatments on cytokine levels in liver: To determine the 
degree to which chronic ethanol feeding stimulates pro-inflammatory states and 
whether NAC treatment reduces cytokine activation we used a bead-based 24-
panel cytokine multiplex ELISA system.  Thus to profile cytokine activation in this 
model we measured hepatic levels of the following cytokines: pro-inflammatory 
(TNF-α, IFN-γ, IL-1α, IL-1β, IL-2, IL-5, IL-6, IL-9, IL-12, IL-17, IL-18); anti-
inflammatory (IL-4, IL-10, IL-13); chemokines (MIP-1α, MCP-1, RANTES, GRO/KC 
(CXCL-1), IP-10 and eotaxin), leptin and growth factors (G-CSF, GM-CSF, and 
VEGF).  
Pro-inflammatory cytokines: Hepatic levels of TNF-α, IFN-γ, IL-1β, IL-2, IL-5, IL-6, 
IL-9, and IL-12p were similarly expressed in the livers of control- and alcohol-TEN 
fed rats, irrespective of treatment with NAC (p>0.05) (Figure 2.8). However the 
levels of IL-1α (p=0.048) were higher in ethanol-TEN fed rats as compared to 
control-TEN fed rats, with no obvious benefit of treatment with NAC (Figure 3.1 A). 
IL-17 (Figure 3.1 B) and IL-18 (Figure 3.1 C) are both involved in microbial 
defense; in particular IL-18 induces cell-mediated immunity following injection with 
lipopolysaccharide (LPS). Although both IL-17 and IL-18 were expressed at similar 





















































































Figure 3.1:  Effects of control- or ethanol-containing TEN feeding and N-acetylcysteine 
(NAC) on pro-inflammatory cytokine profile (non-significant). A bead-based multiplex ELISA was 
used to measure immunoreactivity (see Methods and Materials). Immunoreactivity to (A) TNF-α, (B) 
IL-2, (C) IL-6 and (D) IL-12p were measured. Liver tissues were homogenized in Tris-HCl buffer 
containing protease and phosphatase inhibitors. Samples containing 200mg protein were incubated 
with the beads, and capture antigens were detected with biotinylated secondary antibodies and 
phycoerythrin-conjugated Streptavidin. Data are expressed as fluorescence light units corrected for 
protein concentration. Inter-group comparisons were made using the Kruskal-Wallis one-way 










114	  |	  P a g e 	  
	  
treatment with NAC served to further up-regulate these levels with the biggest 
difference between control-TEN and NAC-treated alcohol-TEN fed rats (p<0.01) in 






Figure 3.2: Effects of control- or ethanol-containing TEN feeding and N-acetylcysteine 
(NAC) on pro-inflammatory cytokine profile (significant). A bead-based multiplex ELISA was used to 
measure immunoreactivity (see Methods and Materials). Immunoreactivity to (A) IL-1-α, (B) IL-17 
and (C) IL-18 were measured. Liver tissues were homogenized in Tris-HCl buffer containing 
protease and phosphatase inhibitors. Samples containing 200mg protein were incubated with the 
beads, and capture antigens were detected with biotinylated secondary antibodies and 
phycoerythrin-conjugated Streptavidin. Data are expressed as fluorescence light units corrected for 
protein concentration. Inter-group comparisons were made using the Kruskal-Wallis one-way 









































































Anti-inflammatory cytokines: There were no differences observed in the hepatic 
expression levels of IL-4, IL-10 and IL-13 between the control- and alcohol-TEN 
fed rats.  Similarly, co-administration of NAC had no significant effect (Figure 3.3). 
Chemokines: GRO/KC, eotaxin, and IP-10 expression were essentially identical in 
livers of all rats in the study, with no beneficial effects of NAC. The expression 
levels of MCP-1 and MIP-1α were generally low in control- and ethanol-TEN fed 
rats, and were upregulated in both groups with NAC treatment, in essence, 
showing no significant modulation of chemokine expression with treatment (Figure 
3.4).  
 
Figure 3.3: Effects of control- or ethanol-containing TEN feeding and N-acetylcysteine 
(NAC) on anti-inflammatory cytokine profile (non-significant). A bead-based multiplex ELISA was 
used to measure immunoreactivity (see Methods and Materials). Immunoreactivity to (A) IL-4, (B) 
IL-10 and (C) IL-13 were measured. Liver tissues were homogenized in Tris-HCl buffer containing 
protease and phosphatase inhibitors. Samples containing 200mg protein were incubated with the 
beads, and capture antigens were detected with biotinylated secondary antibodies and 
phycoerythrin-conjugated Streptavidin. Data are expressed as fluorescence light units corrected for 
protein concentration. Inter-group comparisons were made using the Kruskal-Wallis one-way 
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Growth factors: Hepatic expression levels of VEGF and GM-CSF were essentially 
similar in control- and alcohol-TEN fed rats, with no effect of NAC co-
administration. G-CSF hepatic levels were upregulated in alcohol-TEN fed 
compared to control-TEN fed rats (p<0.05). In both groups co-treatment with NAC 
ameliorated these levels (Figure 2.11 C).  
Leptin: In human subjects serum leptin correlates with degree of alcoholic 
steatosis, therefore we wanted to profile leptin levels with steatohepatitis and 
assess the therapeutic benefits of NAC. Leptin levels were similar in control- and 





Figure 3.4: Effects of control- or ethanol-containing TEN feeding and N-acetylcysteine 
(NAC) on chemokine and growth factor profile (significant). A bead-based multiplex ELISA was 
used to measure immunoreactivity (see Methods and Materials). Immunoreactivity to (A) MCP-1, 
(B) MIP-1α and (C) GCSF were measured. Liver tissues were homogenized in Tris-HCl buffer 
containing protease and phosphatase inhibitors. Samples containing 200mg protein were incubated 
with the beads, and capture antigens were detected with biotinylated secondary antibodies and 














































































protein concentration. Inter-group comparisons were made using the Kruskal-Wallis one-way 
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3.4 DISCUSSION 
The objective of the present work was to primarily profile key cytokines that 
mediate inflammation and subsequent tissue destruction with alcohol-mediated 
liver injury.  Secondarily the study aimed to determine other less well-studied 
cytokines, chemokines and growth factors that may also be of value in determining 
likely worse outcomes in alcoholic steatohepatitis and to determine the effects of 
anti-oxidant therapy in reducing the injurious consequences of alcohol.  
The effects of alcohol-TEN feeding in this model were increased 
inflammation associated with apoptosis, necrosis and architectural disarray. In 
addition there was corresponding increased triglyceride and ceramide 
accumulation (see previous chapter). Finally, the effect of NAC was to primarily 
reduce the inflammatory response. These findings are described more extensively 
in the preceding section.  
The degree of inflammation is directly proportional to the amounts of pro-
inflammatory relative to anti-inflammatory cytokines. Traditionally measurements of 
cytokines are done in serum, although measurement in other tissues particularly 
adipocytes (Naveau et al., 2010) has been described.  Cytokines are signaling 
molecules that have systemic immunomodulating functions, i.e. endocrine 
properties, therefore we hypothesized that hepatic cytokines spill over into the 
bloodstream thus, measurement of hepatic cytokines would be reflective of serum 
cytokines. In this model, pro-inflammatory cytokines IL-1α, IL-17 and IL-18 were 
upregulated from basal levels with NAC treatment. Thus anti-oxidant treatment 












paradox could be that in early disease (i.e. before the onset of fibrosis as is the 
case in this model) a predominant pro-inflammatory is appropriate as an immune 
response to LPS-mediated endotoxaemia, and this response is improved by 
treatment, however with prolonged insult and aberrant stimulation of the immune 
response, this results in cell necrosis and subsequent fibrosis. Our model is not 
that of acute alcoholic hepatitis, but can be characterized as a sub-acute injury 
model given the period of exposure to alcohol and lack of fibrosis. Furthermore, IL-
1α has almost identical functions to TNF-α, which may suggest that either is 
sufficient to induce an inflammatory response.  Therefore the lack of significant up-
regulation of TNF-α in this model, as has been reported by others (Bird et al., 
1990; Gobejishvili et al., 2006; Kishore, McMullen, Cocuzzi, & Nagy, 2004; Latvala 
et al., 2005; McClain, Hill, Song, Deaciuc, & Barve, 2002), may be explained on 
this basis. An alternative explanation (as stated in the previous chapter) could be 
that previous studies measured TNF-α in isolated hepatic Kupffer cells, whereas 
we measured total hepatocyte TNF-α levels; which could have masked actual 
differences between the groups. In contrast none of the anti-inflammatory 
cytokines were significantly different stratified by diet or treatment. One would have 
expected alcohol to downregulate anti-inflammatory cytokines and attenuation by 
NAC treatment. The reasons for this are not clear. Chemo-attractant ability was 
enhanced with co-treatment with NAC (upregulation of MCP-1 and MIP-1α), and a 
similar effect was noted with levels of G-CSF. This finding may suggest that their 
down-regulation with TEN feeding with or without alcohol has a mechanism 
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could be indicative of the reparative process undertaken by injured hepatocytes in 
an attempt to regenerate. 
The pathogenesis of alcoholic liver disease is very similar to that of non-
alcoholic steatohepatitis; in this context the role of leptin in alcoholic stetohepatitis 
would be informative in further understanding pathogenesis in ALD. Leptin, in 
addition to endocrine functions, modulates the immune system. Its effect is that of 
pro-inflammatory cytokine activation, thus promoting a Th1 response (Fernandez-
Riejos et al., 2010; Tsochatzis, Papatheodoridis, & Archimandritis, 2006). In this 
study there was no difference in hepatic expression of leptic levels in control- and 
alcohol-TEN fed rats.  Perhaps this is not surprising noting that leptin is produced 
in adipocytes, therefore hepatic measurements are not likely to be representative 
or give reliable results.  
To summarize, this model of ethanol-induced steatohepatitis in a rat showed 
evidence of steatosis and inflammation associated with an imbalance in favor of 
pro-inflammatory cytokine and chemokine activation. Whilst the administration of 
anti-TNF agents have to date yielded mixed results in both animal models and 
humans, the quest for other agents that can be targeted against dysregulated 
immune function remains important and therefore, understanding the role of key 
cytokines is an important step towards achieving this goal. The inflammatory 
response in this model was not sufficiently robust; hence an accurate assessment 
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Table 9: Contributions of “important” cytokines to immunologic responses  





Induces other cytokines 
Causes T-cell stimulation 
Induces metalloproteinases and 
prostaglandins 
Increases adhesion molecule 
expression 
IL-2  T cells  Increases T-cell proliferation 
Activates B-cells 
IL-4 (anti) T cells Signal for immunoglobulin switch 
and increases IgE 
Decreases production of pro-
inflammatory cytokines 
Suppresses delayed type 
hypersensitivity (Th1 cells) 
IL-5 T cells 
Possibly mast cells 
Triggers activated B-cell and 
eosinophil differentiation and 
proliferation 
Regulates expression of genes 
involved in proliferation, cell 
survival and maturation of B-cells 
and eosinophils 
IL-6 Many cells Stimulates B- and T-cell 
proliferation 
Acute phase reactant 
Induces natural protease inhibitor 
(TIMP) 
IL-12 (p70) Macrophages Increases interferon-gamma 
production and Th1 cell 
differentiation 
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IL-17 Many cells Implicated in many autoimmune 
and inflammatory diseases 
Role in microbial defense  
IL-18 Macrophages Together with IL-12, induces cell-
mediated immunity following 
infection with e.g. LPS 
Stimulates natural killer cells and 
certain T-cells to release interferon 
gamma that activates other 
macrophages, IFN gamma and IL-
12  
Inhibits IL4-dependent IgE and 
IgG1 production 
TNF-alpha T cells 
Macrophages 
Induces cachexia 
Induces other cytokines (i.e. 
RANTES) 
Stimulates T-cells 
Induces metalloproteinases and 
prostaglandins 
Increases adhesion molecule 
expression 
IFN-gamma T cells  Increases adhesion molecules 
Promotes HLA-DR expression, 
activation of T-cells, NK cells, and 
macrophages 




Myeloid differentiation, and 
macrophage activation 










Is involved in the acute 
inflammatory response 














NK cells and dendritic cells 
Promotes T-cell adhesion to 
endothelial cells 
CCL11 (Eotaxin) Epithelial cells 
Endothelial cells 
Smooth muscle cells 
Many cells 
Chemotactic to eosinophils 
CCL2 (MCP-1) Monocytes 
Macrophages 
Dendritic cells 
Chemotactic to monocytes, 
memory-T and dendritic cells 
CCL3 (MIP-1α) Dendritic cells 
NK cells 
Other cells 
Mediates monocyte and neutrophil 
chemotaxis 
CCL5 (Rantes) T-cells and T-cell clones, but 
not T-cell lines 




Increases adherence of 
monocytes to endothelial cells 
Growth factors 
VEGF Many cells  Fibroblast proliferation, and 
angiogenesis 
 























Ceramide inhibitors ameliorate alcohol-induced steatohepatitis 
in an ex-vivo liver slice culture model 
 
ABSTRACT 
Background: Steatohepatitis with attendant activation of pro-inflammatory 
cytokines, insulin resistance, and increased levels of reactive oxygen species 
(ROS) caused by mitochondrial dysfunction, endoplasmic reticulum (ER) stress, 
lipotoxicity, and DNA damage, play pivotal roles in the pathogenesis of chronic 
alcohol-related liver disease (ALD). Recent studies demonstrated roles for 
increased expression of pro-ceramide genes and ceramide accumulation in 
relation to severity of both ALD and non-alcoholic liver disease (NAFLD), since 
cytotoxic ceramides cause insulin resistance and lipotoxicity in liver.  
Hypothesis:  Severity of hepatic steatosis, cytotoxicity, and ER dysfunction can be 
abated by treatment with chemical inhibitors of ceramide synthesis.  
Methods:  Adult male Long Evans rats were pair-fed with isocaloric liquid diets 
containing 0% or 37% ethanol by caloric content for 8 weeks.  Precision-cut fresh 
liver slices (150 µm thick) were cultured and treated with vehicle, 25 µM fumonisin 












were subjected to histological studies, measurement of cytotoxicity (G6PD 
release), insulin and ER stress signaling.  
Results: Ethanol-exposed cultures exhibited steatohepatitis with significantly 
higher mean levels of triglyceride accumulation and G6PD release relative to 
control. Desipramine significantly reduced neutral lipid and ceramide levels, and 
ceramide inhibitor treatments in general lessened the severity of steatohepatitis, 
reduced ethanol-mediated up-regulation of ER stress markers, and restored insulin 
network signaling. While PERK was downregulated by ceramide inhibitor 
treatment, insulin signaling molecules were unaffected.  
Conclusions:  Reversing the histopathological, biochemical, and molecular 
indices of chronic ALD will likely require a multi-pronged approach aimed at 
minimizing lipotoxicity, ER stress, and insulin resistance. The ex vivo precision cut 
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4.1 INTRODUCTION 
Chronic alcohol consumption is a major cause of chronic liver disease. The 
progression of liver disease through the stages of chronic hepatitis, fibrosis and 
cirrhosis and ultimately end-stage liver disease including hepatocellular carcinoma 
is well described (de Alwis & Day, 2008). In contrast the progression of relatively 
benign alcoholic steatosis to the malign steatohepatitis is less well understood. 
Several factors associated with progression of disease include impaired lipid 
metabolism and homeostasis (lipotoxicity), oxidative stress, pro-inflammatory 
cytokine activation, and insulin resistance (Carter-Kent et al., 2008; Farrell & 
Larter, 2006).  
The role of ceramides as key mediators of lipotoxicity with attendant 
increased inflammation, oxidative stress, and insulin resistance in both ALD and 
NAFLD has been discussed in the second chapter. Additionally the structural and 
functional roles of ceramides, particularly in promoting insulin resistance were 
similarly reviewed. Finally ceramide synthetic and degradation pathways were 
outlined in the second chapter; as such the reader is referred to it. However, for 
revision, a figure depicting the metabolic pathways of sphingolipids is included in 
this chapter (Figure 4.1).  In this chapter we investigate the role of ceramides in 
attenuating lipotoxic-associated insulin resistance by employing an ex vivo slice 
culture model of ASH, and by simultaneously administering ceramide inhibitor 
treatment. Our work in Chapter 2 showed evidence that ceramide accumulation as 
a result of upregulated ASMase activity likely induced the lipotoxicity and attendant 












inhibitors of ceramide synthesis will ameliorate these effects. In fact, in rodent and 
human experimental conditions of lipid infusions the administration of myriocin, 
inhibitor of serine palmitoyl transferase, improved glucose uptake and inhibition of 
hepatic gluconeogenesis (Holland, Brozinick et al., 2007).  
 
 
Figure 4.1: Schematic representation of sphingolipid metabolism including the de novo, 
hydrolysis and salvage pathways (Source: Lin, C. F., Chen, C.L., & Lin, Y.S, 2006) 
 
Ceramide inhibitors work by blocking enzymes in the synthetic or degradation 
pathways of ceramide synthesis. For our purposes, we selected three ceramide 
inhibitors that have been used in both animal and human experiments, based on 
published data. Fumonisin B1 is a mycotoxin produced from F. moniliforme, a 
prevalent fungus of corn and other grains (Gelderblom et al., 1988). It functions 
as an inhibitor of ceramide synthase (sphingosine N-acyltransferase) (Balsinde, 
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formation of ceramide from sphinganine and fatty acyl-CoA via de novo synthesis 
or from sphingosine via ceramidase-mediated ceramide degradation. The 
consequences of ceramide synthase inhibition include increased tissue and 
serum concentrations of sphinganine, sphingosine, and their 1-phosphate 
metabolites as well as decreases in complex sphingolipids downstream of 
ceramide (Riley et al., 1999). Myriocin is an amino fatty acid antibiotic derived 
from Mycelia sterilia. It is a potent immunosuppressant, but its relevance in this 
context is that it is a potent inhibitor of serine palmitoyltransferase (Ki = 0.28 nM), 
the enzyme that catalyzes the first step of sphingolipid biosynthesis (Hidari, 
Ichikawa, Fujita, Sakiyama & Hirabayashi, 1996). Serine palmitoyltransferase 
inhibition by myriocin results in a decrease of de novo synthesis of free sphingoid 
bases and ceramide (Miyake, Kozutsumi, Nakamura, Fujita, & Kawasaki, 1995). 
Therefore, myriocin has been shown to have a potential effect of being used as a 
therapeutic agent to treat fumonisin-related diseases based on its ability to block 
fumonisin B1-induced accumulation of free sphingoid bases (Riley et al., 1999). 
Lastly, desipramine, a tricyclic anti-depressant, induces irreversible intracellular 
proteolytic degradation that is specific to the acid sphingomyelinases and 
therefore, has been widely used as a specific acid sphingomyelinase inhibitor 
(Albouz et al., 1981; Hurwitz, Ferlinz & Sandhoff, 1994). Therefore, it inhibits the 
generation of ceramide via the degradation pathway. Thus the use of a 
combination of both ceramide de novo synthesis and catalytic pathway inhibitors, 
would allow us to evaluate the broad roles of ceramide inhibition in this model, 













Moreover alcohol causes organelle dysfunction particularly that of 
mitochondria (reviewed by Hoek JB et al) and the endoplasmic reticulum (ER) 
(Hoek, Cahill, & Pastorino, 2002). The metabolism of alcohol causes altered redox 
potential, oxidative stress and acetaldehyde adducts, all of which are implicated in 
inducing ER stress. The unfolded protein response (UPR), upregulation of protein 
chaperones and with prolonged insult induction of apoptosis are the key regulatory 
mechanisms involved in reducing ER stress. An interesting and recent 
development is the role of the ER in ALD, particularly as is mediated by 
homocysteinemia (Hamelet, Demuth, Paul, Delabar, & Janel, 2007; Ji & Kaplowitz, 
2003; Werstuck et al., 2001). Its contribution has been demonstrated in various 
animal models, with resultant altered expression of genes of the UPR (Esfandiari, 
Villanueva, Wong, French, & Halsted, 2005; Ji & Kaplowitz, 2003; Ji, Mehrian-Shai, 
Chan, Hsu, & Kaplowitz, 2005; Tazi et al., 2007).  Notwithstanding, the role of ER 
stress in the pathogenesis of alcoholic liver disease has not been completely 
elucidated and thus deserves further study. 
Studying the metabolic effects of alcohol and that of administered therapy 
requires a model that elegantly represents human disease. While this has been 
achieved in vivo, with the various animal models of ALD, the ability to do controlled 
experiments at different time points and under varying conditions is expensive and 
time-consuming. Precision-cut liver slices (PCLS) are ideally suited for this 
purpose. PCLS have been used successfully in drug metabolism and toxicity 
studies (Ekins, 1996; Gandolfi, Wijeweera, & Brendel, 1996; Groneberg, Grosse-
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induced hepatocarcinogenesis (Godoy, Diaz Gomez, & Castro, 1983, 1984; 
Goodall, 1984; Mirvish, Ji, Makary, Schut, & Krokos, 1987). The advantage of this 
system in addition, is in its ability to retain tissue organization and maintain cell-to-
cell matrix interactions (Groneberg et al., 2002) and therefore closely recapitulates 
the in- vivo situation.  
Therefore we hypothesized that the use of rat model of alcoholic 
steatohepatitis in an in-vivo system whereby chemical inhibitors of ceramide 
synthesis or degradation could be directly administered to the liver would be ideally 
suited to test the utility of PCLS and simultaneously the effects of treatment on the 












4.2 MATERIALS AND METHODS 
Materials: The rats were purchased from Harlan Sprague Dawley Inc (Indianapolis, 
Indiana) and the diet in powder form from BioServ (Frenchtown, NJ). Dulbecco’s 
modified Eagle’s medium used for culture was from Sigma-Aldrich (St Louis, Mo) 
and the medium was enriched with amino acids, penicillin and streptomycin from 
Lonza (Basel, Switzerland). Precision-cut slices of liver tissue were obtained using 
the McIlwain Tissue Chopper from Ted Pella Inc (Redding, CA). The same 
methods and protocols described in Chapter 2 were utilized for this experiment for 
the measurement of protein, lipids and the performance of PCR and ELISAs. 
Additionally, to measure cytotoxicity levels the VybrantTM Cytotoxicity Assay Kit 
from Molecular Probes Inc (Eugene, OR) was used.  
Experimental Model: Adult male Long Evans rats were fed a liquid control- or 
ethanol-containing diet (37% by caloric content), housed and monitored as 
described previously (de la Monte et al., 2008) for a period of 5 months. Livers 
harvested at sacrifice were cut into smaller 8mm cores that were used to generate 
precision-cut slice cultures (150um thick) using the McIlwain Tissue Chopper. This 
was done under a hood following strict aseptic techniques. The liver slices were 
placed in 300µl full medium in 24-well multiwell culture plates (Greiner Bio-One, 
Monroe, NC) and separated with fine-needle forceps under a dissection 
microscope. The slices were subsequently maintained in a culture medium 
supplemented with vehicle, 25 µM fumonisin B1, 10 µM myriocin, or 50 µM 
desipramine (Table 10), in an incubator for up to 72 h. In addition, at harvest a 
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histopathological analysis in order to serve as a control for the histology from the 
liver slices. After intervals of 24, 48 and 72 hours each of incubation, liver slices 
were homogenized in weak lysis buffer or TRIzol for protein and RNA extraction 
respectively, or immersion fixed in Histochoice. The experiments were performed 
in accordance with protocols approved by Institutional Animal Care and Use 
Committee at the Lifespan-Rhode Island Hospital, and comply with the National 




Table 10:  Ceramide inhibitors used in experiment  
Name Abbreviation Formula weight Enzyme 
Final 
concentration 
Fumonisin B1 Fumo 721.8 Ceramide Synthase 25 µM 




Desipramine HCL Desi 302.84 Acid Sphingomyelinase 50 µM 















Histopathology: The same histopathological criteria that were used in the in-vivo 
ASH model were used to analyze both the sliced and unsliced “control” liver tissue. 
(See Chapter 2) 
Lipid studies: Lipids were measured from protein homogenates of liver tissue. Lipid 
content was measured using the Nile red fluorescence-based microplate assay as 
described (Lyn-Cook et al., 2009) and triglycerides were measured using the 
Serum Triglyceride determination Kit was purchased from Sigma-Aldrich Co (St 
Louis, MO).  Results were normalized to protein concentration.  Ceramide 
immuoreactivity was measured in protein extracts using a direct-binding ELISA as 
previously described. 
Cytotoxicity assay: Following incubation of liver slices after 24, 48 and 72 hour time 
points, and prior to homogenization, 50µl of the full medium bathing the slices was 
aspirated and transferred to a white Optiplate for cytotoxicity (G6PD release) 
measurements.  We added 50µl of the 2X Resazurin/reaction mixture and 
incubated the plate at 37ºC for 30 minutes.  Fluorescence was read in a 
SpectraMax M5 microplate reader (Molecular Devices Corp., Sunnyvale, CA) at an 
absorbance of 530 nm and emission of 590 nm. The assay was performed 
according to the manufacturer’s protocol. Results were normalized to protein 
concentration. 
 
Duplex Enzyme-Linked Immunosorbant Assay (ELISA): To quantify ER stress 
markers, we measured immunoreactivity to protein kinase RNA-like endoplasmic 










138	  |	  P a g e 	  
	  
inhibitory factor 2-α (eIF2-α) and 78 kiloDalton glucose-regulated protein 78 
(GRP78) using duplex ELISA.  Tissue homogenates were prepared in radio-
immunoprecipitation assay buffer containing protease and phosphatase 
inhibitors, as previously described (Moroz et al., 2008). Thus the control antibody 
(large ribosomal protein or RPLPO) was measured in the same well as the 
antibody of interest, giving a more reliable result.  Briefly, 50µl of protein was 
adsorbed to the bottom of 96-well Maxisorp plate overnight at 4°C. After blocking 
with a 1% BSA-Tris buffered saline solution for 3 hours, the samples were 
incubated with mouse monoclonal primary antibodies (0.1-1.0 µg/ml) for 1 hour at 
room temperature.  Horseradish peroxidase (HRP)-conjugated anti-mouse 
secondary antibodies (1:10000) and Amplex Red soluble flourophore substrate 
were used to detect immunoreactivity (Cohen, Tong, Wands, & de la Monte, 
2007).  Amplex Red fluorescence was measured (Ex 530 nm/Em 590 nm) in a 
M5 microplate reader. To detect the biotin-labelled RPLPO we used anti-RPLPO-
biotin antibodies conjugated with streptavidin-alkaline phosphate and 4-MUP 
substrate, and measured the fluorescence at an excitation of 360 nm and 
emission of 450 nm. Negative controls included reactions in which the primary or 
secondary antibody was omitted. 
Multiplex ELISA: We used bead-based multiplex ELISAs to examine the integrity of 
insulin and IGF-1 signaling networks as before.  
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Assays:  Liver tissue was homogenized in QIAzol reagent. RNA isolated using the 












was reverse transcribed with random oligodeoxynucleotide primers and the AMV 
First Strand cDNA synthesis kit. The cDNAs were used to measure gene 
expression by qPCR with universal probe-based primer pairs (Roche Diagnostics 
Corporation, Indianapolis, IN). The Lightcycler Roche instrument and software 
(Roche Diagnostics Corporation, Indianapolis, IN) were used to detect amplified 
signals from triplicate reactions.  Relative mRNA abundance was corrected to actin 
measured in the same well as the samples in a duplex system. Template-free 
reactions served as negative controls. 
Statistical Analysis: Data depicted in box plots reflect group median, 95% 
confidence interval limits and range (whiskers), while tabulated data reflect means 
± SEMs for each group. Inter-group comparisons were made using two-way 
ANOVAs with post-hoc Bonferroni tests.  Significant P-values are indicated within 
the panels. Data were analyzed using GraphPad Prism 5 software (GraphPad 
Software, Inc., San Diego, CA).  Significant P-values (<0.05) are shown within the 
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4.3 RESULTS 
Effects of ethanol and ceramide inhibitors on steatohepatitis: H&E stained sections 
of liver slices of control-fed rats demonstrated the expected cord-like architecture, 
normal hepatocyte nuclei and absent portal lympho-mononuclear inflammatory cell 
infiltrates, and scattered hepatocytes with macrosteatosis i.e. grade 1 (Figure 4.2 
A-D, right panel). In contrast, in vivo chronic ethanol exposure caused 
steatohepatitis; ethanol-fed livers exhibited a disordered architecture with micro-
vesicular steatosis that was predominantly distributed in Zone 2, wide sinusoids, 
and loss of nuclei grades 2-3 (Figure 4.2 E-H, right panel).  Treatment with 
ceramide inhibitors led to an improvement in the histological appearance of 
alcoholic steatohepatitis compared to vehicle, with the most effect seen with 
fumonisin B1 (Figure 4.2 G, right panel). In addition, histological slides were 
obtained from liver tissue harvested de novo from control (Figure 4.2 A-C, left 
panel) and ethanol-fed (Figure 4.2 D-F, left panel) rats i.e. the livers were not 
sliced.  These were used to serve as controls for the histological appearance and 
quality of liver slices.  The architectural integrity of the liver slices at histology was 
maintained and the same detail as in the quality-control slides was seen. Overall, 
there were clearly discernible effects of ceramide inhibitor treatments, particularly 
fumonisin B1 on the histological appearance of the control and ethanol-fed liver 
slices. 
Hepatic steatosis was further characterized by measuring neutral lipid, 












hours demonstrated a higher mean level of neutral lipids in livers of ethanol- 
relative to control-fed rats treated with vehicle, however the difference was not  
 
 
Figure 4.2: Effects of chronic ethanol feeding and ceramide inhibitor treatment on 
steatohepatitis (72 hours). Adult male Long Evans rats were fed for 5 months with a control or 
ethanol diet (37% by caloric content), and treated with vehicle or ceramide inhibitors viz: fumonisin 
B1 (fumi), myriocin (myr) and desipramine (desi).  Paraffin-embedded histological sections (5 µm 
thick) of whole pieces of liver (left panel) or liver slices (right panel) were stained with H&E and 
photographed at 40x (A, D), 160x (B, E), and 400x (C, F) magnifications in left panel and 400x 
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marked (data not shown). In control-fed rats, treatment with ceramide inhibitors 
resulted in similar or reduced levels of neutral lipids as in the vehicle-treated group, 
suggesting that these agents have a lipid-lowering effect under basal conditions. 
However, at 48 hours post-incubation (Figure 4.3 A) ceramide inhibitors did not 
reduce ethanol-induced elevations of neutral lipid accumulation, as evidenced by a 
near doubling of neutral lipid accumulation in ethanol-fed rats (p<0.001). Similarly 
at 24 hours (Figure 4.4 A) triglyceride accumulation in ethanol-fed rats was higher 
than that in control-fed counterparts more so with fumonisin B1 (p<0.05) and 
myriocin (p<0.001) treatments than desipramine. Similar or lower levels were seen 
with ceramide inhibitors in control-fed rats. Ceramide inhibitors did not lead to a 
reduction of triglyceride levels as shown by increasing ratios of ethanol to control 
levels. At 72 hours hepatic neutral lipid (Figure 4.3 C) in livers of vehicle-treated 
rats was comparably lower to that observed at 48 hours in both the control- and 
ethanol-fed rats. Although neutral lipid levels were lower in the control-fed rats 
treated with ceramide inhibitors relative to the 48-hour time point, neutral lipid 
levels were marginally increased with myriocin and desipramine. In ethanol-fed 
rats however, treatment with ceramide inhibitors led to marked reductions in 
neutral lipid with the most effects seen with myriocin and desipramine. At 48 hours 
(Figure 4.3 B) ceramide inhibitor treatment reduced ethanol-induced elevations of 
triglycerides, most effective was myriocin (p<0.01). 
Ceramides were measured at 48 and 72 hours. At 48 hours (Figure 4.3 B), ethanol 
resulted in markedly increased levels of ceramide versus those in control-fed rats 












similar or lower than in vehicle-treated rats. However, after 48 hours ceramide 
inhibitors did not significantly reduce ethanol-induced elevations of ceramide; the 
least effective agent was fumonisin B1 (p<0.001). At 72 hours (Figure 4.3 D) 
ceramide levels were reduced in both control- and ethanol-fed rats with ceramide 
inhibitor treatments, and fumonisin and desipramine were most effective in 
reducing ethanol-induced increases in ceramides.   
 
Figure 4.3:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on neutral 
lipid and ceramide accumulation at 48 and 72 hours post-culture. Liver slices from culture were 
homogenized in weak lysis buffer, and the protein extract was used to measure (A) neutral lipid at 
48 hours and (C) at 72 hours and (B) ceramide at 48 hours and (D) at 72 hours, using the Nile Red 
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measured by the BCA method). Data depicted in box plots reflect group median, 95% confidence 
interval limits and range (whiskers). Inter-group comparisons were made using two-way ANOVAs 
with post-hoc Bonferroni tests.  Significant P-values are indicated within the panels. 
 
 
Figure 4.4:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on 
triglyceride accumulation. Liver slices from culture were homogenized in weak lysis buffer, and the 
protein extract was used to measure trigylceride at (A) 24 hours and (B) 48 hours using a 
commercially available kit (see Material and Methods). The results were normalized to protein 
concentrations (as measured by the BCA method). Data depicted in box plots reflect group median, 
95% confidence interval limits and range (whiskers). Inter-group comparisons were made using 
two-way ANOVAs with post-hoc Bonferroni tests.  Significant P-values are indicated within the 
panels. 
 
Effects of ethanol and ceramide inhibitor treatments on cytotoxic levels in liver: The 
cytotoxicity assay used measures the release of cytosolic enzyme glucose 6-
phosphate dehydrogenase (G6PD) from damaged cells.  The fluorescent signal 
detected (proportional to G6PD) correlates with the number of dead cells in the 
sample.  Measurements at 24 hours (Figure 4.5 A), exhibited higher levels of 












rats treatment with all ceramide inhibitors marginally reduced ethanol-induced 
increases towards control levels to a similar degree. At 48 hours (Figure 4.5 B), the 
ratio of G6PD release in ethanol- versus control-fed rats was higher than at 24 
hours; myriocin (p<0.001) and desipramine (p<0.01) were the least effective in 
reducing ethanol-induced elevations.  In contrast at 72 hours (Figure 4.5 C) G6PD 
release is at similar levels in fumonisin B1- and vehicle- treated rats, but is lower in 
ethanol-fed rats treated with desipramine (p<0.0001) than any other group.  
 
Figure 4.5:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on 
cytotoxicity. Liver slices from culture were homogenized in weak lysis buffer, and the protein extract 
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commercially available kit (see Material and Methods). The results were normalized to protein 
concentrations (as measured by the BCA method). Data depicted in box plots reflect group median, 
95% confidence interval limits and range (whiskers). Inter-group comparisons were made using 
two-way ANOVAs with post-hoc Bonferroni tests.  Significant P-values are indicated within the 
panels. 
 
Effects of ethanol and ceramide inhibitor treatments on ER stress markers in liver: 
To investigate the role of ER stress in this model we measured hepatic mRNA 
levels of activating transcription factor-4 (ATF-4) (Figure 4.6 A), GRP78 (Figure 4.6 
B) and CHOP (Figure 4.6 C) at 48 hours. Levels of ATF-4, GRP78 and CHOP 
were similarly low in vehicle-treated control- and ethanol-fed rats whereas control-
fed rats treated with ceramide inhibitors had upregulated levels of ATF-4, GRP78 
and CHOP compared to their ethanol-fed counterparts. The effects of ceramide 
inhibitor treatments (myriocin and desipramine more than fumonisin B1) were 
significant with marked reductions in ethanol-fed rats by at least 40%.  Therefore 
treatment with ceramide inhibitors had a downregulating effect on ER stress mRNA 
levels associated with long- term ethanol feeding. 
Correlative protein expression of ER stress was assayed using duplex 
ELISAs.  We measured PERK and eIF2-α levels and their corresponding 
phosphorylated proteins at 48- and 72-hour time points. At 48 hours total levels of 
PERK (Figure 4.7 A) and eIF2-α (Figure 4.7 D) in vehicle and treated rats were not 
significantly different in control- and ethanol-fed rats, except for eIF2-α levels that 












treatment. Although levels of phosphorylated PERK (Figure 4.7 B) and eIF2-α 
(Figure 4.7 E) were reduced by both myriocin (p<0.001) and desipramine 
(p<0.001) in ethanol-fed rats, a calculated ratio of phosphorylated to total levels 
was only significant for PERK with fumonisin B1 treatment (p<0.01). At 72 hours 
total PERK and eIF2-α levels were similar in vehicle-treated rats.  In treated rats 
total PERK (Figure 4.8 A) levels in ethanol-fed rats were reduced to similar levels 
as in control-fed rats with myriocin (p<0.01) and desipramine (p<0.001) treatments.   
!" #" $"
 Figure 4.6:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on ER 
stress signaling network genes. Total RNA extracted from cultured liver slices was reverse 
transcribed (see Materials and Methods) and the resulting cDNAs were used as templates to 
measure (A) ATF-4, (B) GRP78 and (C) CHOP. mRNA abundance was corrected for using Actin as 
the control gene. Data depicted in box plots reflect group median, 95% confidence interval limits 
and range (whiskers). Inter-group comparisons were made using two-way ANOVAs with post-hoc 
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By contrast total eIF2-α levels (Figure 4.8 D) in control- and ethanol-fed rats were 
similar with fumonisin B1 and desipramine treatments, and higher in ethanol-fed 
rats with myriocin treatment (p<0.01). Phosphorylated eIF2-α levels (Figure 4.8 E) 
were higher levels in ethanol- compared to control-fed rats with desipramine 
treatment (p<0.05).  A calculated phosphorylated/total PERK ratio (Figure 4.8 C) 
showed higher levels in all groups in control- relative to ethanol-fed rats.  A 
calculated phosphorylated/total eIF2-α level (Figure 4.8 F) showed a reduction in 
ethanol-induced rises with myriocin treatment (p<0.05) but a further increase with 
desipramine (p<0.001). Collectively therefore, at 48 hours fumonisin B1 was 
effective in reducing active PERK levels in ethanol-fed rats, however at 72 hours 
there was no effect of all ceramide inhibitors on PERK levels as the profile was 
almost identical between the vehicle and treated groups. In contrast myriocin was 
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Figure 4.7:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on 
downstream mediators of ER stress signaling at 48 hours. Liver protein homogenates were used in 
bead-based Multiplex ELISAs to measure the immunoreactivities of (A) total PERK, (D) eIF2a and 
their phosphorylated counterparts (B, E respectively). In addition, the phosphorylated/total protein 
ratios (C, F respectively) wer  calculated to assess relative levels of phosphorylation of each 
protein. Data depicted in box plots reflect group median, 95% confidence interval limits and range 
(whiskers). Inter-group comparisons were made using two-way ANOVAs with post-hoc Bonferroni 


















Figure 4.8:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on 
downstream mediators of ER stress signaling at 72 hours. Liver protein homogenates were used in 
bead-based Multiplex ELISAs to measure the immunoreactivities of (A) total PERK, (D) eIF2a and 
their phosphorylated counterparts (B, E respectively). In addition, the phosphorylated/total protein 
ratios (C, F respectively) were calculated to assess relative levels of phosphorylation of each 
protein. Data depicted in box plots reflect group median, 95% confidence interval limits and range 
(whiskers). Inter-group comparisons were made using two-way ANOVAs with post-hoc Bonferroni 
















Effects of ethanol and ceramide inhibitor treatments on insulin and IGF signaling 
mechanisms in liver:  Previous studies demonstrated that steatohepatitis produced 
by high fat diet or chronic ethanol feeding impairs insulin and IGF signaling in the 
liver. We re-investigated this concept and also interrogated the potential 
therapeutic effects of ceramide inhibitors on ethanol-mediated inhibition of 
insulin/IGF signaling by measuring mRNA levels of insulin, IGF-1, and IGF-2 
polypeptides, their corresponding receptors, and IRS-1 and IRS-4 by qRT-PCR 
analysis (Figure 4.9). The qRT-PCR analyses demonstrated similarly low mean 
levels of measured polypeptides in vehicle-treated rats except of IGF-2 receptor 
and IRS-4, which were lower in rats fed ethanol compared to control diet. 
Furthermore levels of insulin, IGF-1, IGF-2, insulin and IGF-1receptors, IRS-1 and 
IRS-4 were lower in ethanol- versus control-fed rats with all ceramide inhibitors.  
Analysis of the upstream signaling networks using multiplex ELISAs 
revealed similar mean levels of total and phosphorylated IN-R, IGF-1R, and IRS-1 
in all groups (Figure 4.10). With respect to phosphorylated/total ratios the only 
significant difference was observed with IN-R, with a lower mean in ethanol- 
relative to control-fed rats (p<0.05) with vehicle. Therefore, chronic ethanol feeding 
lead to a suppression of hepatic signaling through IN-R and thus no protective 





















Figure 4.9:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on 
upstream insulin signaling network genes. Total RNA extracted from cultured liver slices was 
reverse transcribed (see Materials and Methods) and the resulting cDNAs were used as templates 
to measure (A) insulin, (B) insulin-like growth factor 1, (C) insulin-like growth factor 2 and their 
corresponding receptors (D, E, F respectively), as well as (G) IRS 1 and (H) IRS 4. mRNA 
abundance was corrected for using Actin as the control gene. Data depicted in box plots reflect 
group median, 95% confidence interval limits and range (whiskers). Inter-group comparisons were 
made using two-way ANOVAs with post-hoc Bonferroni tests.  Significant P-values are indicated 
within the panels.  
 
Downstream signaling through insulin/IGF-1 in liver (Figure 4.11) showed similar mean 
levels of total GSK-3β, PRAS40 and p70S6K, in all groups. Signaling through Akt on the 
other hand was impaired in ethanol- relative to control-fed rats treated with vehicle 
(p<0.001), signified by lower mean hepatic levels in the former. There was no difference 












insulin signaling polypeptides. Hepatic pS473-pAkt /total Akt ratio (p<0.01), pT246-
PRAS40/total PRAS40 ratio (p<0.05) and pTpS421/424-p70S6K/total p70S6K ratio (p<0.01) 
were significantly reduced by chronic ethanol- relative to control-feeding with vehicle, 
and ceramide inhibitor treatment had no significant effect in ameliorating the effects of 





  Figure 4.10:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on upstream 
mediators of insulin/IGF signaling.  Liver protein homogenates were used to measure immunoreactivity 
corresponding to (D) insulin receptor (IN-R), (E) insulin-like growth factor 1 receptor (IGF-1R), (F) IRS-1, 
and their corresponding phosphorylated proteins pYpY1162/1163-IN-R, pYpY1135/1136-IGF-1R, and pS312-IRS-1 (A, 
B, C) with a bead-based Multiplex ELISA platform. In addition, the phosphorylated/total protein ratios (G, 
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plots reflect group median, 95% confidence interval limits and range (whiskers). Inter-group comparisons 
were made using two-way ANOVAs with post-hoc Bonferroni tests.  Significant P-values are indicated 
within the panels.  
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Figure 4.11:  Effects of chronic alcohol feeding and ceramide inhibitor treatment on downstream 
mediators of insulin/IGF signaling.  Liver protein homogenates were used to measure immunoreactivity 
corresponding to (E) Akt, (F) GSK-3β, (G) PRAS40, (H) p70S6K, and their corresponding phosphorylated 
proteins pS473-Akt, pS9-GSK3β, pT246-PRAS40 and pTpS421/424-p70S6K (A-D) with a bead-based Multiplex 
ELISA platform. In addition, the phosphorylated/total protein ratios (I-L) were calculated to assess relative 
levels of phosphorylation of each protein. Data depicted in box plots reflect group median, 95% confidence 
interval limits and range (whiskers). Inter-group comparisons were made using two-way ANOVAs with post-














The present study sought to evaluate primarily the effects of ceramide inhibitor 
treatment on ethanol-induced steatohepatitis, particularly in reference to 
cytotoxicity, ER stress and impairments in insulin signaling.  Secondary we 
aimed to study the utility and reliability of this in-vivo slice culture system as an 
alternative approach to studying the therapeutic applications and implications of 
a myriad of liver diseases. Our hypothesis is based on evidence that mediators of 
alcoholic steatohepatitis include ceramide-induced lipotoxicity and insulin 
resistance, oxidative stress and pro-cytokine activation. To achieve this we 
utilized PCLS as these have been shown to be useful on toxicology and 
pharmaceutical studies (Parrish et al., 1995), and would be well suited for our 
purposes.  
Effects of ethanol: The main findings were that the full pathophysiological 
spectrum of alcoholic liver disease expected in rodent models of disease was 
seen as evidenced by the histological features, corroborated by the accumulation 
of lipid, including ceramide in ethanol-treated rats.  As expected, ethanol-fed rats 
exhibited higher cytotoxic levels consequent to the attendant inflammation and 
possibly lipid peroxidation.  Furthermore we observed IGF-2-mediated 
transcriptional and Akt-, PRAS40- and p70S6K-mediated post-transcriptional 
impairments of insulin signaling. Ethanol- or obesity-induced impairments in 
insulin signaling have been shown in our previous studies (de la Monte et al 
2008, Denucci, SM 2010) and other laboratories (Svegliati-Baroni et al., 2006; 
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metabolism, we demonstrated significant ethanol inhibition of signaling 
downstream of PI3 kinase-Akt through p70S6K, and mTOR-dependent PRAS40 
pathways, indicating that chronic ethanol feeding inhibits protein synthesis 
(Berven & Crouch, 2000; Nascimento & Ouwens, 2009). 
Effects of ceramide inhibitors: Our results showed that the administration of 
fumonisin B1 was most effective in improving the histological appearance of the 
liver slices. The effect of ceramide inhibitors on lipid accumulation was mirrored 
in quantitative reductions in neutral lipid accumulation at 72 hours with myriocin 
and desipramine treatments, and triglyceride accumulation at 48 hours with 
myriocin treatments. The ‘dominant’ effects of fumonisin and myriocin suggest 
that inhibition of ceramide synthesis may be more important than inhibition of 
ceramide degradation, in ameliorating ceramide-induced lipototoxicity. Although 
the half-life of these inhibitors has not been tested in in-vivo systems, it is likely 
that the half-life is longer than 48 hours, as these agents were more effective 
after longer incubations. On the other hand, at the 24 hour and 48 hour time 
points, neutral lipid and triglyceride accumulations respectively were not different 
in the control and ethanol-fed rats; this could be explained by the fact that the 
slices were not maintained in an alcohol chamber during incubation, thus 
resulting in an “alcohol off” effect.  It will therefore be crucial in future experiments 
to include the use of an alcohol chamber to control for this.  
 With regard to cytotoxicity, in the initial phases post-incubation there is no 
difference in G6PD release in control and ethanol-fed rats. This may be due to 












diet or treatment. After 48 hours incubation, the ‘true’ effects of diet and 
treatment can be appreciated, and these correlate well with the effects seen on 
lipid accumulation, with desipramine resulting the most effective reduction in 
levels of cytotoxicity. Once again ceramide inhibitors were most effective after 
longer incubation periods. 
 Most evident in this model was the up-regulating effect of alcohol on 
markers of ER stress, and the effectiveness of fumonisin on PERK levels at 48 
hours and myriocin on eIF2-α at 72 hours, at both transcriptional and post-
transcriptional levels in reducing alcohol-induced ER stress.  Alcohol causes ER 
stress not only by the altered redox potential generated with its metabolism, but 
also as a result of the associated metabolic stress, and steatosis.  Therefore, the 
effect of ceramide inhibitors on ER stress proves the principle of the key role of 
ER stress in producing steatohepatitis with chronic alcohol feeding. 
The in-vivo system: Historically PCLSC is fraught with problems of intra- and 
inter-laboratory variability not least in our hands.  In our experiments we did not 
use a rotating platform during incubation, which has been reported by some to 
give superior results (Hashemi, Dobrota, Till & Loannides, 1999).  However given 
that after 48 hours lipid studies and cytotoxicity levels showed a correlation it is 
likely that viability of cells was not negatively impacted by not using a rotating 
platform. In addition, the mechanical stress suffered by the slice culture 
technique and subsequent incubation did not impair the architectural integrity of 
the liver slices (see histology).  As mentioned an area of improvement in future 
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maintain high concentrations of ethanol exposure on the slices, to off - set the 
“ethanol-off” effect that was evident in our model.  
Thus we provide evidence that PCLSC is a robust reliable model for studying and 
understanding the pathophysiology of alcoholic steatohepatitis. Furthermore, 
notwithstanding technical improvements in the experimental procedures that can 
be implemented, it provides a user-friendly alternate in-vitro system by which the 
metabolic effects of toxic insults and therapeutic effects can be studied.  This 
utility can have wide-ranging impact in the understanding of disease processes 
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 CHAPTER 5 
 
Re-activated Wnt signaling is crucial in the pathogenesis of HCC 
in a double transgenic mouse model that constitutively over-
expresses the HBx and IRS-1 genes in liver 
 
ABSTRACT 
Background: Hepatocellular carcinoma (HCC) is associated with aberrant 
growth factor signaling. Both insulin/IGF and Wnt/β-catenin signaling pathways 
have been individually implicated in the pathogenesis of HCC. Previous data 
have shown that crossing the single genes to create a double transgenic (ATX 
and IRS-1) mouse resulted in HCC associated with upregulation of IGF1 and 
Wnt3 and Frizzled7 mRNA transcripts. To date despite active research in the 
field, there are no therapeutic molecules targeting this pathway, therefore, 
identifying the target genes of Wnt signaling remains critical for understanding β-
catenin-mediated carcinogenesis. 
Aim: The purpose of this work is to characterize alterations of the Wnt/β-catenin 
signaling pathway, and the gene expression pattern of components of canonical 
and non-canonical Wnt signaling in a double transgenic mouse model of HCC. 
Methods: We analyzed liver tissue from double transgenic (ATX and IRS-1) mice 
sacrificed at 3, 6, 9, 12, 15, 18, 21 and >21 months (n=12 per time point) by qRT-
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Results:  Tumours developed only in the male mice generally after 15-18 
months. The majority of canonical and non-canonical Wnt ligands, receptors and 
downstream targets including target genes were upregulated in mice without 
tumours at early time points. However, some genes including Wnt 1, 2, 3, 4, 6, 
7b, 11 and Fzd8, 2, 3 and Fzdb were also upregulated in HCC (occurring at later 
time points), suggesting re-activation of Wnt signaling in HCC. Specifically Wnt5b 
and Wnt7b were significantly upregulated in double transgenic mice with 
tumours, suggesting they may be key regulators in HBV-related HCC. 
Surprisingly, some of the Wnt negative regulators, Wif1, Sfrp1, 2 and 4 were 
upregulated, which may be indicative of epigenetic regulation; however further 
studies are required to examine this. 
Conclusions: Our study identified several candidate genes of Wnt signaling, 
particularly Wnt5b and 7b that are dysregulated and appear to be carcinogenic in 
mouse HCC. These genes may serve as useful potential therapeutic targets for 





















Cirrhosis is associated with decreased hepatocyte proliferation and is the chief 
risk factor for the development of hepatocellular carcinoma (HCC). Progression 
of liver disease to HCC occurs in a step-wise fashion, initially with the 
development of pre-neoplastic dysplastic nodules (DN), followed by well-
differentiated HCC associated with more molecular abnormalities (Farazi & 
DePinho, 2006). Many factors are involved in the process of promoting 
hepatocarcinogenesis once cirrhosis is established. These include alterations in 
the genetic sequence coding for proto-oncogenes or tumour-suppressor genes 
important for growth or anti-growth signals respectively, commonly by way of 
mutations (Hussain, Hofseth, & Harris, 2003). Mutations of p53, p16, and β -
catenin have been described in HCC (Herath, Leggett, & MacDonald, 2006), 
however do not account for all cases of HCC. There are other molecular events 
that predispose a cirrhotic liver to transform to HCC, and these include resistance 
to apoptosis, activation of telomerase and of oncogenic pathways i.e. Wnt/β-
catenin, PI3K/Akt and others (El-Serag & Rudolph, 2007).  
 Furthermore, changes in gene expression as a result of heritable changes 
of genes, albeit not of the sequence itself, that influence phenotype are involved 
in the pathogenesis of HCC. These are referred to collectively as epigenetic 
modifications, which fall into 3 broad groups: changes in methylation status, 
histone deacetylation (linked with transcriptional repression), and micro-RNA 
regulations. Typically with HCC there is global hypomethylation of the genome, 
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(Calvisi et al., 2007) but hypermethylation of the promoter regions of genes with 
a high content of cytosine-guanosine nucleotides (CpG islands). 
Hypermethylation of CpG islands results in transcriptional repression of tumour 
suppressor genes, thus promoting proliferation, evasion of apoptosis and 
eventual cancer. Additionally, although normal ageing can be associated with 
hypermethylation (Esteller, 2008), hypomethylation appears to be the pre-
dominant mechanism of gene expression regulation in aging (Rodriguez-Rodero, 
Fernandez-Morera, Fernandez, Menendez-Torre, & Fraga, 2010). As many 
malignant diseases including HCC are associated with aging, the investigation of 
age-related epigenetic modifications being responsible for HCC is interesting. We 
hypothesized that impairments in Wnt signaling at various time points in the 
progression to HCC can uncover critical clues about which components of 
activated or downregulated signaling are important for hepatocarcinogenesis. 
The relevance of this study could be the potential use of activators or inhibitors of 
Wnt signaling that can be targeted for the treatment of HCC. 
 HBV accounts for over half of virus-related HCC cases worldwide (Parkin, 
Bray, Ferlay, & Pisani, 2005) but more so in the East and Africa. While the 
mechanism of HBV hepatocarcinogenesis is still being sought, a small protein, 
the hepatitis B x protein (HBx), encoded for by the hepatitis B x gene has been 
shown in many studies to affect many pathways involved in the promotion of 
cancer. HBx is an oncogenic multifunctional protein that up-regulates proto-
oncogenes (c-myc, N-myc and c-jun), transcription factors (AP-1, NF-κB and 












Mitchell, & Yen, 1990), and is involved in the regulation of apoptosis (Benn & 
Schneider, 1995; Gottlob, Fulco, Levrero, & Graessmann, 1998; Marusawa et al., 
2003). More importantly HBx regulates a variety of pathways including Ras-
Raf/MAPK, SAPK/JNK, PI3K/Akt (Doria, Klein, Lucito, & Schneider, 1995; Y. H. 
Lee & Yun, 1998; Natoli et al., 1994) including the Wnt pathway. HBx can 
activate Wnt/β-catenin signaling by inhibiting GSK-3β via several mechanisms or 
by stabilizing β-catenin independently of GSK-3β (Cha, Kim, Park, & Ryu, 2004; 
Q. Ding et al., 2005; Jung, Kwun, Lee, Arora, & Jang, 2007). 
Wnt/β-catenin signaling is a highly conserved pathway that has roles in 
proliferation, cell fate determination, cell cycle, apoptosis and motility. Wnt 
signaling is quiescent in normal cells and is expressed at very low levels in liver. 
With canonical signaling, in this inactive state, intracellular β-catenin is primed for 
ubiquitin-proteosome degradation by the degradation complex (APC/Axin/GSK-
3β). In the active state, Wnt ligands bind to Frizzled receptors at the cell 
membrane, and these co-operate with LRP, to transmit the signal to Dishevelled, 
which associates with the degradation complex, thereby phosphorylating and 
inactivating GSK-3β, thus allowing for the accumulation of β -catenin.  β -catenin 
then translocates to the nucleus to increase transcription of target genes that 
promote carcinogenesis by increasing cell proliferation, angiogenesis, anti-
apoptosis and the laying down of extracellular matrix (Avila, Berasain, Sangro, & 
Prieto, 2006). The role of β-catenin in HCC is evident in the fact that 17-40% of 
human HCC show a nuclear accumulation of β-catenin (Hsu et al., 2000; Nhieu 
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pathways of Wnt signaling i.e. planar cell polarity (PCP) pathway (that regulates 
the cytoskeleton and cell motility particularly during embryogenesis) and 
Wnt/Calcium pathway (that promotes the transcription of nuclear factor of 
activated T cells (NFAT), independently of β-catenin). 
 Insulin signaling favours cell growth and survival, and in human HCC the 
insulin signaling pathway is dysregulated as a result of increased expression of 
IGF-2 (Breuhahn et al., 2004; de La Coste et al., 1998; Longato et al., 2009; 
Sohda, Yun, Iwata, Soejima, & Okumura, 1996), or IRS-1 (Alexia, Fallot, Lasfer, 
Schweizer-Groyer, & Groyer, 2004; Breuhahn, Longerich, & Schirmacher, 2006). 
Indeed IRS-1 is overexpressed in 90% of human HCC, and is associated with 
increased signaling downstream through PI3kinase/Akt and Erk/MAPK, which 
regulate growth, motility and invasiveness, and IRS-1 correlates significantly with 
tumour size (Ito, Sasaki, & Wands, 1996; Tanaka, Mohr, Schmidt, Sugimachi, & 
Wands, 1997).  
 Initial studies in our laboratory using this model demonstrated no increased 
HCC development in mice carrying the IRS-1 single transgene (Mohr, Banerjee, 
Kleinschmidt, Bartolome Rodriguez, & Wands, 2008; Tanaka et al., 1997). 
However when IRS-1 was cross-bred with the hepatitis B x (ATX) transgene 
there was progressive hepatocellular injury and turnover, dysplasia, and 
eventually HCC development over time, beginning at 15 months of age, and 
predominantly in males, in double transgenic mice (Longato et al., 2009). In the 
same study there was upregulation of Wnt 1, Wnt 3 and AAH, all of which are 












 In this longitudinal mouse model of HCC, where the mice could be followed 
for at least 3 months to over a 2 year period, we aimed to characterize a broader 
spectrum of Wnt signaling components (i.e. ligands, receptors, target molecules 
including negative regulators) at the various time points in wild type and double 
transgenic mice, as well as to correlate these signaling changes with the possible 
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5.2 MATERIALS AND METHODS 
Transgenic Mouse Models: The mice were purchased from and bred at Charles 
River laboratories, and heterozygous mice expressing the IRS-1 gene were 
mated with heterozygous mice expressing HBx (ATX gene). Transgenic 
expression was achieved by using a liver-specific promoter, the human alpha-1 
antitrypsin regulatory region for the ATX mice and albumin promoter for IRS-1 (T. 
H. Lee et al., 1990; Tanaka et al., 1997).  Thus there were 4 groups of mice viz: 
wild type (WT), ATX single transgenic, IRS-1 single transgenic and IRS-1/ATX 
(double transgenic). Non-transgenic littermates were used as controls. In this 
study 2 groups of animals viz: wild type and ATX/IRS-1 (double transgenic) were 
compared. To map out time course of histological and molecular changes, mice 
were sacrificed at time points 3, 6, 9, 12, 15, 18, 21 or more months and liver 
samples were collected for qRT-PCR analysis of Wnt pathway genes. During the 
course of breeding, the mice were monitored; food, activity levels and hydration 
were checked daily. 
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Assays:  Liver tissue was homogenized in QIAzol Lysis Reagent. RNA was 
isolated using the EZ1 RNA Universal Tissue Kit and the BIO Robot EZ1 (Qiagen 
Inc., Valencia, CA), was reverse transcribed with random oligodeoxynucleotide 
primers and the AMV First Strand cDNA synthesis kit purchased from Roche 
Applied Science (Indianapolis, IN). The cDNAs were used to measure gene 
expression by qPCR with a Wnt Signaling Pathway RT2 Profiler PCR Array kit 












canonical and Wnt target genes. The Roche instrument and software were used 
to detect amplified signals from triplicate reactions.  Relative mRNA abundance 
was calculated from the ng ratios of specific mRNA to control genes 
[(hypoxanthine phosphoribosyltransferase1 (HPRT1), ribosomal protein L13a 
(RPL13A), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), actin beta 
(ACTB) and beta-2 microglobulin (B2M)] supplied with the kit. Template-free 
reactions served as negative controls. 
Statistical analysis: The comparison was made between the wild type versus the 
double transgenic mice. Similarly we did an analysis of the gene expression fold 
change between double transgenic and wild type by calculating a ratio. The data 
was also compared over time using a line chart. To compare pre-malignant 
disease and HCC the data was plotted in bar graphs depicting the time points 3 
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5.3 RESULTS 
Gene expression patterns over time in WT and DT mice without tumours  
To compare patterns of gene expression over time in mice that did not develop 
tumours i.e. under baseline conditions, we analyzed the data at individual time 
points from 3 to greater than 21 months. We measured the fold change in gene 
expression by plotting a ratio of DT expression levels over WT (Figures 5.1, 5.2, 
5.3). There were three observed distinct patterns viz: some genes were highly 
expressed at 3 months (5-40 fold higher in DT than WT), and over time gradually 
declined either precipitously or in a step-wise fashion to very low levels. These 
were the Wnt ligands Wnt1, Wnt3, Wnt8a, Wnt8b and Wnt9a, the frizzled and 
related receptors Fzdb, Fzd3, Sfrp2 and Sfrp4 and downstream genes Dvl1, 
GSK-3β, Tcf4, Pygo1, Sox17, Foxn1 and Fos1. The second pattern observed 
was that of genes that were upregulated (2 to 15-fold) at 3 months, rose to higher 
levels (at 6-12 months), and then steadily declined to lower levels by about 18 
months. These include ligands Wnt3a, Wnt6, Wnt7a, Wnt7b, Wnt10a, Wnt11 and 
Wif1, Wisp1 and further downstream genes Dkk1, Lef1, Pitx2, Fgf4, Pitx2 and 
Fshb. The third group are those genes that from 3 to 24 months were essentially 
unchanged, and these are ligands Wnt2, Wnt4, Wnt5b, and Wnt16 and receptors 
Fzd2, Fzd6, Fzd7, Fzd8 and Sfrp1, and further downstream Tcf3, Nlk and Tle2. 
Wnt2b was different in that it had very low levels of expression until 17 months, 















 Figure 5.1: Analysis of the relative mRNA transcript fold difference of Wnt ligand signaling 
genes in mice that did not develop tumours over time from time points 3 to > than 21 months 
(represented in a line chart as a ratio of double transgenic (DT) mice over the wild type (WT) 
mice. RNA extracted from liver was reverse transcribed and the cDNAs were used to measure 
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(J) Wnt7b, (K) Wnt8a, (L) Wnt8b, (M) Wnt9a, (N) Wnt10a, (O) Wnt11, (P) Wnt16, (Q) Wisp1 and 




 Figure 5.2: Analysis of the relative mRNA transcript fold difference of Wnt receptor 
signaling genes in mice that did not develop tumours over time from time points 3 to > than 21 
months (represented in a line chart as a ratio of double transgenic (DT) mice over the wild type 
(WT) mice. RNA extracted from liver was reverse transcribed and the cDNAs were used to 
measure (A) Fzdb, (B) Fzd2, (C) Fzd3, (D) Fzd6, (E) Fzd7, (F) Fzd8, (G) Sfrp1, (H) Sfrp2 and (I) 













 Figure 5.3: Analysis of the relative mRNA transcript fold difference of Wnt downstream 
signaling genes in mice that did not develop tumours over time from time points 3 to > than 21 
months (represented in a line chart as a ratio of double transgenic (DT) mice over the wild type 
(WT) mice. RNA extracted from liver was reverse transcribed and the cDNAs were used to 
measure (A) Dkk1, (B) Dvl1, (C) GSK-3β, (D) Lef1, (E) Tcf3, (F) Tcf4, (G) Pitx2, (H) Pygo1, (I) 
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Tumours in wildtype (WT) versus tumours in double transgenic (DT) mice 
Gene expression of Wnt ligands: Analysis of gene expression of Wnt ligands 
(calculated relative to housekeeping control gene) in wild type (WT) (n=4) and 
double transgenic (DT) mice (n=8) that developed tumours showed that out of a 
panel of 18 Wnt genes studied, the majority of them were either significantly or 
moderately upregulated in DT compared to WT, and unlike two genes that were 
higher in WT (Figure 5.4). Gene expression of Wnt5b was greater than 20-fold 
and that of Wnt7b greater than 15-fold higher in DT compared to WT.  Wnt1, 
Wnt3, Wnt3a, Wnt6, Wnt7b, Wnt8b, Wnt9a, Wnt10a, Wnt11, Wif1 and Wisp1 
mRNA transcripts were at least between 5 and 12-fold higher in DT than WT and 
those of Wnt2, Wnt4, Wnt7a and Wnt16 were 2 to 3-fold higher. Contrastingly, 
Wnt2b and Wnt8a had lower gene expression in DT compared to WT. 
Gene expression of Frizzled and Sfrps: All measured inhibitors of frizzled i.e. 
sfrps were upregulated in DT relative to WT (Figure 5.5). The highest was sfrp4 
(upregulated 20-fold), followed by sfrp2 (4-fold) and sfrp1, which was 1.5-fold 
upregulated in DT compared to WT. Fzd8 was significantly upregulated (4-fold) 
compared to other frizzled proteins i.e. Fzdb, Fzd2, Fzd3 with more modest 
upregulation (1 to 2.5-fold increases) in DT compared to WT.  By contrast Fzd6 













 Figure 5.4: Analysis of the relative gene expression of Wnt signaling genes in WT and DT 
mice with tumours. RNA extracted from liver was reverse transcribed and the cDNAs were used 
to measure (A) the 18 afore-mentioned Wnt ligands by qPCR using a PCR Array Kit (see 
Materials and Methods). In (B) gene expression is expressed as a fold difference calculated as a 














 Figure 5.5: Analysis of the relative gene expression of Wnt signaling genes in WT and DT 
mice with tumours. RNA extracted from liver was reverse transcribed and the cDNAs were used 
to measure (A) the 9 afore-mentioned Wnt receptors and related proteins by qPCR using a PCR 
Array Kit (see Materials and Methods). In (B) gene expression is expressed as a fold difference 













Gene expression of downstream genes of Wnt signaling: Genes of canonical 
signaling were significantly upregulated i.e. Foxn1 and Lef1 (≥ than 20-fold 
increase) and compared to other genes in DT versus WT (Figure 5.6). Other 
canonical genes that were more moderately upregulated (2 to 10-fold) in DT 
compared to WT include Ctbp2, Dkk1, Dvl1, GSK-3β, Porcn and Pygo1.  The 
target genes of Wnt signaling, Fosl1, Myc and Pitx2 were marginally upregulated 
(at least 1-fold) in DT compared to WT, and the genes involved in developmental 
processes such as growth and proliferation that were modestly upregulated were 
Fgf4, and Fshb and those downregulated were Rhou and Slc9a3r1 in DT relative 
to WT. Finally the remainder of the panel measured genes that are negative 
regulators of Wnt signaling i.e. Nlk and Tle2, and these were downregulated 
whereas Ppp2r5d was upregulated in DT compared to WT. 
 
Gene expression in pre-malignant versus HCC lesions 
Wnt ligands: To understand more clearly the differences in signaling that occur at 
different stages of progression to HCC, we stratified the data according to the 
different time points from 3 to 21 months (representing the pre-malignant phase) 
versus HCC (Figure 5.7). Wnt1, Wnt3, Wnt3a, Wnt5b, Wnt9a, Wnt11 and Wisp1 
had essentially similarly low levels of gene expression in the WT mice at 3, 6, 12, 
15, 18, 21 months and in HCC with some fluctuations e.g. higher levels of Wnt9a 
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 Figure 5.6: Analysis of the relative gene expression of Wnt signaling genes in WT and DT 
mice with tumours. RNA extracted from liver was reverse transcribed and the cDNAs were used 
to measure (A) the 21 afore-mentioned Wnt downstream targets by qPCR using a PCR Array Kit 
(see Materials and Methods). In (B) gene expression is expressed as a fold difference calculated 















 Figure 5.7a: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
expression HCC is represented on its own. RNA extracted from liver was reverse transcribed and 
the cDNAs were used to measure (A) Wnt1, (B) Wnt2, (C) Wnt2b, (D) Wnt3, (E) Wnt3a, (F) Wnt4, 
(G) Wnt5b, (H) Wnt6, (I) Wnt7a, (J) Wnt7b, (K) Wnt8a, (L) Wnt8b, (M) Wnt9a, (N) Wnt10a, (O) 




















 Figure 5.7b: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
expression HCC is represented on its own. RNA extracted from liver was reverse transcribed and 
the cDNAs were used to measure (A) Wnt1, (B) Wnt2, (C) Wnt2b, (D) Wnt3, (E) Wnt3a, (F) Wnt4, 
(G) Wnt5b, (H) Wnt6, (I) Wnt7a, (J) Wnt7b, (K) Wnt8a, (L) Wnt8b, (M) Wnt9a, (N) Wnt10a, (O) 

















In DT mice however, gene expression levels were markedly upregulated at 3 
months and in HCC, suggesting a re-activation of Wnt signaling in HCC. Gene 
expression levels of Wnt4, Wnt6, Wnt7a, Wnt7b, Wnt8b, Wnt10a and Wif1 were 
generally similar with mild fluctuations at all time points including HCC in WT, but 
were upregulated at 3, 6, 12 and 15 months, but not 18 and 21 months, and in 
HCC in DT, showing evidence of activation at earlier time points which wanes but 
is reactivated in HCC. Wnt16 had a similar profile with the exception that gene 
expression levels were high at 18 months and in HCC in DT. Gene expression 
levels of Wnt 8a were low at all time points in WT mice except in HCC where 
they were higher than in DT in HCC, whereas expression levels in DT were the 
highest in DT at 3 months, but lower in HCC. Finally Wnt2 and Wnt2b had similar 
profiles in premalignant stages as in HCC with DT mice having overall higher 
levels than WT in the former, and WT having at least 2-fold higher levels than DT 
in the latter. 
Gene expression of Frizzled and Sfrps: The gene expression of the receptors 
frizzled and related proteins showed some similar profiles to Wnt ligands. Fzdb, 
Fzd2, Fzd8, sfrp2 and sfrp4 exhibited low mRNA transcript levels in WT mice at 
all time points, whereas DT mice had elevated levels at 3 months only and in 
HCC (Figure 5.8). Fzd3 and sfrp1 were expressed at similar levels in WT mice 
but had higher expression at 6, 12 and 15 months than at 3 months in DT mice, 
in the premalignant stages than in HCC. The remainder of measured receptors 
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 Figure 5.8a: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
expression HCC is represented on its own. RNA extracted from liver was reverse transcribed and 
the cDNAs were used to measure (A) Fzdb, (B) Fzd1, (C) Fzd2, (D) Fzd3, (E) Fzd4, (F) Fzd5, (G) 
Fzd6, (H) Fzd7, (I) Fzd8, (J) Sfrp1, (K) Sfrp2 and (I) Sfrp4 by qPCR using a PCR Array Kit (see 




















 Figure 5.8b: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
expression HCC is represented on its own. RNA extracted from liver was reverse transcribed and 
the cDNAs were used to measure (A) Fzdb, (B) Fzd1, (C) Fzd2, (D) Fzd3, (E) Fzd4, (F) Fzd5, (G) 
Fzd6, (H) Fzd7, (I) Fzd8, (J) Sfrp1, (K) Sfrp2 and (I) Sfrp4 by qPCR using a PCR Array Kit (see 
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Gene expression of downstream genes of Wnt signaling: The gene expression of 
Dvl1, GSK-3β, Lef1, Porcn, Ppp2r5d, Pygo1, Fosl1, Foxn1, Sox17 and Tcf4 was 
at low levels in WT mice at all time points, however in DT mice, was at higher 
levels at 3 months and in HCC suggesting similar activation patterns early in 
development and later in carcinogenesis (Figures 5.9 a and b). Other genes i.e. 
Dkk1, Fgf4 and Pitx2 had low expression in WT mice, but higher levels of 
expression in the earlier time points of 3, 6, 12 (peak levels) and 15 months, with 
a decline in HCC in DT mice. Axin, Ctbp1, Ep300, Ccnd1, Lrp6, Nkd1 and Nik 
had lower gene expression levels at all time points including HCC in DT 
compared to WT, with increasing levels from 3 months and mostly peaking at 15 
months. Lrp5 and Myc mRNA transcripts were higher in the WT mice at earlier 
time points until 12-15 months, where the levels in DT are higher, including in 
HCC. Finally Bcl9 and Ctbp2 gene expression levels were higher in DT mice than 
WT at all time points including HCC, with a much higher level of Ctbp2 in HCC. 
















 Figure 5.9a: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
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the cDNAs were used to measure (A) Axin1, (B) Bcl9, (C) Ctbp1, (D) Ctbp2, (E) Dkk1, (F) Dvl1, 
(G) Ep300, (H) GSK-3β, (I) Lef1, (J) Porcn, (K) Ppp2r5d and (I) Pygo1 by qPCR using a PCR 































 Figure 5.9b: Analysis of the gene expression of Wnt signaling genes in WT and DT mice 
represented in bar graphs. The time points 3, 6, 12, 15, and 21 months represent the pre-
neoplastic phase, before the mice developed HCC. For comparison of Wnt ligand gene 
expression HCC is represented on its own. RNA extracted from liver was reverse transcribed and 
the cDNAs were used to measure (A) Ccnd1, (B) Fgf4, (C) Fosl1, (D) Foxn1, (E) Lrp5, (F) Lrp6, 
(G) Myc, (H) Nkd1, (I) Nik, (J) Pitx2, (K) Sox17 and (I) Tcf4 by qPCR using a PCR Array Kit (see 
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5.4 DISCUSSION 
Previous data from this model reported by our laboratory demonstrated that the 
combination of the ATX and IRS-1 transgenes caused premalignant changes in 
the liver, with three cases showing lesions typical of HCC and increased β -
catenin immunoreactivity (Longato et al., 2009). In the same study only Wnt3, 
Fzd3 and Fzd7 were evaluated, and these were significantly upregulated in the 
double transgenic mouse compared to other groups. The aim of this study was to 
characterize components of all three Wnt signaling pathways (canonical and non-
canonical) at various time points in the progression to HCC with the purpose of 
uncovering critical molecules of activated or downregulated Wnt signaling that 
are important for hepatocarcinogenesis, particularly in HBV-related HCC. These 
signaling molecules can be potentially targeted in designing therapeutic agents 
against HCC. In DT mice without tumour, 58% of measured Wnt ligands, 
receptors and downstream genes were activated compared to WT mice. 
Activation of Wnt signaling was dominant particularly at an early time point (3 
months), in some cases with Wnt activation peaking at 6 to 12 months time point, 
and then declining at the later stages. It is noteworthy that overall, the mice that 
developed tumours were male and at time points beyond 15-18 months. In this 
context, it is interesting that various components of canonical and non-canonical 
Wnt signaling were upregulated in non-tumour tissue at between 3-12 months 
and also in HCC suggesting that re-activation of these genes is necessary for the 
development of HCC, as these levels had declined beyond 12 months at 












overexpression of normal or mutant β -catenin is insufficient to cause 
tumorigenesis in experimental models (Nejak-Bowen & Monga). Furthermore, 
HBx in association with activated Wnt1-activated Wnt signaling was shown to be 
necessary to stabilize β-catenin in hepatoma cells (Cha et al., 2004). Moreover, 
previous studies using either of the transgenes alone did not result in HCC (Mohr 
et al., 2008; Tanaka et al., 1997), therefore our study highlights the critical role of 
not only the two transgenes (ATX and IRS-1), but a transactivator and signaling 
molecule co-operating together to cause cancer, because this re-activation was 
not observed in the WT mice. In DT mice that developed tumours 89% of Wnt 
ligands were upregulated, with 50% having at least a 5-fold increase compared 
to WT mice with tumours. The most striking upregulations were those of Wnt5b 
and Wnt7b. This latter finding places these two signaling components as 
attractive potential signatures for HBV-related HCC versus non-HBV HCC and 
could be targeted when seeking for therapies for HCC. Corresponding to 
activated Wnt signaling, the target genes Fosl1 and Myc were similarly 
upregulated. Conversely, Wnt 2, Wnt2b and Wnt8a were downregulated in DT 
compared to WT mice, inferring that the binding of these ligands to receptors 
may be inhibitory and therefore protective. Quite surprisingly some inhibitors e.g. 
Wif1, Sox17, sfrp4 and sfrp2, which typically antagonize Wnt signaling, were 
upregulated in DT tumours. A possible explanation for these opposite effects 
may be that these inhibitory modulators may have been epigenetically regulated 
with resultant transcriptional activation rather than suppression in these mice. 
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2008) and Wif1 (Z. Ding, Qian, Zhu, & Xiong, 2009) occurs in HCC and is 
associated with downregulation of these molecules, therefore in our study there 
may have been promoter hypomethylation resulting in transcriptional activation 
rather than repression. The epigenetic contribution to our findings in this study 
was not pursued and is a potential future area of study to further explain these 
findings. By contrast Fzd6 and Fzd 7 were downregulated in DT versus WT mice 
with tumours. This finding is in sharp contrast to previous studies reporting 
overexpression of Fzd7 in HCC and subsequent accumulation of β -catenin 
(Longato et al., 2009; Merle et al., 2004; Merle et al., 2005). Considering that our 
study utilized the same tissue as that used by Longato and Merle, this finding is 
incongruous. An explanation for this may be the small number of samples (N=12 
per group) used in our study, and sampling error compared to the larger numbers 
(N=30) used in other studies. Downregulation of Fzd6 and Fzd7 may be 
explained on the basis of ligand binding specificity in Wnt signaling; there are 19 
Wnt ligands that can bind to 10 different frizzled receptors, or other co-receptors 
including LRP, therefore the combinations of ligand-receptor interactions are 
diverse and complex, and may be context-specific. Regarding the remainder of 
Wnt components measured, in both WT and DT mice with tumours, canonical 
Wnt downstream signaling genes including GSK-3β were for the most part 
upregulated and negative regulators downregulated in DT relative to WT 
tumours. GSK-3β is a key molecule in Wnt signaling because with Wnt binding, it 
is phosphorylated and thus deactivated, thus allowing β -catenin to avoid the 












activation of target genes. The upregulation of GSK-3β mRNA transcripts in our 
study is consistent with its oncogenic potential and subsequent HCC 
development because overexpression of GSK-3β is associated with the 
accumulation of β-catenin (p<0.05) (Ban, Singh, Krishnan, & Seow, 2003), which 
is critical for tumorigenesis.  
 Recent advances in molecular techniques have allowed for efficient high 
throughput screening of molecular pathways that are responsible for many 
disease processes. This understanding is crucial in HCC, as newer treatment 
targets are urgently needed, either as monotherapy or dual therapy with 
sorafenib. The importance of this study is in its identification of potential disease 
markers for HBV-related HCC and therefore potential therapeutic targets within 
the Wnt signaling cascade. The disadvantage of PCR arrays however, is that in 
analyzing multiple genes at once, many genes are upregulated and without 
correlative protein determinations, it is difficult to interpret the significance of this 
regulation. To further understand the findings of this study, an extension to this 
study will require analysis of the epigenome, to characterize the role of age-
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Ceramide-Induced Lipotoxicity Promotes Insulin Resistance in 
Alcoholic Steatohepatitis in Humans 
 
ABSTRACT 
Background:  Alcoholic steatohepatitis (ASH) has high mortality and 
mechanistically is associated with lipotoxicity-associated hepatic insulin 
resistance, pro-cytokine activation and increased endoplasmic reticulum (ER) 
stress.   
Hypothesis: Ceramides are important mediators of insulin resistance, ER stress, 
and cytokine activation in the progression of alcoholic liver disease (ALD).  
Methods: Human liver tissue from normal subjects (n=8) and those with clinical 
and laboratory features of ALD (n=8) were analyzed for lipid content, insulin, pro-
ceramide and ER stress signaling and pro-cytokine activation using both ELISA 
and qT-RT-PCR assays.  
Results: Neutral lipids (p=0.03) and ceramide (p=0.01) levels were higher in the 
ALD group of patients, and in the latter case there was a correlation with 
upregulation of ceramide synthesis and degradation pathway gene expression. In 
the alcohol group, due to suppressed signaling, there was a compensatory 
upregulation of the mRNA transcripts of the insulin receptor (p<0.0001), IGF-1 
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receptors at protein expression level. In addition, we observed up-regulation of ER 
stress genes that are involved in both the UPR and ER stress-induced apoptosis, 
including CHOP (p=0.013) and BAX (p=0.0003). However, pro-cytokine activation 
was not evident; on the contrary, IL-6 was downregulated in the alcohol group, 
which may infer alcohol-induced loss of its hepato-protective effect.  
Conclusions: The role of ceramides in alcoholic steatohepatitis is increasingly 
being recognized. Ceramides are potent cell signaling molecules, which also play a 
role in inducing the insulin resistance ad ER stress implicated in the pathogenesis 
of ALD. Therefore the potential for future use of ceramide inhibitors in clinical 
settings is immense, and they may become an important part of the treatment 























Chronic alcohol abuse is pervasive in all societies. Alcohol is responsible for up to 
50% of all cause end-stage liver disease and alcoholic liver-related deaths account 
for close to 60% of all deaths from alcohol use (Beier & McClain, 2010). Alcoholic 
liver disease (ALD) encompasses a potentially progressive spectrum of disease 
that is characterized by histopathological features ranging from simple fat 
accumulation in the liver (steatosis), to a malign condition typified by steatosis with 
inflammation and apoptosis (steato-hepatitis). More concerning however, is that 
consumption levels of about 80g/day are associated with hepatocellular carcinoma 
(HCC) (Hassan et al., 2002; Schoniger-Hekele et al., 2000). Alcoholic steato-
hepatitis (ASH) is associated with high mortality rates in the short-term, up to 7% 
during an average hospital stay of 6.5 days (Liangpunsakul, 2010). The critical 
question is the mechanism(s) of progression from simple steatosis to steato-
hepatitis, as not all patients progress in this manner. While active intense research 
has been on going, the mechanisms remain elusive. Current treatments for ALD 
are limited, and/or ineffective, therefore an understanding of newer mechanisms of 
progression will allow for the potential development of newer targeted treatments 
for this common and growing condition. 
Progression of ALD is mediated by multiple factors including but not limited 
to, oxidative stress, pro-inflammatory cytokine activation and dysregulation of 
clotting (Arteel, 2003; Beier et al., 2008; Beier et al., 2009; de la Monte, Longato, 
Tong, DeNucci, & Wands, 2009; Iimuro, Gallucci, Luster, Kono, & Thurman, 1997). 
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disease and contributes to the pathogenesis and progression of liver injury (Farrell 
& Larter, 2006; Ussher et al., 2010). Although the role of impaired lipid metabolism 
and homeostasis with resultant lipotoxicity in ALD has been less well 
characterized, there is some evidence for its role in the progression of disease (de 
la Monte, Longato et al., 2009). Lipotoxic states impair either binding or 
downstream signal transduction of insulin signaling thereby causing insulin 
resistance (de la Monte et al., 2008; Denucci et al., 2010; Pang et al., 2009) which 
compromises reparative and regenerative mechanisms in the liver, as intact 
signaling is required for liver remodeling and repair following injury (de la Monte & 
Wands, 2005; Giovannone et al., 2000). 
 Our group has studied the effects of ceramide inhibition on steatosis, ER 
stress and insulin resistance, with an improvement in all indices, however these 
studies were performed in animal models of ALD (Setshedi, Tong et al., 2010). 
Therefore one of the aims of this study was to evaluate the role of ceramides in 
promoting IR in human liver tissue of alcoholics.  
Much of the liver injury of ALD is thought to be due to the serial oxidation 
and metabolism of alcohol to acetate. These reactions result in the generation of 
reactive oxygen species, an altered redox ratio and other metabolic effects, which 
are implicated in alcohol-induced endoplasmic reticulum (ER) stress. The unfolded 
protein response (UPR), upregulation of protein chaperones and with prolonged 
insult, induction of apoptosis is the key regulatory mechanisms involved in inducing 
ER stress. Furthermore, sphingolipids as emerging bio-effector molecules are also 












depend on the fatty acid chain length (Prieur, Roszer, & Ricote, 2010; Senkal, 
Ponnusamy, Bielawski, Hannun, & Ogretmen, 2010; Spassieva, Mullen, 
Townsend, & Obeid, 2009).  
Moreover the role of pro-cytokine activation effected mainly via toll-like 
receptor 4-MyD88 complex and downstream, TNF-α is well known (Szabo & Bala, 
2010). More interestingly is the role of sphingolipids in TNF-mediated hepatocyte 
apoptosis (reviewed by Fernandez-Checa et al, 2005) (Fernandez-Checa, Colell, 
Mari, & Garcia-Ruiz, 2005), thus linking pro-cytokine activation and ceramides in 
the pathogenesis of ALD (Nikolova-Karakashian & Rozenova, 2010). Therefore 
possibly the individual independent drivers of advanced stages of ALD combine 
either additively or synergistically to amplify liver injury. Our study aimed to 
interrogate the role of and relationships between ceramides and its link to insulin 
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6.2 MATERIALS AND METHODS 
Patients and specimens: The samples utilized for the analysis comprise of liver 
tissue from normal subjects (n=8) who had no discernible liver disease, 
designated “controls” and liver from those with a significant history of alcohol 
consumption with clinical and laboratory features of ALD (n=8). These tissue 
samples were gratefully donated to our laboratory, the Liver Research Center of 
Brown University (a collaborative effort) from the Coro laboratory facility, a 
collaborator. The liver tissues were coded and had been de-identified, therefore 
were exempt from Human Ethics approval at our institution, the Lifespan IRB 
committee as no specific sensitive patient information was available.  
Materials:  The same materials described in Chapter 2, to process and analyze 
tissue for protein (ELISA) and RNA (qRT-P R) applications were applied; as such 
the reader is referred to that chapter.  
Lipid studies: Lipids were measured directly from the protein homogenates and the 
readings corrected for by sample protein concentration as measured by BCA.  
Multiplex ELISA: We used bead-based multiplex ELISAs to examine the integrity of 
insulin and IGF-1 signaling networks, or measure immunoreactivity to selected pro-
inflammatory cytokines and chemokines in liver tissue as previously outlined. 
Regarding pro-inflammatory cytokine and chemokine activation, we measured 
immunoreactivity to interleukin (IL) 1β, IL-6, IL-8, IL-18, TNF-α, IFN-γ, IP-10, MIP-












Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Assays:  The same method as previously described was used, with the exception 
that primers reactive to human tissue were used (Table 11). Relative mRNA 
abundance was calculated from the ng ratios of specific mRNA to 18S for the 
insulin genes and hypoxanthine phosphoribosyltransferase 1 (HPRT) for the pro-
ceramide and ER stress genes, measured in the same samples (Moroz, Tong, 
Longato, Xu, & de la Monte, 2008). Template-free reactions served as negative 
controls. 
Statistical Analysis: Data depicted in box plots reflect group median, 95% 
confidence interval limits and range (whiskers).  Intergroup comparisons were 
made using Student t-tests. Data were analyzed using GraphPad Prism 5 software 
(GraphPad Software, Inc., San Diego, CA).  Significant P-values (<0.05) are 
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Table 11:  Human Primer Pairs Used for qRT-PCR Assays 





Insulin For TTC TAC ACA CCC AAG TCC CGT C 189 134 
Insulin Rev ATC CAC AAT GCC ACG CTT CTG C 322  
Insulin 
Receptor 





Rev CGT AGA GAG TGT AGT TCC CAT 
CCA C 
1161  
IGF-1 For CAC TTC TTT CTA CAC AAC TCG 
GGC 
1049 130 
IGF-1 Rev CGA CTT GCT GCT GCT TTT GAG 1178  
IGF-1 
Receptor  
For TAC TTG CTG CTG TTC CGA GTG G 295 101 
IGF-1 
Receptor  
Rev AGG GCG TAG TTG TAG AAG AGT 
TTC C 
395  
IGF-2 For CTG ATT GCT CTA CCC ACC CAA G 1024 76 
IGF-2 Rev TTG CTC ACT TCC GAT TGC TGG C 1099  
IGF-2 
Receptor 

















IRS-1 For TGC TGG GGG TTT GGA GAA TG 4527 46 
IRS-1 Rev GGC ACT GTT TGA AGT CCT TGA CC 4572  
IRS-2 For  AAA ATT GGC GGA GCA AGG C 753 64 
IRS-2 Rev ATG TTC AGG CAG CAG TCG AGA G 816  
IRS-4 For  CCG ACA CCT CAT TGC TCT TTT 
C 
570 74 
IRS-4 Rev TTT CCT GCT CCG ACT CGT TCT C 643  
Pro-Ceramide signaling 
CERS-1 For CAA TGT GGG CAT CCT TGT T 669 61 
CERS-1 Rev GGT GAA CTC AAG CTG CAC G 729  
CERS-2 For ACT TCT GGT GGG AAC GTC TG  370 73 
CERS-2 Rev ACA CGT CCA TCT CGG TCT TC  442  
CERS-4 For GCA GGT GAT ACA CCA CTT CG 944 91 
CERS-4 Rev TAA CAG CAG CAC CAG AGA GAG 
GC 
1034  
UGCG For GAT CAG GTG GAC CAA ACT ACG 1109 71 
UGCG Rev AGC ATT CTG AAA TTG GCT CAC 1179  
CERD2 For GAC CAT GTC TGG ACG AAG ACT TC 1626 77 
CERD2 Rev CAA CAG TCA TGT TCT GCA TCC C 1702  
CERD3 For GGC AGT GGC TAT AGC ATA TGG 367 85 
CERD3 Rev AGA CCA GGC GGA TGA ACT G  451  
GM3 
synthase 
For TGC TGC TGA TAC TGG GTC TG 1710 77 
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synthase 
SPTLC-1 For CGC GCT ACT TGG AGA AAG A 1324 77 
SPTLC-1 Rev CTC TGT TTG TTC CAC CGT GA 1400  
SPTLC-2 For ATC GGT GTC GTT GTG GTT G 1659 82 
SPTLC-2 Rev TGG TAT GAG CTG CTG ACA GG 1740  
SMPD-1 For GCA CAC CTG TCA ATA GCT TCC 1142 78 
SMPD-1 Rev TGG CCA TCG CTT CAT AGA G 1219  
SMPD-3 For  AGG ACC TGC TGT CTG CTG 
TC 
3956 76 
SMPD-3 Rev TTG CAG CTC AAT GGG TGA C 4031  
ER Stress Signaling 
BAX For TGA CCC CTG ACC TCA CTG T 763 82 
BAX Rev TGA GCA ATT CCA GAG GCA GT 844  
EDEM For GCT GAG TGA TTA CCT TAG CCA CA 5504 72 
EDEM Rev TGG ACA GGA AAG CTC AGG AT 5575  
CHOP For GTC ATT GCC TTT CTC CTT CG 192 61 
CHOP Rev GTC CTC ATA CCA GGC TTC CA 252  
P58IPK For CTG AAG GAG CAA GAG ACC ATC  2182 76 
P58IPK Rev TTA ATC CAA AGT CTA AGC CTG 
GAT A 
2257  
GRP78 For TGA AGG TGA AAG ACC CCT GA 1654 107 
GRP78 Rev CAA AGG TGA CTT CAA TCT GTG G 1760  
ATF4 For AAG GAG TTC GAC TTG GAT GC  1156 78 












HERP For ACT GTC GTT GCA GAG ATT GC 322 107 
HERP Rev GTT CGG TCT CGG ACT CCA T 428  
WARS For CTG GAC GGG TGG ACT TAG C 2667 77 
WARS Rev GAG GCC TGC CTA GAC ATC TG  2743  
Wnt Signaling 
Wnt1 For 
CGA ACC TGC TTA CAG ACT CCA A 
329 84 
Wnt1 Rev 
TCA GAC GCC GCT GTT TGC G 
412  
Wnt3 For ACT TCG GCG TGT TAG TGT CC 607 130 
Wnt3 Rev CAT TTG AGG TGC ATG TGG TC 736  
Wnt4 For GGA GGA GAC GTG CGA GAA AC 221 68 
Wnt4 Rev CCA GGT TCC GCT TGC ACA TCT 288  
Wnt5a For TTC TCC TTC GCC CAG GTT GTA A 418 79 
Wnt5a Rev CTT CTG ACA TCT GAA CAG GGT 496  
Wnt5b For CCA ACT CCT GGT GGT CAT TAG C 251 68 
Wnt5b Rev CTG GGC ACC GAT GAT AAA CAT C 318  
Sfrp1 For AGG CGG ATT TCC CTG GTA GT 2359 64 
Sfrp1 Rev TAG GGC AAC CAC GGA CTC TT 2422  
Sfrp5 For GTC AAA ATG CGC ATC AAG GA 776 65 
Sfrp5 Rev TTC TGG GCT CCA ATC AGC TT 840  
Fzd3 For TGG CTA TGG TGG ATG ATC AAA G 2172 78 
Fzd3 Rev TGG AGG CTG CCG TGG TA 2247  
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Fzd6 Rev GCT ACT GCA GAA GTG CCA TGA T 2001  
Fzd7 For CAACGGCCTGATGTACTTTAAGG 731 121 
Fzd7 Rev CATGTCCACCAGGTAGGTGAGA 851  
AAH For GGG AGA TTT TAT TTC CAC CTG 
GG 
1647 257 
AAH Rev CCT TTG GCT TTA TCC ATC ACT GC 1903  
Humbug For GCT GGG TTG ATT GAG GAT GTG 
TG 
1873 302 
Humbug Rev GCA GGG GGA AAA AGT CAC CTT 
ATC 
2174  
Notch1 For AGG ACC TCA TCA ACT CAC ACG C 6035 117 
Notch1 Rev CGT TCT TCA GGA GCA CAA CTG C 6151  
Jagged1 For TGT CTG TGT CCC ACT GGT TTC 
TC 
2047 148 
Jagged1 Rev AGT TCT TGC CCT CAT AGT CCT 
CG 
2194  
HES1 For CCA AAG ACA GCA TCT GAG CA 318 91 
HES1 Rev TCA GCT GGC TCA GAC TTT CA 408  
*Abbreviations: qPCR, Quantitative Polymerase Chain Reaction; For, Forward Primer; Rev, Reverse Primer; 
mRNA, Messenger Ribonucleic Acid; rRNA, Ribosomal Ribonucleic Acid; IGF, Insulin Growth Factor; IRS, Insulin 
Receptor Substrate; CERS, Ceramide Synthase; UGCG, UDP-Glucose Ceramide Glucosyltransferase; CERD, N-
Acylsphingosine Amidohydrolase (Ceramidase); GM3 Synthase, Ganglioside Monosialo Synthase; SPTLC, Serine 
Palmitoyltransferase; SMPD, Sphingomyelin Phosphodiesterase; BAX, Bcl-2-Associated X Protein; EDEM, 
Endoplasmic Reticulum Degradation-Enhancing α -Mannosidase-like Protein; CHOP, C/EBP Homolog Protein; 
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6.3 RESULTS 
Hepatic steatosis was further characterized by quantification of lipids. We 
measured neutral lipid, triglyceride and ceramide content. The Nile Red assay 
demonstrated higher mean levels of neutral lipids in the alcohol relative to control 
group of patients (p=0.03) (Figure 6.1 A). Triglyceride levels (mol/g) on the other 
hand, were not significantly different between the two groups (Figure 6.1 B). 
Similar to neutral lipid accumulation, hepatic ceramide levels were higher in the 
alcohol versus to the control group (p=0.01) (Figure 6.1 C).  
 
Figure 6.1: Lipid and ceramide accumulations in the liver of patients with alcoholic liver 
disease (ALD) or controls. Measurements were made from protein homogenates of fresh frozen 
liver tissue obtained from these patients. We measured (A) neutral lipid content using the Nile Red 












were normalized to tissue protein content. Box plots depict medians (horizontal bars), 95% 
confidence interval limits, and range (whiskers).  Inter-group comparisons were made using t-tests. 
Significant P-values are indicated within the panels.  
 
Hepatic gene expression levels of ceramide pathway genes: To determine if 
increased hepatic ceramide was mediated by increased pro-ceramide gene 
expression or sphingomyelinase enzymatic activity, we measured mRNA levels of 
ceramide synthases 1, 2, and 4 (CERS), UDP-glucose ceramide 
glucosyltransferae (UGCG), ceramidase 2 and 3 (CERD), ganglioside monosialo 
synthase (GM3), serine palmitoyl transferase 1 and 2 (SPTLC), and 
sphingomyelinase 1 and 3 (SMPD) by qRT-PCR analysis (Figure 6.2).  The genes 
selected for analysis were based on previous studies, which demonstrated the 
mRNA transcripts that were modulated with increasing steatohepatitis; however 
these experiments were conducted in animal models (de la Monte, Longato et al., 
2009; de la Monte, Tong, Lawton, & Longato, 2009; Lyn-Cook et al., 2009; Shah et 
al., 2008). The levels of (A) CERS1 (p=0.025), (D) UGCG (p=0.0006), (G) GM3 
synthase (p=0.006), (H) SPTLC1 (p=0.0001), (J) SMPD1 (p=0.036) and (K) 
SMPD3 (p=0.019) were upregulated in alcoholic patients compared to controls.  In 
contrast, however, levels of (E) CERD 2 were markedly down-regulated in the 
alcohol compared to the control group (p=0.04), while mean levels of (B) CERS2, 














Figure 6.2:  Gene expression levels of mediators of pro-ceramide signaling, measured in 
control and ALD human liver tissues. RNA extracted from liver was reverse transcribed to 
measure (A) CERS1, (B) CERS2, (C) CERS4, (D) UGCG, (E) CERD2, (F) CERD3, (G) GM3-
synthase, (H) SPTLC1, (I) SPTLC2, (J) SMPD1 and (K) SMPD3 mRNA expression by PCR. 
mRNA abundance was corrected for using HPRT as the housekeeping gene. Inter-group 














Effects of ethanol on Insulin and IGF signaling mechanisms in liver:  Based on the 
fact that previous studies demonstrated that steatohepatitis produced by high fat 
diet or chronic ethanol feeding impairs insulin and IGF signaling in the liver in 
animal models (de la Monte et al., 2008; Svegliati-Baroni et al., 2006; Yeon, 
Califano, Xu, Wands, & De La Monte, 2003) we re-investigated this concept in 
human liver tissue. We measured mRNA levels of insulin, IGF-1, and IGF-2 
polypeptides, their corresponding receptors, and IRS-1, IRS-2, and IRS-4 by qRT-
PCR analysis (Figure 6.3), and IR, pYpY1162/1163-IR, IGF-1R, pYpY1135/1136-IGF-1R, 
IRS-1, pS312-IRS-1 (Figure 6.4), Akt, pS473-Akt, GSK-3β, pS9-GSK3β, p70S6K, 
pTpS421/424-p70S6K, PRAS40, and pT246-PRAS40 (Figure 6.5) immunoreactivities by 
multiplex ELISA. The qRT-PCR analyses demonstrated similar mean levels of (A) 
insulin, (B) IGF-1, (G) IRS-1, and (H) IRS-2 expression in all groups.  Hepatic (D) 
insulin receptor (p<0.0001), (E) IGF-1R (p<0.0001), and (F) IGF-2R (p0.008) 
mRNA levels were significantly higher in the alcohol group. Contrastingly however, 
(C) IGF-2 polypeptide (p<0.0027) and (I) IRS-4 (p=0.04) expression was lower in 
livers of alcohol compared with control patients.  
At protein expression level (Figure 6.4), analysis of the upstream signaling 
networks using multiplex ELISAs revealed similar mean levels of (A) IR, even 
though its phosphorylated counterpart (D) pYpY1162/1163-IR was increased in the 
alcohol group (p=0.0005). This null effect correlates with the calculated (G) 
phosphorylated to total IR levels seen. Signaling via the IGF-1R was upregulated 
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correcting phosphorylated IGF-1R by total levels (H), alcohol results in suppressed 
levels (p=0.0008) as compared to those observed in the control group.  
 
 
Figure 6.3: Gene expression levels of mediators of the insulin/IGF signaling cascade, 
measured in control and ALD human liver tissues. RNA extracted from liver was reverse 
transcribed to measure (A) insulin, (B) IGF-1, (C) IGF-2, (D) insulin receptor, (E) IGF-1 receptor, (F) 
IGF-2 receptor, (G) IRS-1, (H) IRS-2 and (I) IRS-4 mRNA expression by PCR. mRNA abundance 
was corrected for using 18S as the housekeeping gene. Inter-group comparisons were made using 















Figure 6.4: Protein expression levels of upstream polypeptides of the insulin/IGF 
signaling cascade, measured in control and ALD human liver tissues. Liver protein homogenates 
were used to measure immunoreactivity in fluorescence units corresponding to (A) insulin 
receptor, (B) IGF-1R, (C) IRS-1, (D) pYpY1162/1163-IR, (E) pYpY1135/1136-IGF-1R, (F) pS312-IRS-1 with a 
bead-based Multiplex ELISA platform (see Methods and Methods).  (G-I) In addition, the 
phosphorylated/total protein ratios for were calculated to assess relative levels of phosphorylation 
of each protein.  Data were analyzed statistically using t-tests.  Significant P-values are indicated 





















Figure 6.5: Protein expression levels of the downstream polypeptides of the insulin/IGF 
signaling cascade, measured in control and ALD human liver tissues. Liver protein homogenates 
were used to measure immunoreactivity in fluorescence units corresponding to (A) Akt, (B) GSK-
3β, (C) PRAS40, (D) p70S6K, (E) pS473-Akt, (F) pS9-GSK3β, (G) pT246-PRAS40 and (H) pTpS421/424-
p70S6K with a bead-based Multiplex ELISA platform (see Methods and Methods). (I-L) In 
addition, the phosphorylated/total protein ratios for were calculated to assess relative levels of 
phosphorylation of each protein.  Data were analyzed statistically using t-tests.  Significant P-













Furthermore although total levels of (C) IRS-1 were lower in the alcohol compared 
to the control group (p=0.036), the calculated (I) phosphorylated to total ratio was 
higher in the alcohol group (p=0.023).  
Downstream signalling, through insulin/IGF-1 in liver, showed similar mean 
levels of PRAS40 and p70S6K, and in both groups (Figure 6.5). Mean total hepatic 
(A) Akt levels were significantly higher in the alcohol compared to control group 
(p=0.0002). In contradistinction, while total (B) GSK-3β were downregulated in the 
alcohol group (p=0.017), the calculated (J) phosphorylated to total ratio was higher 
in the alcohol versus the control group (p=0.038).  
Effects of ethanol on markers of endoplasmic reticulum (ER) stress: We measured 
the mRNA transcripts of several genes involved in the ER stress response using 
qRT-PCR (Figure 6.6). Overall there was an upregulation of these proteins in the 
livers of patients with ALD compared to controls. Specifically, mean mRNA levels 
of (A) BAX (p=0.0003), (D) CHOP (p=0.013), (G) GRP78 (p=0.0006), (H) ATF4 
(p<0.0001), (J) HERP (p=0.024) and (K) WARS (p=0.044) were all higher in the 
alcohol relative to the control group. The mean gene expression levels of (B) 















 Figure 6.6:  Gene expression levels of mediators of the ER stress signaling cascade 
measured control and ALD human liver tissues. RNA extracted from liver was reverse transcribed 
to measure (A) BAX, (B) EDEM, (C) CHOP (D) P58IPK, (E) GRP78, (F) ATF4, (G) HERP and (H) 
WARS mRNA expression by PCR. mRNA abundance was corrected for using HPRT as the 
housekeeping gene. Inter-group comparisons were made using t-tests.  Significant P-values are 




















Effects of ethanol on cytokine levels in liver: Activation of pro-inflammatory 
cytokines, including TNF-α, IL-6, and IL-1β, is a common feature of steatohepatitis 
(Carter-Kent, Zein, & Feldstein, 2008; Larter & Farrell, 2006; Tilg & Hotamisligil, 
2006). We measured hepatic levels of these cytokines, including IP-10, MIP-1, IL-
18, β-NGF, IL-8, IFN-γ and TRAIL by multiplex ELISA to determine the degree to 
which alcohol stimulates pro-inflammatory cytokine activation (Figure 6.7). All 
measured cytokines were similarly expressed in both study groups (A-F, I); except 
 for (G) IL-1β (p=0.028), (H) IL-6 (p=0.009) and (J) TRAIL (p=0.01) that had lower  








































Figure 6.7: Cytokine expression levels measured in control and ALD human liver tissues. 
Liver protein homogenates were used to measure immunoreactivity in fluorescence units 
corresponding to (A) IP-10, (B) MIP-1, (C) IL-18, (D) β-NGF, (E) IL-8, (F) IFN-γ, (G) IL-1β and (H) 
IL-6, (I) TNF-α and (J) TRAIL with a bead-based Multiplex ELISA platform (see Methods and 














The pathogenesis of ALD in terms of progression of disease from relatively 
‘benign’ states, to more aggressive disease with worse outcomes has enjoyed 
much attention in the literature in part because it is as yet not fully elucidated.  A 
clearer understanding of underlying disease mechanisms will be useful to prevent 
or limit progressive liver disease. The literature supports the roles of pro-cytokine 
inflammation, oxidative stress, lipotoxicity-induced insulin resistance and other 
related mechanisms; however the majority of these studies were performed in 
animal models. In this study of human ALD we aimed to evaluate the contribution 
of each of these mechanisms to disease, and thus by extension the reliability and 
applicability of utilized animal models. 
 The main findings were an elevation of neutral lipids and more importantly, 
ceramides in the alcohol group. The measurement of neutral lipid encompasses 
some measurement of triglycerides, however the finding of unelevated triglycerides 
in this study is interesting, as these lipids have been touted as the primary cause of 
hepatic steatosis, and this was evident in a previous study from our laboratory 
utilizing a rat model of alcoholic steatohepatitis (Denucci et al., 2010; Setshedi, 
Longato, Ronis, Wands, & De La Monte, 2010). Another explanation for similar 
levels of triglycerides in the study groups could be that the ‘controls’ in fact had 
some degree of steatosis. Information about their ultrasound examinations is not 
known. In this context therefore, it may be that ceramides play an important role in 
not just the steatosis, but also the ensuing steatohepatitis, as they are signaling 
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ceramide gene expression. Interestingly, the data supports that both de novo 
synthesis and degradation pathways of ceramide are involved in generating 
increased levels, and moreover more complex sphingolipids i.e. glucosylceramide 
(catalyzed by increased UGCG), and GM3 synthase (catalyzing the formation of 
GM3 ganglioside). These complex sphingolipids are important for many biological 
actions including cell differentiation, senescence, apoptosis, and proliferation. In 
this context however, their up-regulation could potentially explain the insulin 
resistance (Aerts et al., 2007; Bijl et al., 2009; Summers, 2010; Tagami et al., 
2002; Yamashita et al., 2003; Yew et al., 2010; Zhao et al., 2009) seen in the 
alcohol group of patients, mechanistically by impairing IR binding due to their 
accumulation in cell membrane lipid rafts (Inokuchi, 2007). Analysis of the mRNA 
transcripts of insulin signaling revealed that the receptors (IR, IGF-1R and IGF-2R) 
were all upregulated, probably signaling a compensatory response to the prevailing 
insulin resistance. At protein expression level, mean levels of IGF-1R and Akt were 
reduced and similar when using the ratio respectively, in the alcohol group. Total 
GSK-3β levels were similarly lower in the alcohol group, thus overall, suggesting 
suppressed insulin signaling by alcohol.  It is established that alcohol suppresses 
insulin signaling both at receptor level and downstream, by affecting various 
components of signaling (de la Monte et al., 2008; Svegliati-Baroni et al., 2006; 
Yeon et al., 2003). Suppression of insulin signaling is detrimental to the ability of 
injured hepatic cells to regenerate and recover, thus resulting in cycles of injury, 












 There was a widespread up-regulation of genes of ER stress in the alcohol 
relative to the control group. More important was the up-regulation of BAX and 
CHOP which signify apoptotic signaling, a late consequence of ER-induced stress. 
This finding suggests that alcohol consumption in this model was either moderate 
to severe or sufficiently prolonged to induce apoptosis. Probably the most 
anomalous of the data was in the cytokine expression measurements. There was 
no difference in the levels of measured cytokines, except for IL-1β, IL-6 and 
TRAIL, which were downregulated. The lack of up-regulation of the prototypical 
pro-inflammatory cytokines e.g. TNF-α in this study may be explained on the basis 
that these measurements were done on whole liver tissues and not isolated 
Kupffer cells, thus potentially masking true cytokine levels. Furthermore, the 
unreliability of our measurements could be because typically cytokines are 
measured in serum. Finally, another possibility could be that cytokine elevation 
following the acute alcoholic hepatitis phase is probably not marked; this study was 
performed in liver tissues of patients who had chronic hepatitis at least and 
potentially fibrosis/cirrhosis. The role of IL-6 in promoting a pro-inflammatory 
response and thereby causing hepatocyte injury is controversial. Earlier studies 
suggested its role to be mediate injury (Hill et al., 1992) whereas more recent 
studies have proved it to be hepato-protective (El-Assal, Hong, Kim, Radaeva, & 
Gao, 2004; Fukumura et al., 2007; Hong et al., 2002; Hong et al., 2004; 
Yamaguchi et al., 2011) in animal in vivo and in vitro models. Contrastingly in a 
human study of serum IL-6 levels, these were elevated and correlated with severity 










232	  |	  P a g e 	  
	  
in this study possibly led to an abrogation of the protective effects as was evident 
in the alcohol group.  
 To summarize, our results confirmed that ceramides are novel toxic lipids 
key to the pathogenesis of human ALD. Mechanistically, increased ceramide levels 
occur as a result of upregulation of pro-ceramide synthetic and degradation genes 
and the result thereof is impaired insulin signaling. Consequently, the use of 
ceramide inhibitors may in future become part of the management armamentarium 
of ALD. This is crucial as currently there are not as yet FDA-approved treatments 
for ALD (Frazier, Stocker, Kershner, Marsano, & McClain, 2011). The results of 
this study correlate well with our own work done previously, in animal models. 
Therefore the animal models in use today are truly representative of human 
disease, and therefore are critical in testing hypotheses, that are crucial for the 
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Triad of dysregulated signaling in human hepatocellular 
carcinoma (HCC) suggests a multi-pronged approach is needed 
for therapeutic targeting 
 
ABSTRACT 
Background: Previous studies highlighted potential roles of aberrantly increased 
activation of Insulin/Insulin Receptor Substrate (IRS), canonical Wnt/β-Catenin, 
or Notch-Jagged-Aspartyl-(asparaginyl)-β-hydroxylase (AAH) as mediators of 
HCC pathogenesis or progression.  In addition, a role for pro-inflammatory 
mediators of cell injury, turnover, and DNA damage is under investigation in HCC 
development. To re-focus the fundamental question, which has direct relevance 
to future diagnostic and therapeutic strategies, we examined the extents to which 
each these 3 pathways were upregulated in HCC versus peri-tumour (pre-
malignant) liver tissue, and also evaluated the potential contributions of pro-
inflammatory cytokines as mediators of progressive liver injury and DNA 
damage. 
Methods: Paired surgically resected HCCs (n=8) and tumour-free peri-HCC 
livers (n=8) were used to measure gene expression by qRT-PCR analysis, and 
immunoreactivity by either multiplex or duplex ELISAs. 
Results: Insulin Pathway: HCC was associated with significantly upregulated 
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signaling through IGF-1R (p=0.001) and IRS1 (p=0.015), and inhibition of GSK-
3β activity relative to peri-tumour liver tissue. Wnt/β-catenin: HCCs had 
significantly increased mRNA expression of Wnt 3 (p<0.0001), Wnt5A (p=0.004), 
and Wnt5B (p=0.01) ligands, and Frizzled-6 receptor (p=0.02), and decreased 
expression of sFRP1 (p=0.01) and sFRP5 (p=0.008) relative to peri-tumour 
tissues. Notch: HCCs had significantly increased expression of multiple Notch 
pathway-related genes and proteins, including AAH, humbug, Notch-1, Jagged-1 
and HES-1, relative to peri-tumour tissues. Inflammation: Multiplex ELISAs used 
to measure 24 different cytokines/chemokines, demonstrated increased 
expression of only IFN-γ, and significantly reduced levels of IL-1b, IL-6, TRAIL, 
MIP-1 and b-NGF in HCC relative to peri-tumour liver tissue. 
Conclusions: HCCs are associated with simultaneous dysregulation of 3 major 
signaling pathways that likely crosstalk through various mechanisms, including 
GSK-3β. The prominent down-regulation of several pro-inflammatory cytokines 
suggests that compromised host surveillance mechanisms rather than 
inflammation-mediated cell injury and DNA damage may contribute to the 
pathogenesis or progression of HCC. Altogether, the data suggest that effective 
therapeutic targeting of HCCs will require multi-pronged approaches that 
abrogate dysregulation of the Insulin/IRS, Wnt/β-catenin, and Notch pathways 
















Chronic hepatitis secondary to viral infections hepatitis B and C (HBV and HCV), 
alcohol, and obesity are the commonest causes combined for the development of 
cirrhosis-driven hepatocellular carcinoma (HCC). HCC is the fifth most common 
malignancy, with an estimated half million new cases diagnosed per year globally 
(Llovet, Burroughs, & Bruix, 2003). It has the third highest cause for cancer-
related death (Parkin, Bray, Ferlay, & Pisani, 2005), due to late discovery, thus 
rendering the prognosis particularly dismal (median survival 1-2 months) (Lau & 
Lai, 2008), and while therapeutic options are available for early localized 
tumours, these are fraught with challenges: only about a third of patients are 
suitable for curative procedures and there is chemo-resistance to available 
drugs. Correspondingly, the impact of HCC globally is significant. In this context, 
it is critical to understand the dominant molecular factors resulting in HCC so that 
the development of newer diagnostic markers and/or therapeutic agents might be 
possible. 
For malignant transformation cells have to acquire the ability to become 
insensitive to anti-growth signals and have self-sustaining growth signals, in 
addition to having the propensity to replicate and avoid apoptosis (Hanahan & 
Weinberg, 2000).  In animal and human studies, many signaling pathways (e.g. 
insulin/IGF, Wnt/β-catenin, Transforming Growth Factor-α/Epidermal Growth 
Factor and others) that are involved in survival and/or anti-apoptosis including 
chemoresistance to sorafenib (Chen et al., 2011) are dysregulated in HCC. 
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data to show that Insulin/IGF signaling is upregulated in HCC (Breuhahn et al., 
2004; Cantarini et al., 2006; Lund, Schubert, Niketeghad, & Schirmacher, 2004; 
Schirmacher et al., 1992; Sohda, Yun, Iwata, Soejima, & Okumura, 1996; Tovar 
et al., 2010). Similarly, dysregulated Wnt/β-catenin signaling occurs in HCC (Hsu 
et al., 2000; Nhieu et al., 1999; Prange et al., 2003; Wong, Fan, & Ng, 2001) and 
results in increased transcription of transcription factors T-cell factor (TCF) and 
Lymphoid enhancer factor (LEF) that promote carcinogenesis (Aoki, Hecht, 
Kruse, Kemler, & Vogt, 1999; Korinek et al., 1998). In addition, dysregulated 
activation of Wnt/ β -catenin, seen in 80% of HCC is associated with the 
development of tumor and progression (Lustig & Behrens, 2003; Reya & Clevers, 
2005; Vincan, 2004). 
The Insulin/IGF pathway favours growth, survival and energy metabolism 
(de la Monte & Wands, 2005) by transmitting intracellular signals via the binding 
of a ligand to transmembrane receptors. Binding causes a conformational 
change of the intracellular receptor, activates and phosphorylates tryrosine 
kinases that act on downstream targets such as the insulin receptor substrate 
(IRS) polypeptides, and Akt.  
The Wnt/β-catenin pathway is evolutionarily conserved and is critical for 
multiple functions particularly cell fate, which determines whether a cell 
progresses to or avoids differentiation; the latter promotes carcinogenesis 
(Hanahan & Weinberg, 2000). In the active state Wnt ligand binds to its 
transmembrane receptor (Frizzled/Dishevelled) and through a series of signaling 












β-catenin escapes phosphorylation and enters the nucleus to attach to TCF /LEF 
transcription factors, to effect increased cell motility, which impacts on tumor 
invasiveness and migration.  
Less well studied however, in regulating cell fate determination is the role 
of Notch signaling, and even fewer studies evaluate its role in 
hepatocarcinogenesis. Notch signaling involves several catalytic reactions and 
occurs when ligands (Jagged and Delta-like) bind Notch 1-4 transmembrane 
receptors, resulting in the liberation of the intracellular domain of Notch-1 (NICD) 
which translocates to the nucleus to associate with the CSL for transcriptional 
activation of Notch target genes i.e. hairy enhancer of split (HES) and HES-
related repressor protein (HERP/HEY). Notch signaling is upregulated in HCC 
and is particularly vital for cell motility, and therefore invasiveness and potentially 
metastasis. 
These three pathways intersect at many levels for instance, Notch and 
Jagged are hydroxylated by AAH, an enzyme regulated by insulin/IGF and all 
three are upregulated in many cancers (HCC, cholangiocarcinoma and 
pancreatic cancer). 
Therefore we elected to evaluate the roles of insulin/IGF, Wnt/ β -catenin 
and Notch signaling in promoting human HCC at different stages of disease, to 
gain a varied understanding of the molecular factors that act in concert to 
promote HCC. Since the molecular drivers of HCC are complex, a multi-pronged 
approach to therapy is essential; hence a determination of a potential molecular 
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targeting it, many pathways that promote cancer cell survival could be 
simultaneously interrupted. To our knowledge there are no studies that have 
evaluated these pathways together. Finally, since cytokine activation associated 
with chronic HBV and HCV contributes to the development of HCC (Budhu & 



























7.2 MATERIALS AND METHODS 
Patients and specimens: The samples utilized for the analysis were liver tissue 
obtained from patients who had undergone hepatic resection for HCC. Informed 
consent was obtained prior to surgery. They comprise of liver tissue from the 
HCC (n=8) and liver from the surrounding area, referred to as the peri-tumor 
tissue (n=8). These tissue samples were gratefully donated to our laboratory, the 
Liver Research Center of Brown University (a collaborative effort) from Korea 
and Italy. The majority of patients had either HBV or HCV infection or alcohol-
related HCC. With respect to the normal tissue used as controls, this tissue was 
obtained from similarly aged patients who presented at Brown University Medical 
School for abdominal exploratory surgery for a possible solitary lesion in the liver 
(n=6). The liver tissue was obtained from normal areas in the periphery of the 
liver. In the first part of the analysis we compared liver tissue from normal 
subjects to that in adjacent peri-tumour liver tissue. In the second part of the 
analysis we compared peri-tumour tissue versus HCC. Our experimental protocol 
was exempted from Human Ethics approval by our institution, Lifespan IRB 
committee because the liver tissue was coded and de-identified by the 
collaborators, thus no specific sensitive patient information was available. 
Materials:  Similar materials and methods as those previously described in 
chapter 2 were used. 
Multiplex ELISA: We measured immunoreactivity to the insulin signaling 
components as previously described. For cytokine and chemokine assessments 
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1, β -nerve growth factor (β-NGF), interferon gamma (IFN-γ), IL-6 and tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL).  
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
Assays:  This was performed as previously described. 
Statistical Analysis: Data depicted in box plots reflect group median, 95% 
confidence interval limits and range (whiskers), while tabulated data reflect 
means ± SEMs for each group.  Intergroup comparisons were made using paired 
t-tests. Data were analyzed using GraphPad Prism 5 software (GraphPad 
Software, Inc., San Diego, CA).  Significant P-values (<0.05) are shown within 
























Insulin/IGF signaling in control versus peri-tumor tissue and peri-tumor 
versus HCC 
Gene expression: The expression of mRNA transcripts of IGF-1 (p<0.0001), IGF-
2 (p<0.0001) and their corresponding receptors (p=0.04) and p<0.0001 
respectively were down-regulated in the peri-tumour tissue as compared to 
normal tissue. By contrast, insulin, insulin receptor, and IRS-1, 2 and 4 were not 
significantly different between the control and peri-tumour tissues (Figure 7.1 A-
I). When comparing peri-tumour and HCC tissues, mRNA transcripts of IGF-1, 
insulin receptor and its receptor IGF1R were similar (Figure 7.2 B, D, E). 
Significantly however, IGF-2 mRNA in HCC was significantly lower than that in 
the paired surrounding tissue (p=0.03), while its receptor IGF-2R was 
upregulated (p<0.0001) (Figure 7.2 C, F). Comparing normal to peri-tumour 
tissues, gene expression of IRS-1, 2 and 4 was similar (Figure 7.1 G, H). 
Contrastingly however, IRS 1 (p=0.0018), 2 (p=0.002) and 4 (p=0.0005) were 
upregulated in HCC compared to peri-tumour tissue, and this effect was more 
marked with IRS-4 (Figure 7.2 G, H, I). 
Protein expression: Upstream insulin signaling polypeptides were measured 
using a bead-based multiplex ELISA. Total insulin receptor levels were higher in 
HCC than in adjacent tissue (p=0.01), whereas its phosphorylated counterpart 
showed similar levels in both groups (Figure 7.3 A, D). To accurately assess 
relative levels of the active signaling polypeptides we measured a ratio of 
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Figure 7.1:  Gene expression levels of mediators of the Insulin/IGF signaling cascade, 
measured in control and peri-tumour human liver tissues. RNA extracted from liver was reverse 
transcribed to measure (A) insulin, (B) IGF-1, (C) IGF-2, (D) insulin receptor, (E) IGF-1 receptor, 
(F) IGF-2 receptor, (G) IRS-1, (H) IRS-2 and (I) IRS-4 mRNA expression by PCR. mRNA 
abundance was corrected for using 18S as the housekeeping gene. Inter-group comparisons 
were made using t-tests.  Significant P-values are indicated within the panels. 
 
phosphorylated insulin receptor levels were downregulated in HCC versus peri-
tumor tissue (Figure 7.3 G). Contrastingly while total IGF-1R levels were lower in 
HCC than peri-tumour tissue (p=0.008), the calculated phosphorylated to total 













Total IRS-1 levels in HCC were higher than in peri-tumour tissue (p=0.046), 
however with a calculated ratio, there was a reversal with HCC having lower 
levels than those observed in peri-tumour tissue (p=0.015) (Figure 7.3 C, I). 
  
Figure 7.2:  Gene expression levels of mediators of the Insulin/IGF signaling cascade, 
measured in peri-tumour and HCC human liver tissues. RNA extracted from liver was reverse 
transcribed to measure (B) IGF-1, (C) IGF-2, (D) insulin receptor, (E) IGF-1 receptor, (F) IGF-2 
receptor, (G) IRS-1, (H) IRS-2 and (I) IRS-4 mRNA expression by PCR. mRNA abundance was 
corrected for using 18S as the housekeeping gene. Inter-group comparisons were made using t-
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Figure 7.3: Protein expression levels of upstream polypeptides of the Insulin/IGF 
signaling cascade, measured in peri-tumour and HCC human liver tissues. Liver protein 
homogenates were used to measure immunoreactivity in fluorescence units corresponding to (A) 
insulin receptor, (B) IGF-1R, (C) IRS-1, (D) pYpY1162/1163-IR, (E) pYpY1135/1136-IGF-1R, (F) pS312-IRS-1 
with a bead-based Multiplex ELISA platform (see Methods and Methods).  (G-I) In addition, the 
phosphorylated/total protein ratios (G-I) for were calculated to assess relative levels of 
phosphorylation of each protein.  Data were analyzed statistically using t-tests.  Significant P-














Downstream signaling signaling through Akt (Figure 7.4 A, E, I) and PRAS40 
(Figure 7.4 C, G, K) was not significantly different in peri-tumour and HCC 
tissues. However whereas signaling through GSK-3β was markedly up-regulated 
in HCC relative to peri-tumour tissues when measuring total (p=0.0002) and 
phosphorylated (p=0.002) levels, a ratio of phosphorylated to total GSK-3β levels 
showed a significant down-regulation (p=0.005) in HCC tissues (Figure 7.4 B, F, 
J). p70S6K is a serine/threonine kinase that acts downstream of mammalian 
target of rapamycin (mTOR) and promotes protein synthesis when activated. In 
HCC although total levels of p70S6K (Figure 7.4 D) were higher than those in 
peri-tumour tissues (p=0.039), when corrected for by a ratio calculation of 
phosphorylated to total levels (Figure 7.4 L), p70S6K levels were lower in HCC 






















Figure 7.4: Protein expression levels of the downstream polypeptides of the insulin/IGF 
signaling cascade, measured in peri-tumour and HCC human liver tissues. Liver protein 
homogenates were used to measure immunoreactivity in fluorescence units corresponding to (A) 
Akt, (B) GSK-3β, (C) p70S6K, (D) PRAS40, (E) pS473-Akt, (F) pS9-GSK3β, (G) pTpS421/424-p70S6K 
and (H) pT246-PRAS40 with a bead-based Multiplex ELISA platform (see Methods and Methods). 
(I-L) In addition, the phosphorylated/total protein ratios for were calculated to assess relative 
levels of phosphorylation of each protein.  Data were analyzed statistically using t-tests.  













Wnt/β-catenin signaling in control versus peri-tumour tissue and peri-
tumour versus HCC 
Using qT-RT-PCR, we measured mRNA levels of components of the Wnt 
signaling cascade. Of the measured ligands Wnt 1, 3, 4, 5A and 5B, Wnt 3 
(p<0.0001), Wnt 5A (p=0.004) and Wnt 5B (p=0.01) mRNA transcripts were 
significantly upregulated in HCC versus peri-tumour tissues (Figure 7.5 B, D, E). 
Both transcripts of secreted Frizzled-related protein (FRP-1) (p=0.01) and sFRP-
5 (p=0.008) were lower in HCC than peri-tumour tissues (Figure 7.5 F, G). While 
levels of Frizzled-3 (Fzd-3) and Fzd-7 were similarly expressed (Figure 7.5 H, J), 
those of Fzd-6 were higher in HCC than in peri-tumour tissues (p=0.02) (Figure 
7.5 I). Therefore enhanced Wnt signaling in HCC is mediated via Wnts 3 and 5 
and frizzled-6 and downregulated inhibited Frizzled’s soluble counterparts (which 



















Figure 7.5a:  Gene expression levels of mediators of the Wnt/β-catenin signaling 
cascade, measured in peri-tumour and HCC human liver tissues. RNA extracted from liver was 
reverse transcribed to measure (A) Wnt 1, (B) Wnt 3, (C) Wnt 4 (D) Wnt 5A, (E) Wnt 5B, (F) 
sFRP1, (G) sFRP5, (H) Fzd 3, (I) Fzd 6 and (J) Fzd 7 mRNA expression by PCR. mRNA 
abundance was corrected for using 18S as the housekeeping gene. Inter-group comparisons 
















Figure 7.5b:  Gene expression levels of mediators of the Wnt/β-catenin signaling 
cascade, measured in peri-tumour and HCC human liver tissues. RNA extracted from liver was 
reverse transcribed to measure (A) Wnt 1, (B) Wnt 3, (C) Wnt 4 (D) Wnt 5A, (E) Wnt 5B, (F) 
sFRP1, (G) sFRP5, (H) Fzd 3, (I) Fzd 6 and (J) Fzd 7 mRNA expression by PCR. mRNA 
abundance was corrected for using 18S as the housekeeping gene. Inter-group comparisons 
were made using t-tests.  Significant P-values are indicated within the panels. 
 
Notch signaling in peri-tumor versus HCC: 
Cell motility is enhanced by the hydroxylation of Notch by aspartyl-(asparaginyl)-
β-hydroxylase (AAH), and both these molecules are involved with tissue 
invasiveness and motility (de la Monte et al., 2006; Ince, de la Monte, & Wands, 
2000; Lavaissiere et al., 1996; Maeda et al., 2003). AAH (p=0.0014) and Humbug 
(p<0.0001) mRNA transcripts were higher in HCC than adjacent peri-tumour 
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which encodes a truncated isoform of AAH is thought to promote malignant 
progression of various types of tumors (Lee, 2008; Maeda et al., 2004; Wang et 
al., 2007). At the cell membrane, Notch-1 (p<0.0001) and jagged-1 (p=0.0022) 
were significantly upregulated in HCC compared to peri-tumour tissue (Figure 7.6 
C and D). Downstream signaling through HES-1 was similarly upregulated 
(p<0.0001) in HCC as compared to peri-tumour tissue (Figure 7.6 E). 
 
Cytokine activation in peri-tumor versus HCC tissues  
Protein expression of IP-10, IL-18, IL-8 and TNF-α were similarly expressed in 
peri-tumour as compared to HCC tissue (Figure 7.7 A, C, E, I). Protein levels of 
IL-1β (p=0.01), MIP-1 (p=0.001), β -nerve growth factor (β-NGF) (p=0.004), IL-6 
(p=0.044), and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 
(p=0.05) were downregulated in HCC relative to peri-tumour tissues (Figure 7.7 
G, B, D, H, J). Levels of IFN-γ by contrast were marginally higher in HCC 



















Figure 7.6:  Gene expression levels of mediators of the Notch signaling cascade, 
including AAH/Humbug measured in peri-tumour and HCC human liver tissues. RNA extracted 
from liver was reverse transcribed to measure (A) AAH, (B) Humbug, (C) Notch-1 (D) Jagged-1 
and (E) HES-1 mRNA expression by PCR. mRNA abundance was corrected for using 18S as the 
housekeeping gene. Inter-group comparisons were made using t-tests.  Significant P-values are 














Figure 7.7: Cytokine expression levels measured in peri-tumour and HCC human liver 
tissues. Liver protein homogenates were used to measure immunoreactivity in fluorescence units 
corresponding to (A) IP-10, (B) MIP-1, (C) IL-18, (D) β-NGF, (E) IL-8, (F) IFN-γ, (G) IL-1β and (H) 
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7.4 DISCUSSION 
Stepwise progression of liver disease of any aetiology from normal, to pre-
malignant and ultimately a malignant phenotype is governed by many factors, not 
least of which are signaling cascade impairments that modulate growth, 
proliferation and apoptosis. Analysis of the differences in signaling impairments, 
if any, at various stages of liver disease may give key clues to the molecular 
aspects of disease that might lead to the identification of diagnostic markers that 
can be used for detecting early disease or indeed of additional therapeutic 
agents to target HCC. Our study aimed to evaluate the differences in Insulin/IGF, 
Wnt, and Notch signaling in normal, peri-tumour and tumour human liver tissue 
and to consider how in concert, these pathways may mediate 
hepatocarcinogenesis. 
 The findings were that in peri-tumour tissue, as compared to normal liver 
gene expression for ligand availability and binding was downregulated as 
evidenced by lower mRNA transcripts of IGF-1 and 2, and their corresponding 
receptors. When comparing peri-tumour to HCC tissues on the other hand, 
although there is no difference in the expression of IGF-1 mRNA transcripts and 
that of IGF-1R, IGF-2 transcripts are lower, while those of IGF-2R are higher in 
the latter suggesting a compensatory overexpression of IGF-2R as a result of 
reduced gene expression for IGF-2 ligand. A similar finding of overexpression of 
IGF-2R in 100% of HCC was reported in a previous paper from our laboratory 
(Cantarini et al., 2006). Correlative protein expression data suggests that IGF-2 












insulin receptor and IGF-1R because IGF-2R does not transmit signals, rather it 
functions to sequester IGF-2. Upregulated Insulin/IGF signaling in HCC 
compared to normal or peri-tumour tissues was evidenced in this study by the 
universal increased gene expression of IRS-1 to 4 polypeptides; similar results to 
those shown by others (Boissan et al., 2005; Cantarini et al., 2006; Nishiyama & 
Wands, 1992) thereby promoting increased protein expression for the survival of 
HCC cells. 
 Signaling through IGF-1R in HCC in this study is significant for two reasons: 
it was shown to be involved in tumour dissemination (Chen, Boyartchuk, & Lewis, 
2009), and to be the sole receptor through which pro-tumourigenic effects are 
seen (Nussbaum et al., 2008). Correspondingly, signaling through IGF-1R was 
operative in this study. 
Furthermore, more downstream, upregulated insulin signaling was 
mediated by GSK-3β and p70S6K thus promoting glycogen and protein 
accumulation respectively that is needed for cell survival and regeneration. GSK-
3β is an important substrate of Wnt signaling, in inactive states, the GSK-
3β/APC/Axin complex phosphorylates and thereby marks β -catenin for 
degradation, thus GSK-3β is a negative regulator of oncogenesis. However 
overexpression of GSK-3β has been shown in many different types of tumours, 
suggesting its role as a tumour promoter. In fact overexpression of GSK-3β was 
noted in cancerous versus normal mouse liver tissue (Gotoh, Obata, Yoshie, 
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both upstream and downstream in HCC to promote the pro-survival and 
proliferation of transformed neoplastic cells. 
 For many causes of liver disease a solitary insult does not seem sufficient 
to result in significant disease, for instance, overexpression of IRS-1 in 
combination with alcohol in a transgenic mouse model of HCC resulted in 
significantly more impairments of insulin and Wnt signaling, including the 
expression of AAH, effects typically seen in HCC (Longato, de la Monte, 
Califano, & Wands, 2008). Similarly IRS-1 overexpression by itself did not result 
in tumours (Mohr, Banerjee, Kleinschmidt, Bartolome Rodriguez, & Wands, 
2008), therefore showing the need for interactive signaling. 
Upregulation of the Wnt/β-catenin signaling was mediated by ligands 
Wnt3, 5A and B and as expected, the secreted frizzled proteins were 
downregulated, because these antagonize the action of the Wnt ligands (Leyns, 
Bouwmeester, Kim, Piccolo, & De Robertis, 1997; S. Wang, Krinks, Lin, Luyten, 
& Moos, 1997). Downstream signaling was mediated via frizzled-6; this finding, 
contrasts with other reports where frizzled-7 was the dominant downstream 
effector associated with beta-catenin nuclear accumulation (Merle et al., 2005). 
Moreover, the quoted study showed that Wnt3 interacts with and is likely 
activated by Fzd-7, thereby enhancing Wnt signaling and tumour cell migration. 
This discrepancy with previous data may be due to the fact that there are many 
Wnt receptors, the ligand specificity of which has not been fully elucidated. 
Therefore in different types of tissues, differences in ligand-receptor binding 












components of Notch signaling including its upstream regulator AAH were 
upregulated in HCC relative to peri-tumour tissues. Although AAH has been 
shown by others to be upregulated in HCC (Cantarini et al., 2006), the role of 
Notch signaling is less clear with divergent results from different laboratories 
(Gao et al., 2007; Gao et al.; Gramantieri et al., 2007; Wang et al., 2009; Wang 
et al.; Wang et al., 2009). One explanation of this could be that Notch signaling 
was evaluated in different in vivo and in vitro systems in these studies, and it is 
well known that signaling is dependent on the tissue and cell type, and the 
required function at the time. Upregulation of Notch-1 and Jagged in our study 
suggests that in human HCC Notch signaling is activated and is therefore key in 
promoting malignant transformation. 
Finally in virus- and/or alcohol-associated HCC there is attendant 
inflammation, which is induced by cytokine activation. Therefore HCC is 
associated with cytokine activation. Various cytokines can have opposing effects 
depending on the cellular state, thus there is no consistency across the available 
data on activation of individual cytokines. The majority of measured cytokines 
were either unchanged or downregulated in HCC compared to peri-tumour tissue 
except for IFN-γ. IFN-γ is used successfully in the treatment of viral hepatitides, 
and thus its upregulation in HCC may be suggestive of its role in attempting to 
clear hepatocytes of the virus and/or of transformed abnormal cells. However 
additional mechanistic studies evaluating this concept are necessary. 
 To summarize this study was novel in that all 3 significant pathways 
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components of all three pathways. We posit that because a single “hit” seems 
insufficient to cause significant disease, the combination of insulin/IGF, Wnt/β-
catenin and Notch signaling results in growth, proliferation of abnormal cells and 
avoidance of apoptosis likely by the upregulation of Notch by AAH and the pro-
oncogenic effects of GSK-3β, stimulated by both Insulin/IGF and Wnt signaling. 
Relevance of this study could be in the targeting of respective signaling pathways 
either through the use of specific tyrosine kinase inhibitors or neutralizing 
antibodies. The pro-tumourigenic effects of IGF-II such as proliferation, anti-
apoptosis, and migration are transmitted through its receptor IGF-1R, therefore 
selective inhibition of this tyrosine kinase by small molecule compounds might 
reduce IGF-II-driven tumour growth. It has already been shown that an antibody 
to Wnt-1 reduced viability and proliferation of cell lines likely by promoting 
apoptosis and decreasing the transcriptional activities of beta-catenin (Wei, 
Chua, Grepper, & So, 2009), therefore this approach is promising. 
Alternatively, specific molecules within the respective pathways could be 
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Chronic liver disease and its complications of cirrhosis and hepatocellular 
carcinoma (HCC) are serious conditions with high morbidity and mortality, not to 
mention economic burden. In particular, other than the increasing prevalence of 
obesity, chronic hepatitis infection (B and C) and alcohol are the main 
aetiological factors. The underlying mechanisms of progression of disease of any 
aetiology to more severe phenotypes including steato-hepatitis, cirrhosis and 
HCC are incompletely understood, despite active on-going research in this field. 
Notwithstanding, the role of aberrant signaling cascades in these disease 
processes has come to the fore in recent times and since proteins that contribute 
to or are responsible for activating these pathways can be identified and isolated, 
this approach to studying disease mechanisms is exciting, feasible and may 
likely advance the understanding of these diseases. Thus the broad aim of this 
work was to characterize signaling impairments in two major pathways that are 
known to contribute, to varying degrees, to alcoholic liver disease (ALD) and 
HCC viz: insulin/IGF and Wnt/β-catenin signaling. In addition, we sought to 
evaluate the role of the less well-characterized Notch signaling pathway in HCC. 
 Previous studies conducted in our laboratory have shown that alcoholic 
steatohepatitis in a rat model is associated with insulin resistance, lipotoxicity and 
oxidative and ER stress. While triglycerides are the main lipid responsible for 












the features of ASH, the malign form of ALD. In this work we have shown both in 
in vivo and ex vivo experiments of ASH and in human ALD tissue that ceramide-
induced lipotoxicity accounts for the insulin resistance that is implicated in 
progression of ALD. The mechanism for the insulin resistance is increased acid 
sphingomyelinase activity. Furthermore, in interrogating possible therapeutic 
options we showed that although oxidative stress is an important element of the 
pathophysiology of ALD, and is likely partly responsible for the ceramide-
mediated lipotoxicity, treatment with anti-oxidants alone is not sufficient to quell 
the attendant insulin resistance. However, our ex vivo studies showed that 
treatment with ceramide inhibitors ameliorated the ER stress associated with 
ALD, suggesting therefore, the important role of ER stress as a mediator of 
disease progression (as seen in the human ALD study). Together these findings 
attest to the complex pathophysiological mechanism of ALD and therefore the 
necessity of a multi-pronged approach to treating this disease. In this context, our 
work contributes to current knowledge in both the pathophysiological 
mechanisms of progression to ASH (specifically oxidative and ER stress), and 
the potential therapeutic strategies that can be employed to treat this condition 
(Figure 8.1). 
 Consequently, the clinical implications of these findings firmly place 
ceramides as culprits that can be directly targeted in combination with other 
treatments to treat ALD, particularly ASH. This treatment would be a novel 
addition to the hitherto lack of effective or registered treatments for ALD. This 
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 Figure 8.1: Mechanisms of progression to alcoholic steatohepatitis. The mechanisms of 
progression of alcoholic steatosis to steatohepatitis are thought to be mediated by oxidative and 
endoplasmic reticulum (ER) stress, DNA and mitochondrial dysfunction and lipotoxicity, to 
mention a few. Ceramides are toxic lipids that modulate signaling. In this model of alcoholic 
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growth and regeneration. The administration of anti-oxidant therapy i.e. N-acetylcysteine (NAC) 
and/or ceramide inhibitors led to an amelioration of the effects of chronic alcohol consumption. 
 
 
 Perhaps the most unexpected results from our experiments were the lack of 
pro-inflammatory cytokine activation in the rat model of ASH and in human HCC 
liver tissue. This finding contrasts quite strikingly with published reports. In terms 
of the animal ASH model, these findings are perhaps less surprising when looked 
at in the context of the fact that this model did not show significa t inflammation 
histologically. Pro-cytokine inflammation is generally implicated in acute/sub-
acute models of alcoholic hepatitis, which was not the case in this study, which 
was of chronic steatohepatitis. In human HCC, previous reports have yielded 
varying results as to the role and importance of cytokine activation in HCC. The 
role of cytokine activation seems to be important particularly in virus-related HCC 
i.e. HBV or HCV. We did not have any specific information about the aetiology of 
our HCC tissue and likely there are other unknown factors at play that determine 
the extent to which cytokine activation plays a role in HCC. 
 The most interesting data were that from the double transgenic mouse 
model of HCC and human HCC tissue. Our study was novel for the fact that in 
the former two specific Wnt signaling mRNA transcripts were identified as being 
markedly upregulated in the double transgenic mice, thus marking potential HBV-
related HCC signatures that can be utilized in the identification of early pre-
malignant disease. In the latter, the three signaling pathways i.e. insulin/IGF, 












tissue. These were found to be independently aberrant in HCC; our results 
suggest that the cross-talk and co-activation of these pathways collectively 
determines the fate of chronically inflamed and scarred liver tissue, to either 
arrest progression of disease, i,e. at the cirrhosis stage, or to further progression 
to the malignant phenotype, HCC. AAH is linked to both Notch and insulin 
signaling by hydroxylating and enhancing the expression of Notch and Jagged, 
but is itself stimulated by insulin/IGF via the ERK/MAPK and PI-3K/Akt pathways 
(Cantarini et al., 2006; de la Monte et al., 2006; Lahousse, Carter, Xu, Wands, & 
de la Monte, 2006). Additionally, overexpression of aspartyl-(asparagyl)-beta-
hydroxylase (AAH), upregulated both insulin/IGF and Notch signaling (Cantarini 
et al., 2006), suggesting that there is a complex interaction between AAH/Notch 
and insulin signaling cascades. Notably, inhibition of GSK-3β increased AAH 
protein probably by inhibiting the phosphorylation of AAH (Carter et al., 2008), 
and it is known that when activated, Wnt signaling phosphorylates and thereby 
de-activates GSK-3β. Correspondingly, it is possible that deactivation of GSK-3β 
by Wnt could also activate AAH, in this way connecting the Wnt and AAH/Notch 
pathways. Therefore, we hypothesize that the interaction points linking this triad 
of signaling pathways, are likely via AAH and GSK-3β. Upregulation of 
components of these three pathways that ultimately result in increased levels of 
AAH and GSK-3β probably interact to promote cancer formation (Table 8.2). 
These findings are crucial to the understanding of hepatocarcinogenesis. More 
importantly, are the practical implications of this knowledge, and that is that 
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neutralizing antibodies, or tyrosine kinase inhibitor therapy, that can be used as 
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8.2 Future Directions 
 
This body of work has provided key insights into the pathogenesis of ALD and 
HCC. However many mechanistic questions that were beyond the scope of this 
work remain unanswered. One of the mechanisms involved in alcoholic steatosis 
is the downregulation of PPARs. Thus we aim to test the functional effects of 
PPAR agonists in ASH using the PCLSC model, which is amenable to such a 
study. In this way, if PPAR agonists reverse a different pathophysiologic 
mechanism of ASH, they can potentially be combined with ceramide inhibitors for 
their effect in ALD. 
 Furthermore, in the double transgenic mouse we hypothesized that to some 
extent age-related epigenetic regulation was responsible for the aberrant 
signaling changes. In fact, compared to the human HCC tissue, frizzled receptor 
inhibitors, i.e. sfrps were upregulated in the double transgenic mice, which is 
contrary to what would be expected. We hypothesize that this may be due to 
age-related epigenetic regulation in the double transgenic mouse. Thus in the 
next phase of this study we aim to do in the first instance, a methylation-specific 
PCR array analysis, to determine if there is an alteration of methylation that can 
explain the changes in gene expression of Wnt/β-catenin observed at the 
different stages of liver disease. Methylation changes are the most common and 
better-studied epigenetic regulatory modifications, however if this analysis does 
not yield results, we will extend the study to examine the role of histone 
modifications in promoting hepatocarcinogenesis. Secondly it would be important 
to measure Wnt molecules at protein level and β -catenin levels in liver tissue, 












This analysis will shed light as to the functional consequences of Wnt activation 
at cellular level, and on disease phenotype. 
 Finally, in terms of the human HCC tissue analyzed and since preliminary 
results support our hypothesis, it would be desirable to increase the sample 
number to increase the power of our study in future studies. Therefore, firstly, we 
will repeat measurements of gene expression of all three signaling pathways in 
larger samples. Secondly, we will do correlative protein analysis of the signaling 
pathways, including a measurement of β -catenin, to see if it correlates with 
activated signaling. Additionally, to uncover the cross-talk mechanisms of these 
pathways underlying the additive or synergistic promotion of the development of 
HCC, we will do co-immunoprecipitation experiments between each of the three 
signaling pathways and AAH and GSK-3β. The implications of positive results 
from this latter aim are enormous, because this suggests that targeting either 
AAH or GSK-3β alone, can potentially target the three incriminated pathways 
simultaneously.  The clinical importance of this finding cannot be overstated. 
Subsequent experiments could involve administering inhibitors against AAH or 
GSK-3β, remeasuri g gene and protein expression as proof of principle of the 
functions and effects of AAH and GSK-3β in promoting HCC.  
The potential of this and future studies, as outlined provides an exciting prospect 
for the understanding and possible therapeutic discoveries for ASH and HCC, 
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8.3 Publications arising from this work 
 
1. Limited Therapeutic Effect of N-Acetylcysteine on Hepatic Insulin Resistance 
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Monte SM. Alcohol Clin Exp Res. 2011 Jul 25. doi: 10.1111/j.1530-
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